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Vascularization is one of the key components required to engineer three-dimensional (3D) 
tissues and organs. To realize the potential of cell-based approach for vascularizing tissue 
requires scalable production of homogeneous populations of vascular cells that include 
endothelial cells (ECs) and vascular smooth muscle cells (vSMCs). Human embryonic stem 
cells (hESCs) are virtually an unlimited source of differentiated cells including ECs and 
vSMCs. However, current differentiation strategies need improvisation in terms of efficiency, 
reproducibility, and use of xenogeneic (animal-derived) products. To obtain scalable amounts 
of clinically competent vascular cells, we aimed to develop differentiation protocols with 
minimal use of xenogeneic products. Further, we investigated the functionality of hESC-
derived vascular cells to engineer in-vitro vascularized tissue equivalents.  
Under feeder-free and chemically-defined conditions, we demonstrate efficient differentiation 
of hESCs into progenitor populations expressing markers related to endothelial lineage 




PDGFRβ-) and paraxial mesoderm 
(PDGFRβ+CD34-CD31-VEGFR2-) using sequential modulation of Wnt, FGF, BMP and 





 endothelial progenitor cells into homogeneous populations of arterial and 
venous ECs under serum-free conditions by modulating the concentration of VEGF. 
Similarly, the PDGFRβ+CD34-CD31- paraxial mesoderm intermediates were differentiated to 
vSMCs under smooth muscle differentiation conditions. Further, the hESC-derived ECs 
(arterial and venous phenotypes) and vSMCs were extensively characterized for expression of 
corresponding cell surface and intracellular markers, and for their in-vitro functionality. 
Additionally, various angiocrines secreted by all the three vascular progenies were surveyed.   
A prerequisite to realize the full potential of these ECs and vSMCs is their ability to form 
blood vessels. We analyzed this potential by in-vitro 3D co-culture of the hESC-derived 
arterial ECs and vSMCs in a polyethylene-glycol-fibrin gel under serum-free conditions. To 
enable visualization of the ECs and vSMCs in 3D cultures, they were fluorescently labeled 
with eGFP and DsRed2 respectively. Upon 3D co-culture, the arterial ECs formed 
anastomosing endothelial cords; however, they regressed within 6 days of culture. In contrast, 
in the presence of vSMCs, the ECs organized and matured into a microvascular network of 
endothelial tubes (with patent lumen) and the vascular network was stable in culture for 3 
weeks. Further, the microvessels were mature in terms of their barrier function, and also were 
capable of regulating the permeability in responsive to physiological stimulus like histamine. 
 xiv 
 
In summary, we demonstrate the efficient differentiation of hESCs to ECs (arterial and 
venous) and vSMCs in relatively xenogeneic-free microenvironment; and the utility of these 
cells in the fabrication of in-vitro vascularized tissue equivalent. From a future perspective, 
we believe that these hESC-derived ECs, vSMCs and vascularized tissue equivalents could 
























Endothelial cells (ECs) and vascular smooth muscle cells (vSMCs) constitute the principal 
cells of all the small and large, arterial and venous blood vessels in the body. Deficiency of 
ECs and vSMCs in terms of their presence and/or function plays a major role in development 
and progression of various diseases, including cardiovascular diseases (Carmeliet, 2005; 
Carmeliet and Jain, 2000). Further, the development, maintenance and function of all the 
organs in the human body depends on adequate supply of nutrients and removal of waste by-
products, which in turn is depend on adequate blood supply to the organs. Various efforts 
have been reported to construct tissue-engineered blood vessels in-vitro and in-vivo using 
mature ECs and vSMCs (Lokmic and Mitchell, 2008; Novosel et al., 2011; Rivron et al., 
2008).  
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) have shown 
a great promise as a tool to early human development, develop in-vitro testing platforms and 
as a therapeutic cell source. Owing to the capacity to self-renew almost indefinitely and the 
potential to differentiate into lineage-specific cells, hESCs could be used as an unlimited 
source of lineage-committed cells including ECs and vSMCs. Various protocols have been 
reported to differentiate hESCs into vascular cells that include ECs and vSMCs (Cheung and 
Sinha, 2011; Kane et al., 2011). However, one of the major challenges for the use of these 
hESC-derived vascular cells for engineering functional vascular tissues is the heterogeneous 
population of differentiated cells, which may lead to inferior tissue organization, ectopic 
formation of unintended tissue and teratoma formation. Hence, strategies need to be 
developed to efficiently differentiate hESCs towards vascular lineage and to enrich ECs and 
vSMCs prior to their use for vascular tissue engineering. Secondly, most of the current 
protocols to differentiate PSCs to vascular cells utilize various xenogeneic (animal-derived) 
products like serum, feeder cells, matrices that limit the clinical translation potential of these 
cells, and also limit the ability to tune the culture milieu due to the presence of undefined 
components (Kaupisch et al., 2012). Another challenge is the heterogeneous nature of ECs at 
molecular, morphological and functional levels (Aird, 2007a). ECs that form the arteries and 
veins differ in terms of molecular and functional levels, and further, the ECs in different 
tissues display different characteristics (Torres-Vazquez et al., 2003). Similarly, the vSMCs 
also display different characteristics with phenotypes ranging from synthetic to contractile 
types. Additionally, vSMCs arise from diverse developmental origin and display differences 
in their function (Majesky, 2007). Current hESC and iPSC differentiation protocols are 




to be developed that address the specific developmental origins and associated heterogeneity 
among ECs and vSMCs.  
Vascularization is a key component required to engineer three-dimensional (3D) tissues and 
organs which requires the establishment of vascular networks within the tissue construct 
(Novosel et al., 2011). Engineering vascularized 3D tissue constructs requires the use of an 
appropriate scaffold that would encourage the formation of vascular networks, angiogenic 
cells that include ECs or their progenitors and supporting cells, and/or provision of 
appropriate angiogenic signals (Lokmic and Mitchell, 2008).  
Hence, in this doctoral work we aimed to efficiently differentiate hESCs to ECs and vSMCs 
with attention to developmental origins and heterogeneity among these cells in a feeder- and 
serum-free microenvironment. Further we utilize these hESC-derived ECs and vSMCs to 













Review of Literature 




2. Review of Literature 
 
Successful isolation and culture of hESCs (Thomson et al., 1998), and the generation of 
iPSCs (Takahashi et al., 2007; Yu et al., 2007), has initiated a new field of research for 
studying human development, cell therapy, tissue engineering, drug screening and disease 
modeling (Daley and Scadden, 2008). hESCs are derived from the inner cell mass (ICM) of 
the developing blastocyst that can proliferate almost indefinitely upon culture (Thomson et 
al., 1998). iPSCs on the other hand are derived from nuclear reprogramming and induction of 
pluripotency in somatic cells (Park et al., 2008). Both the types of pluripotent stem cells 
(PSCs), hESCs and iPSCs have the potential to differentiate in-vitro into derivatives of the 
three primary germ layers (Figure 1). PSCs could differentiate spontaneously to all the three 
germ layers, however to differentiate to the cell types of interest, reproducible and efficient 
differentiation protocols are needed.  
 
Figure 1. Derivation and differentiation of pluripotent stem cells 
The illustration depicts the derivation of ESCs from the ICM of the blastocyst embryo and iPSCs from 
introduction or expression of pluripotency genes in differentiated somatic cells. The ESCs and iPSCs 
have the ability to self-renew and differentiate to cell types of the three germ layers. 
 
In the present context of engineering vascularized tissue equivalents, the cell types of interest 
that fall the umbrella of vascular lineage includes, ECs, vSMCs or pericytes, hematopoietic 
cells and cardiomyocytes. Differentiation of PSCs into ECs and vSMCs is of growing interest 
for various applications as it provides an access to study vascular development in both 
physiological and diseased states, which otherwise is not possible due to ethical issues. 




cellular and molecular aspects. These cells also provide access to abundant population of cells 
for the pharmaceutical industry to screen and develop novel cardiovascular compounds 
(Rubin, 2008). Finally, in the long term these cells can lend for cellular therapy to repair 
ischemic tissues and develop tissue engineered vascular grafts (Figure 2).  
 
Figure 2. Promise of PSCs in cardiovascular research 
The illustration highlights the potential scope of pluripotent stem cells in cardiovascular research 
ranging from understanding normal physiology, disease mechanisms, developing therapeutics to 
cellular therapy. 
 
Several protocols to differentiate hESCs towards vascular lineage have been reported till date 
(Descamps and Emanueli, 2012; Kane et al., 2011). These protocols involve: (1) embryoid 
body-based differentiation, (2) co-culture of hPSCs over murine stromal cells, (3) culture of 
hESCs or iPSCs as monolayers over extracellular matrix proteins like Matrigel, and collagen 
IV, and/or (4) growth factor, cytokines or small molecule mediated differentiation in serum 
containing/ serum-free conditions. Despite the enormous amount of progress made in 
directing hESCs towards functional cells of the vascular lineage, there remain certain major 
challenges in the hESC differentiation paradigm. These include low differentiation efficiency, 
reproducibility, animal product contamination, tumorigenicity and immunocompatibility 
(Kaupisch et al., 2012).  
Use of xenogeneic (animal-derived) products like serum, Matrigel, feeder cells within the 
culture milieu is associated with two concerns. Xenogeneic products would affect the 
differentiation efficiency and limit the precise control over the differentiation system due to 
the presence of undefined factors and batch variability. Secondly, hESCs cultured or 
differentiated in the presence of xenogeneic products are not compatible with clinical 
applications due to the risk of graft rejection and potential transfer of xenogeneic pathogens 




molecules are believed to assist in achieving PSC-derived progenies differentiated under 
xenogeneic-free conditions.  
A thorough understanding of the progression of lineage commitment and differentiation in-
vivo would aid us in achieving improved differentiation efficiency of PSCs. ECs and vSMCs 
predominantly develop from mesodermal progenitors. To be specific, ECs arise from lateral 
plate mesoderm while vSMCs are known to arise from diverse origins including lateral plate 
mesoderm, paraxial mesoderm and neural crest (Majesky, 2007). To reproduce these complex 
developmental processes in-vitro, requires the dissection of the process into simple steps 
marked by specific biological markers.  
The first few sections of this chapter would focus on understanding the commitment of cells 
in the embryo and PSCs towards mesodermal lineage, followed by their commitment to 
progenitors related to vascular lineage cells (ECs and vSMCs). The next few sections would 
focus on the isolation of these progenitors, terminal differentiation of isolated vascular 
progenitor cells and characterization of the terminally differentiated ECs and vSMCs. Since 
the vascular system is broadly divided into arterial and venous systems, a section is included 
on commitment of ECs towards arterial and venous phenotypes. The final section reviews the 
relevant approaches and biomaterials for co-culture of ECs and vSMCs to engineer 






2.1. Mesodermal induction and associated markers 
The in-vitro differentiation of hESCs in most cases recapitulates the sequential stages of 
development observed in embryological studies. In the developing embryo, the cells of the 
hematopoietic and cardio-vascular lineage arise from subpopulations of mesoderm in a 
defined temporal sequence. An understanding of the embryonic development would facilitate 
their differentiation form hESCs. Mesodermal induction starts with formation of primitive 
streak (PS) from the epiblast which gives rise to the progenitors related to cells of the 
mesoderm and endoderm germ layers.  
2.1.1. Primitive streak and germ layer specification in mammalian embryos 
In mammalian embryogenesis, the generation of the three germ layers (ectoderm, mesoderm 
and endoderm) occurs during the process of gastrulation. The beginning of gastrulation is 
marked by the epithelial-mesenchymal transition (EMT) of certain epiblast cells to from a 
transient structure known as primitive streak (PS) that forms on the posterior midline of the 
embryo. As the epiblast cells undergo EMT, they ingress into the PS (between the epiblast 
and hypoblast) which results in the formation of mesoderm and definitive endoderm germ 
layers (Ciruna and Rossant, 2001). Hence the formation of PS results in transformation of a 
bilayered germ disc (epiblasts and hypoblasts) to a trilayered germ disc consisting of 
ectoderm, mesoderm and endoderm (Figure 3). Due to their ability to contribute to mesoderm 
or endoderm, PS is also referred to as mesendoderm.  
Molecular and lineage tracking studies have divided the PS into anterior, mid and posterior 
regions that exhibit distinct gene expression patterns (Tam and Loebel, 2007). Genes like 
Brachyury (Kispert and Herrmann, 1994) and Mixl1 (Hart et al., 2002) characterize the PS in 
general, while anterior PS preferentially express Foxa2 and Goosecoid (GSC) (Kinder et al., 
2001b); and the posterior PS expresses HoxB1 (Forlani et al., 2003) and Evx1 (Dush and 
Martin, 1992). The cells of the anterior PS form the anterior mesendoderm that gives rise to 
endoderm and axial mesoderm. With progression of gastrulation, the cells migrate through the 
posterior PS and give rise to paraxial, intermediate and lateral mesoderm (Tam and Behringer, 
1997) (Figure 4). The axial mesoderm gives rise to prechordal plate and notochord; paraxial 
mesoderm to somites that further develop to muscles, bone and cartilage; intermediate 
mesoderm to renal and gonadal systems; and the lateral plate mesoderm gives rise to heart, 
blood vessels and hematopoietic cells (Kitagawa and Era, 2010) (Figure 5). This segregation 
of cell fates during gastrulation occurs in a temporal and spatially controlled manner that are 
regulated by coordinated activation of various signaling pathways that include BMP, Nodal, 





Figure 3. Formation of primitive streak, mesoderm and endoderm. 
Cells of the inner cell mass of the embryo forms the bilayered embryonic disc that separates the 
amniotic cavity from the yolk sac (A-B). The bilaminar embryonic disc consists of a layer of epiblast 
(forms the floor of amniotic cavity) and hypoblast (forms the roof of yolk sac) (C). Certain cells within 
the epiblasts in the posterior midline ingress between the epiblasts and hypoblast to form the primitive 
streak (PS) (C-D). A cross-section through the PS shows the ingression of PS cells in between epiblast 
and hypoblast that forms the endoderm €. The epiblast cells are now referred to as ectoderm. Later, the 
mesoderm is formed by additional cells that migrate in between the ectoderm and endoderm resulting 
in the formation of a trilayered embryonic disc (F). Source: Drawn based on an illustration from 
Human Anatomy and Physiology, 7e, Marieb EN, Marieb KH. 
 
 
Figure 4. Segregation of mesoderm during embryogenesis. 
Migration of PS and the mesodermal cells gives rise to different parts of the mesoderm, namely 







Figure 5. Germ layer derivatives 
The schematic flow chart illustrates the embryonic development of various derivatives of the germ 
layers of the embryo. Source: Drawn based on an illustration from http://discovery.lifemapsc.com. 
 
2.1.2. Markers associated with the early stages of mesoderm and endoderm development 
The markers expressed in the early stages of embryonic development are extensive. The 
important markers used in the literature to identify/ track the development of PS, early 
mesodermal subsets and endoderm would be discussed below. 
Brachyury (T) is a transcription factor required for PS development and hence, is expressed in 
the mesendoderm (Wilkinson et al., 1990). Mouse embryos lacking Brachyury exhibit severe 
abnormalities and die by day 10 of gestation (Yanagisawa et al., 1981). The abnormalities 
include lack of migration of cells through PS, and a reduced mesoderm formation. Hence, it is 
commonly used as a marker along with other markers to monitor the development of PS and 
induction of mesoderm. Brachyury is a transient marker that upregualtes with the induction of 
PS and downregulates when the cells undergo specification towards specific mesodermal 




Mixl1 which are expressed in PS and mesoderm; GSC and Foxa2 which are expressed in PS 
and endoderm.  
Mixl1 is a homeobox gene expressed in the PS of gastrulating embryo, and visceral endoderm 
of pre-gastrulation embryo (Pearce and Evans, 1999; Robb et al., 2000). Mixl1 is 
predominantly expressed in the mesoderm/endoderm boundary, and marks the cells fated to 
differentiate to mesoderm and endoderm (Grapin-Botton, 2008; Ng et al., 2005a). Mixl1-null 
mutants die at embryonic day 8.5 and show an enlarged PS and abnormalities in the formation 
of definitive endoderm (Hart et al., 2002). 
In addition to Brachyury and Mixl1, the PS also expresses SNAI1 and SNAI2 as the epiblast 
cells undergo EMT. SNAI belongs to a family of zinc-finger transcription factors that is 
involved in processes required to induce EMT through which the epithelial cells loose 
contacts with adjacent cells and become migratory and invasive (Blanco et al., 2007). In 
addition, to expression of SNAI other markers used to identify cells undergoing EMT include 
loss of E-cadherin and upregulation of CD56 (neuronal cell adhesion molecule, NCAM) 
(Evseenko et al., 2010). 
VEGFR2 (vascular endothelial growth factor receptor-2) is also known as KDR (kinase-insert 
domain containing receptor) in humans and Flk-1 (fetal liver kinase-1) in mice. VEGFR2 is 
well established marker for mesoderm (in particular lateral plate mesoderm) and hemato-
endothelial progenitors in mouse embryos, and differentiated mouse and human ESCs 
(Evseenko et al., 2010; Kataoka et al., 1997; Park et al., 2004; Sakurai et al., 2006; Tan et al., 
2013a; Yamaguchi et al., 1993; Yamashita et al., 2000). Other markers associated with 
commitment to lateral plate mesoderm especially cardiovascular lineage include CD34, 
Mesp1, Nkx2.5, and Isl1 (Mummery et al., 2012). 
FoxA2 and GATA factors are among the various transcription factors expressed in 
mesendoderm and endoderm. FoxA2 is expressed at the onset of gastrulation and is essential 
for the specification of foregut and midgut structures (Grapin-Botton, 2008). Among the 
various Gata genes, Gata4 and Gata6 are expressed in the mesendoderm and endoderm; and 
are involved in the commitment of mesendoderm cells towards endoderm (Grapin-Botton, 
2008). Other markers associated with endoderm specification include Goosecoid (GSC), 
CXCR4, Sox17 and alpha fetoprotein (AFP) (Grapin-Botton, 2008). In early stages of mouse 
embryogenesis, CXCR4 (chemokine receptor 4) is associated with primitive and definitive 
endoderm (Drukker et al., 2012; McGrath et al., 1999). CXCR4 has been used as one of the 
markers of endodermal commitment in early hESC differentiation cultures (Drukker et al., 




PDGFRs are tyrosine kinase receptors that are expressed in the paraxial mesoderm, somites, 
and neural tube (Kataoka et al., 1997; Schatteman et al., 1992). Expression of PDGFRα in 
combination with lack of expression of VEGFR2 is used as a marker for paraxial mesoderm 
progenitors (Sakurai et al., 2006; Sakurai et al., 2012; Tan et al., 2013a). Further, embryos 
lacking PDGFRβ expression show significant lack of pericytes in the brain, lung, and 
gastrointestinal tract (Hellstrom et al., 1999).      
The list of markers that mark the PS, mesoderm and endoderm subtypes are numerous. 
Hence, various markers have been used in the literature to track the above set of populations.  
2.1.3. Role of BMP pathway in primitive streak and germ layer specification 
Genetic studies in mice have demonstrated the critical role of BMP signaling in mesoderm 
formation and dorso-ventral patterning (Winnier et al., 1995). Mouse embryos lacking Bmp4 
or its receptors (Bmpr1, Bmpr2) function fail to gastrulate and form mesoderm (Mishina et al., 
1995; Winnier et al., 1995). BMP antagonists Chordin and Noggin modulate BMP signaling 
and hence influence the cell fate decision during early embryogenesis (Loebel et al., 2003). 
Both Chordin and Noggin antagonize BMP signaling and drives the commitment of 
neuroectoderm towards neural fate. Similarly, the BMP antagonists counteract the mesoderm 
inducing effects of BMP4.  
In contrast to in-vivo studies, observations using ESCs have yielded conflicting results. 
Induction of ESCs with BMP4 inhibits neural differentiation and upregulates Brachyury in a 
dose-dependent manner (Johansson and Wiles, 1995). Under serum-free conditions, BMP4 
has been reported to efficiently induce mouse (Ng et al., 2005a; Nostro et al., 2008; Park et 
al., 2004; Wiles and Johansson, 1999) and human (Davis et al., 2008; Kennedy et al., 2007; 
Ng et al., 2005b; Pick et al., 2007) ESCs to Brachyury expressing PS population capable of 
differentiation to VEGFR2+ (Flk-1+) mesodermal cells. Similarly, BMP4 alone or in 
combination with Activin, rapidly induces BRACHYURY in hESCs (Vallier et al., 2009; Yang 
et al., 2008a; Zhang et al., 2008c). However, Nostro et al., (Nostro et al., 2008) and Tan et al., 
(Tan et al., 2013a) proposed that BMP4 alone is not sufficient in inducing PS. Zhang et al., 
(Zhang et al., 2008c) demonstrated the need for concomitant activation of FGF and 
TGFβ/Nodal/Activin signaling in addition to BMP4 for PS induction of hESCs. Similarly, Yu 
et al., (Yu et al., 2011) have demonstrated the mesoendodermal induction potential of BMP4 
depends on FGF signaling. Under serum containing conditions Xu et al., reported that BMP4 
induces differentiation to homogenous population of trophoectoderm cells (Xu et al., 2002). 
While under chemically defined conditions, Vallier et al., found that BMP4 drives 
differentiation to a heterogenous population of primitive endoderm and trophoectoderm 




mesodermal genes by BMP4 in the presence of FGF, while BMP4 alone induces expression 
of trophoblast-associated genes (Bernardo et al., 2011). Hence, the outcome of BMP signaling 
in in-vitro systems seems to be dependent on the culture milieu and influence of other 
signaling molecules. The integrated role of BMP, Wnt, Nodal and FGF signaling in 
mesendoderm induction of mouse ESCs is highlighted in Figures 6-8. 
 
Figure 6. Intracellular signaling pathways. 
The schematic represents the receptors and intracellular events involved in Nodal, BMP, Wnt and FGF 
signaling pathways. Source: Adapted with permission from (Kimelman, 2006) 
 
 
Figure 7. Signaling pathways controlling lineage choice and differentiation. 
The schematic represents the choice of lineage decision based on studies in mouse ESCs. (A) Nodal, 
Wnt, BMP and FGF signaling pathways co-ordinate to induce mesendoderm induction and inhibit 
neural differentiation. (B) On the other hand, FGF alone inhibits pluripotency and induces commitment 





2.1.4. Role of Nodal pathway in primitive streak and germ layer specification 
Mouse studies have demonstrated that blockade of TGFβ/Nodal/Activin signaling pathway 
abrogates the formation of PS and mesoderm (Conlon et al., 1994). Nodal a member of TGFβ 
family is known to be required for anterior-posterior axis during gastrulation. Mouse embryos 
deficient for Nodal fail to form both mesoderm and definitive endoderm (Brennan et al., 
2001). Intracellular events following activation of TGFβ, Activin, and Nodal operate through 
Smad2 and Smad3 intracellular mediators (Figure 6). Mouse embryos lacking one allele of 
Smad2 and Smad3 display defects in definitive endoderm (Liu et al., 2004). Further, loss of 
Smad3 and one allele of Smad2 results in impaired formation of anterior axial PS; while 
selective deletion of Smad2 and Smad3 from epiblast cells interferes with commitment of 
axial and paraxial mesoderm (Dunn et al., 2004). Additionally, Smad2-Smad3 double 
homozygous mutants lack mesoderm in entirety and fail to gastrulate (Dunn et al., 2004). 
Collectively, these observations suggest the role of TGFβ/Nodal/Activin signaling in early 






Figure 8. Role of intracellular signaling pathways in differentiation towards the three germ 
layers. 
The schematic represents the regulation of induction of mouse ESCs to PS, primary germ layers and 
further tissue specification. Induction of mouse ESCs with Wnt, Activin, BMP4 and/or serum induces 
induction of PS-like cells (row of cells outlined in blue) while inhibits the induction towards ectoderm 
lineage. In contrast, inhibition or lack of activation of these pathways results in differentiation towards 
ectoderm lineage. The posterior PS cells (yellow) express Brachyury and low levels of Foxa2; and 
these cells commit towards Flk1
+
 mesodermal progenitors that differentiates further towards 
cardiovascular and hematopoietic lineages. While the anterior PS cells (dark orange) express 
Brachyury and high levels of Foxa2; and these cells commit towards Foxa2
+
 definitive endoderm cells. 
Source: Adapted with permission from (Murry and Keller, 2008) 
 
Activation of Nodal pathway using Activin A in mouse and human ESCs induces 
specification of PS which further differentiates to mesoderm or endoderm depending on the 
concentration of activin with higher concentrations favoring endoderm (D'Amour et al., 2005; 
D'Amour et al., 2006; Kubo et al., 2004; Vallier et al., 2009) (Figure 8). Based on studies in 
mouse ESCs, it has been suggested that the Brachyury
+
 PS cells exist as two subpopulations 
(Kubo et al., 2004). The Brachyury
+
 PS cells committing to mesoderm lineage had low levels 






that committed to endoderm had higher levels of Foxa2 indicating an anterior PS-like 
subpopulation. Similarly, in hESC-embryoid bodies low doses of Activin A in combination 
with BMP4 and hematopoietic growth factors promotes the development of hematopoietic 
fated mesoderm through induction of Brachyury (Cerdan et al., 2012). However, under 
chemically defined conditions, Activin A is reported to be insufficient in driving 
mesendoderm differentiation (Nakanishi et al., 2009b; Vallier et al., 2009), while a cross talk 
between Activin, FGF and BMP4 signaling efficiently induced mesendoderm differentiation 
(Vallier et al., 2009). Further, the intensity of Activin signaling influences the choice between 
mesoderm or endoderm differentiation of mesendeodermal cells.  
2.1.5. Role of Wnt pathway in primitive streak and germ layer specification 
The formation of PS is considered as the central structural marker for mesodermal and 
endodermal precursors (Tam and Beddington, 1987). Among the various signaling pathways, 
the canonical Wnt signaling has been established as playing a pivotal role in the induction of 
PS and the formation of mesoderm and endoderm. Wnt/β-catenin pathway is mediated via a 
post-translational control over the stability of β-catenin (Sokol, 2011a). Lack of Wnt signal 
leads to a rapid degradation of β-catenin by β-catenin degradation complex. The β-catenin 
degradation complex consists of Axin, adenomatous polyposis coli (APC) and glycogen 
synthase kinase-3 (GSK3) (Figures 6 & 9). Activation of Wnt pathway through either 
frizzled receptors, or Lrp5/6 co-receptors leads to inhibition of GSK3 resulting in inactivation 
of the β-catenin degradation complex. When β-catenin is not degraded, it leads to 
accumulation and translocation of β-catenin from cytoplasmic membrane to the nucleus. In 
the nucleus, the β-catenin binds to members of T-cell factors (TCF) family of transcription 
factors and activates the target genes (Kimelman, 2006; Sokol, 2011b).  
Previous studies have established the essential role of Wnt/β-catenin pathway in mammalian 
germ layer specification. It is well established that Wnt activation leads to stabilization of β-
catenin; in transgenic mouse models constitutive expression of stabilized β-catenin induces 
premature EMT of epiblasts to mesodermal progenitors (Kemler et al., 2004). Lack of Wnt3a 
(Liu et al., 1999) or β-catenin (Huelsken et al., 2000) in mouse embryos result in the diversion 
of ingressing epiblast cells towards neuroectodermal fate rather than mesendoderm which in 
turn results in improper formation of body axis and excessive development of anterior 
neuroectoderm. Similarly, in double-homozygous mutants of Wnt3 co-receptors Lrp5/6, PS 
and mesoderm fail to form (Kelly et al., 2004). In contrast, genetic inactivation of negative 
regulators of Wnt pathway like the Axin1, Tcf3, and dickkopf1 (Dkk1) results in absence of 
head and formation of ectopic axial structures (Sokol, 2011b). These in-vivo studies highlight 





Figure 9. Canonical Wnt signaling pathway. 
The schematic represents the activation of Wnt through frizzled receptors or Lrp5/6 co-receptors result 
in inactivation of β-catenin degradation complex. Inhibition of Wnt results in degradation of β-catenin. 
Inhibition of GSK-3 activity results in stabilization of β-catenin and activation of target genes by the β-
catenin-TCF complex. Source: Adapted from open source article (Sokol, 2011b). 
 
In contrast to in-vivo findings, the role of Wnt/β-catenin signaling in mouse and human ESCs 
has been controversial due to contradictory findings. Studies have reported the activation of 
Wnt/β-catenin signaling maintains pluripotency of both mouse and human ESCs (Hao et al., 
2006; Miyabayashi et al., 2007; Ogawa et al., 2006; Sato et al., 2004; Singla et al., 2006; 
Takao et al., 2007; ten Berge et al., 2011; Wagner et al., 2010). Further, Wnt pathway has 
been implicated in promoting the reprogramming of somatic cells to iPSCs (Lluis et al., 2008; 
Marson et al., 2008). On the other hand, activation using either Wnt3a or GSK3 inhibitors has 
been demonstrated to induce differentiation of ESCs towards PS, mesoderm and endoderm 
(Bone et al., 2011b; Davidson et al., 2012; Nakanishi et al., 2009a; Tan et al., 2013a). These 
controversial observations may be due to differences in dose and duration of Wnt activation, 
differences in differentiation methods and presence of serum or other factors like bFGF in the 
differentiation medium. In hESCs, Wnt signaling and Activin/ Nodal has been reported to 
synergistically induce specification towards anterior PS/ endoderm; while in association with 
BMP signaling induces a posterior PS/ mesoderm fate (Sumi et al., 2008). Similarly, in mouse 
ESCs, Wnt or low levels of Activin induce differentiation to posterior PS; while high levels of 
Activin favor anterior PS fate (Gadue et al., 2006). Murry and colleagues using transgenic 
zebrafish embryos, mouse ESCs and hESCs reported that activation of Wnt/β-catenin 




cardiac induction (Paige et al., 2010; Ueno et al., 2007). Additionally, addition of Wnt3a or 
inhibition of GSK3 markedly reduces the differentiation to ectodermal lineages (Nakanishi et 
al., 2009a; Tan et al., 2013a). Hence, the role of Wnt signaling in mesodermal induction of 
ESCs is dependent on the culture conditions and may be integrated with other signaling 
pathways. 
2.1.6. Role of FGF signaling in mesoderm induction 
Basic fibroblast growth factor (bFGF) is the first identified mesoderm inducer (Bottcher and 
Niehrs, 2005; Slack et al., 1987). Studies in mouse embryos (Ciruna and Rossant, 2001), have 
implicated the role of FGFs in controlling the specification and maintenance of mesoderm by 
regulating the T box transcription factors (Brachyury). Gain-of-function of FGF induces 
mesodermal markers while, inhibtion of FGF blocks mesoderm formation (Bottcher and 
Niehrs, 2005). Studies in mouse embryos (Deng et al., 1994; Yamaguchi et al., 1994) lacking 
FGF receptor 1 (fgfr1), show death of the embryos during late-gastrulation stage with defects 
in cell migration, specification and patterning. Observations of the embryos reveal 
accumulation of cells at the primitive streak, few cells that contribute to the formation of 
mesoderm and endoderm lineages, and failure of EMT. Additionally, the cells that gather at 
the primitive streak form ectopic neural tubes. Similarly, mouse embryos lacking fgf8 display 
sever gastrulation defects that include lack of mesodermal and endodermal tissues (Sun et al., 
1999).  These studies indicate the role of FGF signaling in specification, migration, and 




2.2. Endothelial development and associated markers 
An understanding of the embryonic development of ECs and its precursors could aid in their 
differentiation from hESCs. The embryo develops into three germ layers ectoderm, mesoderm 
and endoderm. The mesoderm further differentiates into axial, paraxial, intermediate and 
lateral mesodermal subtypes. The endothelium is the first tissue to develop during the process 
of vertebrate embryogenesis, as all other organ systems depend on supply of oxygen, nutrients 
and signals. The vascular progenitor cells (termed as hemangioblasts/ angioblasts) arise 
within the lateral plate mesoderm and give rise to the cardiovascular system (heart, blood 
vessels and hematopoietic cells) (Atkins et al., 2011). The progenitors within the lateral plate 
mesoderm migrate as cell clusters known as blood islands or hemangioblastic aggregates or 
hemogenic endothelial aggregates (Eichmann et al., 1998; Jaffredo et al., 1998). The cells at 
the periphery of these aggregates flatten and differentiate into ECs; while the cells in the 
center develop into primitive hematopoietic cells. Formation of such blood islands are seen 
both in the embryo proper (intra-embryonic vasculogenesis) and the yolk sac (extra-
embryonic vasculogenesis). The aggregates of ECs connect with those in neighboring 
aggregates to form a primitive vascular network. This process of de novo formation of 
primitive plexus of vessels from the endothelial progenitors is known as vasculogenesis 
(Coultas et al., 2005; Flamme et al., 1997). The interconnected cords of vessels undergo a 
series of morphogenetic changes involving sprouting, proliferation and migration of the ECs 
and remodeling of the vascular channels. This process of branching and reorganization of 
existing vessels is termed as angiogenesis. Ultimately, the intra-embryonic and extra-
embryonic vascular networks coalesce to form a vascular plexus that connects the embryo to 
the uterine wall. As the endothelial vessels remodel and mature, they recruit mural cells 
(pericytes and vSMCs) resulting in a complex network of arteries, arterioles, capillaries, 
venules and veins (Carmeliet, 2000; Carmeliet, 2005; Coultas et al., 2005; Flamme et al., 
1997) (Figures 10 & 11). While in the adult life, most of the neovascularization occurs 
through angiogenesis (i.e., through endothelial sprouting, intussusception and bridging of 
existing blood vessels). Few evidences point to occurrence of vasculogenesis (i.e., de novo 
blood vessel formation) in the adult life. The endothelial progenitors in the bone marrow and 
circulating angiogenic cells seem to play a role in vasculogenesis and angiogenesis in the 
adult life (Figure 11).  
The early events in the endothelial differentiation and the formation of blood vessels involve 
various signaling and regulatory cues that are not yet fully understood. The earliest marker 
expressed by the endothelial progenitor cells of avian and murine embryos is the VEGF 
receptor, Vegfr2 (Eichmann et al., 1998). VEGF is the pivotal mediator of endothelial 




VEGF-induced responses (Millauer et al., 1993; Shalaby et al., 1997). The Vegfr2+ cells in 
the posterior mesoderm segment generate hemangioblasts that differentiate further to 
hematopoietic cells and ECs; while the Vegfr2+ cells in the anterior mesoderm (angioblasts) 
are committed to endothelial lineage and give rise to ECs only (Eichmann et al., 1998). The 
primitive endothelial progenitors that emerge from the lateral plate mesoderm express 
markers such as CD34, CD31, VE-Cadherin, endoglin and Tie-2 in addition to VEGFR2 
(Cleaver and Melton, 2003; Ema et al., 2006).  
 
Figure 10. Embryonic vascular development. 
Formation of the first vascular channels in the embryo begins with differentiation of mesodermal cells 
in posterior primitive streak (PPS) to hemangioblasts or angioblasts under the influence of BMP4, 
bFGF and VEGF. The VEGFR2+ cells in the PS gives rise to aggregates of hemangioblasts or 
angioblasts that undergo a series of morphogenesis forming vascular cords. The peripheral cells of the 
vascular cords form ECs and the central cells hematopietic cells resulting nascent endothelial tubes 
called primary plexus (primitive vacular plexus). These nascent endothelial vessels mature to form a 
primary capillary plexus. The capillary plexus undergoes a series of morphogenetic process under the 
influence of Ephrin/Eph signaling, PDGF, TGFβ and angiopoietins (Ang) and recruits mural cells to 
form a mature circulatory system. Source: Adapted with permission from (Coultas et al., 2005) 
 
The differentiation of ESC-derived VEGFR2
+
 cells into hematopoietic and ECs in-vitro 
provide proof for the existence of a common progenitor for a common progenitor for both the 
lineages (Park et al., 2004). Further, certain other studies have shown the ability of VEGFR2
+
 
progenitors to differentiate to vSMCs, cardiomyocytes and ECs under appropriate conditions 






progenitors. However certain cell-lineage tracing studies in-vivo has failed to reveal the 
existence of such common progenitors, which might be due to issues related to timing of the 
lineage commitment from the primitive streak (Kinder et al., 2001a). Recent advancements in 
imaging technologies might provide more light on the fate of Vegfr2+ cells. 
 
Figure 11. Vasculogenesis and angiogenesis in embryo and adult life. 
(A) ECs from angioblasts/ hemangioblasts in the embryo, while the mural cells (vSMC/PC) arise from 
progenitors in the mesenchyme and neural crest. The ECs assemble to form a simple capillary network 
known as primary capillary plexus, which matures into a network of arteries, veins and capillaries 
through recruitment of mural cells and angiogenesis. However, in-vitro data from ESCs point to a 
common precursor for ECs and mural cells that assemble to form vascular network. (B) In the adult 
life, new vessels form from existing blood vessels through endothelial cell bridging, intussusception, 
and/or sprouting. The morphogenetic process involved during sprouting angiogenesis is also 
highlighted. Source: Adapted with permission from (Bergers and Song, 2005) 
 
2.2.1. Role of VEGF and VEGFR2 in early vascular development 
Mouse embryos lacking Vegf
-/-
, display severe defects in vascular development and die early 
at mid-gestation (Carmeliet et al., 1996). Similarly, mouse embryos lacking Vegfr1 (Vegfr1
-/-
) 
die at E8.5 to E9.5 due to impaired vascular development; and mice lacking Vegfr2 (Vegfr2
-/-
) 
are embryonic lethal at the same stage with defects in vasculogenesis and hematopoiesis 




completely lacks vasculature (Shalaby et al., 1995).   Similarly, the mice lacking Vegfr3 
(Vegfr3
-/-
) are lethal at the same stage but display unorganized and poorly lumenized large 
vessels indicating its early role in vascular development (Dumont et al., 1998). Neuropilins 
are co-receptors for VEGF, and mice lacking neuropilin 1 (Nrp1
-/-
) display defects in yolk sac 
and vasculogenesis. But, mice lacking neuropilin 2 (Nrp2
-/-
) exhibit only minor defects in 
development of lymphatic system. However, mice with Nrp1/Nrp2 double knockouts die due 
to totally avascular yolk sac similar to mice lacking Vegfr2 (Takashima et al., 2002). The 




 mice indicate the obligate relationship 
between the two receptors and their role in early vascular development. On the other hand, 
overexpression of Vegf by two-three folds results in embryonic lethality at E12.5-E14 due to 
aberrant heart development(Miquerol et al., 2000).  
Hence, a balanced function of VEGF and its receptors play an extremely important role in 
early vascular development.  In addition to VEGF, other signaling pathways like Wnt, Notch, 
Shh, cAMP, TGFβ, FGF and BMP4 are also implicated in early to late vascular development 




2.3. In-vitro differentiation to endothelial/ vascular progenitors 
The potential use of PSCs depends on efficient differentiation protocols to derive tissue-
specific progenitor cells. Various approaches have been reported to induce in-vitro 
differentiation of PSCs towards endothelial or vascular lineage. However, currently, there is 
no standardized protocol available that could be used reproducibly and efficiently across 
different cell lines. The different approaches to differentiate PSCs towards endothelial lineage 
could be categorized as: (1) embryoid body-mediated differentiation, (2) co-culture of hPSCs 
over murine stromal cells, and (3) culture as monolayers over extracellular matrix proteins 
like Matrigel and collagen IV with defined chemical conditions (Figure 12, Tables 1-3).  
 
Figure 12. Current methods for differentiation of pluripotent stem cells towards vascular lineage. 
The schematic illustrates the three major approaches for directing the differentiation of PSCs towards 
vascular lineage: Embryoid body (EB), co-culture and monolayer-based methods. EB-based approach 
range from a simple partial dissociation of PSC colonies followed by suspension culture that yields 
EBs of varying sizes to methods that could precisely control the size of the EBs (Spin-, microwell- and 
micropatterned-EBs). The EBs could be spontaneous differentiated (Sp. Diffrn.) or differentiated under 
the influence of various growth factor combinations (GFs) to yield vascular cells or vascular 
progenitors. Alternatively the PSCs could be differentiated over stromal cell feeder layers like OP9 or 
ECMs like Matrigel, collagen IV to direct the differentiation towards vascular lineage. Source: 
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Serum CD31+ FACS  
(13-15d) 
~2% Gelatin; EM  
(+ Serum) 
Expression of CD31, CD34, 
VEGFR2, VE-Cad, N-Cad, vWF; 
Ac-LDL uptake; MTF.  
















Serum + BPE + 
VEGF 
Expression of CD31, CD34, VE-
Cad, vWF, eNOS, endothelin, 









EB outgrowth EM (+Serum) - Mechanical 
isolation and 
FACS: vWF+ 
- Gelatin; EM  
(+ Serum) 
Expression of CD31, VE-Cad, 
vWF, Tie2, VEGFR2; Ac-LDL 
uptake, MTF. 
- (Cho et al., 






























SFM; BMP4 + 
VEGF + SCF + 
thrompbopoieti






- - Fibronectin; EM 
(+Serum) 
Expression of CD31, VE-Cad, 





(Lu et al., 











CD133+ FACS  
(7-21d) 
~35-50% Gelatin; EM  
(+ Serum) 
Expression of CD31, VE-Cad, 
vWF 









SFM; BMP4 + 
bFGF + VEGF 







? Matrigel; SFM + 
VEGF + bFGF + 
DKK1 
Expression of CD31, VE-Cad; 

























Inducers for EC 
differentiation 
from Progenitors 











BMP4 + VEGF 






~15-40% Fibronectin; EM 
(+Serum) 




(Park et al., 
2013; Zambidis 
















Serum + BPE + 
VEGF 
Expression of CD31, CD34, 
VE-Cad; Ac-LDL uptake, 
MTF, wound healing, 
migration assay, activation by 
TNFα. 
















? MEF feeders; B27 
medium 
Expression of CD31 Cardiomyocytes
, SMCs 






Collagen I gel 
EM with KO 







~3-7% Fibronectin; EM 
+ VEGF  
(+ Serum) 
Expression of CD31, VE-
Cad, vWF; Ac-LDL uptake, 
MTF. 
- (Li et al., 2011; 









- No sorting - Gelatin; EM 
(+ Serum) 
Expression of CD31, VE-
Cad, vWF, eNOS; Ac-LDL 
uptake, MTF  






EM (+ Serum) CD31+ FACS 
(12d) 
~10% Gelatin; EM 
(+ Serum) 
Expression of CD31, VE-
Cad, vWF; Ac-LDL uptake, 
MTF 
















30-40% Gelatin; EM 
(+ Serum) + 
VEGF 
Expression of CD34, CD31, 
VE-Cad, Endoglin, NRP1; 
Ac-LDL uptake, MTF 





















Inducers for EC 
differentiation 
from Progenitors 

















~10% Gelatin; EM + 
VEGF (+ Serum) 
Expression of CD31, CD34, 
VE-Cad, vWF; Ac-LDL 
uptake, MTF. 
SMCs (Chen et al., 
2007b; Ferreira 
et al., 2007; 














~8% Gelatin; EM 
(+ Serum) 
Expression of CD31, CD34, 
VE-Cad, VEGFR2, vWF, 
Ulex, eNOS; Ac-LDL 
uptake; activation by TNFα, 
MTF. 
- (Nourse et al., 
2010) 
hiPSCs EB outgrowth 
+ Cytokines  
+ Feeders 
MEF feeders; 






~6% B27+ VEGF + 
Ascorbic acid 
Expression of CD31 Cardiomyocytes
, SMCs 























~2% Gelatin; EM 
(+ Serum) 
Expression of CD31, VE-Cad - (James et al., 
2010) 






CD31+ FACS  
(14d) 
5-20% Gelatin; EM 
(+ Serum) 
Expression of CD31, VE-
Cad, eNOS, vWF; Ac-LDL 
uptake; chemotaxis, MTF. 
-  (Huang et al., 
2013; Rufaihah 






BMP4 + Serum 
CD31+ FACS  
(12d) 
~20% Gelatin; EM 
(+ Serum) 
Expression of CD31, Ac-
LDL uptake; MTF; 
Angiocrine secretion (Ang1, 
VEGF) 





















Inducers for EC 
differentiation 
from Progenitors 















12%/ 2% Gelatin; EM 
(+ Serum) 
Expression of CD31, CD34, 
VE-Cad, VEGFR2, vWF, 
Ulex; Ac-LDL uptake; MTF. 










~3-8% Gelatin; EM 
(+ Serum) 
Expression of CD31; Ac-
LDL uptake. 


















6-70% Gelatin; EM 
(+ Serum) 
Expression of CD31, VE-
Cad, eNOS, vWF; Ac-LDL 
uptake; MTF. 
- (White et al., 
2013) 









CD31+ FACS  
(14d) 
5-20% Gelatin; EM 
(+ Serum) 
Expression of CD31, VE-
Cad, eNOS, vWF; Ac-LDL 
uptake; MTF. 
Expression of arterial/ 
venous/ lymphatic markers 






































Inducers for EC 
differentiation 
from Progenitors 












~5-20% Fibronectin; EM 
(+Serum) 
Expression of CD31, VE-
Cad, VEGFR2, 
thrombomodulin, eNOS; Ac-
LDL uptake, activation by 























~45% Fibronectin; CDM 
+ VEGF 
Expression of CD31, VE-
Cad, eNOS, Tie2, CD133, E-
Cad, CD105, vWF; Ac-LDL 




(Costa et al., 
2013) 
 
Notes: BPE: Bovine pituitary extract. CDM: animal component-free, chemically defined medium. DM: minimum essential medium + FBS. EM: standard 
endothelial media containing serum (2-5%), VEGF, bFGF and EGF. FACS: flow cytometry assisted cell sorting. KO serum: Knockout serum. MACS: 







Table  2. Differentiation of human PSCs to endothelial progenitors and ECs using co-culture-based approach. 












Inducers for EC 
differentiation 
from Progenitors 














~10-20% Gelatin; EM 
(+ Serum) 
Expression of CD31, VE-Cad; 
Ac-LDL uptake; MTF 
Hematopoietic 
cells 














~10-15% Collagen IV, 
EM+VEGF 
(+ Serum) 
Expression of CD31, VE-Cad, 
CD34, eNOS; angiocrine 
secretion 
SMCs (Oyamada et 
al., 2008; 
Sone et al., 


























Expression of CD31, VE-Cad; 







(Choi et al., 















15-20% Fibronectin; EM 
(+ Serum) 
Expression of CD31, VE-Cad; 
Ac-LDL uptake; MTF 
Hematopoietic 
cells 











~10% Fibronectin; EM 
(+ Serum) 
Expression of CD31, CD34, 
VE-Cad, CD146, VEGFR2, 
eNOS, Tie2, Lectins; Ac-LDL 
uptake; MTF; response to 
calcium signaling agonists 
SMCs (Hill et al., 
2010; Xiong 
et al., 2011) 
hESCs  
(H1, H9) 




CD34+, CD31+ MACS/ FACS 
(d10-12) 
~15-20% Collagen-I; SFM 
+ VEGF 
Expression of CD31, VE-cad, 
vWF, VEGF, VEGFR2, EphB4, 
ephrinB2 






Table  2. Differentiation of human PSCs to endothelial progenitors and ECs using co-culture-based approach. (Continued-1) 












Inducers for EC 
differentiation 
from Progenitors 
















Collagen IV; EM 
+ VEGF 
(+Serum) 
Expression of CD31, CD34, 
VE-Cad, CD105, VEGFR2; 
Ac-LDL uptake; MTF 
SMCs (Marchand et 
al., 2013) 
 
Notes: EM: standard endothelial media containing serum (2-5%), VEGF, bFGF and EGF. FACS: flow cytometry assisted cell sorting. MACS: magnetic 







Table  3. Differentiation of human PSCs to endothelial progenitors and ECs using 2D ECM-based approach. 












Inducers for EC 
differentiation 
from Progenitors 






Collagen IV Serum - Mechanical-
40µm strainer 
(6d) 
- Collagen IV; 
DM+VEGF 
(+Serum) 
Expression of CD31, CD34, 
Tie2, GATA2, AC133, vWF; 
Ac-LDL uptake; Matrigel 
sprouting 
SMCs (Gerecht-Nir 




Collagen IV Serum + VEGF 








~45% Collagen IV; EM 
(+Serum) 
Expression of CD31, GATA2, 
eNOS, Flk1; Ac-LDL uptake; 
MTF. 





Fibronectin EM CD31+ CD105+ 
(CD34+, 
VEGFR2+) 
 No isolation 
(21d) 
~60% - Expression of CD31, VE-Cad; 
Ac-LDL uptake; MTF, wound 
healing, angiocrine secretion. 
- (Howard et 
al., 2013; 





Matrigel KO serum + 
PD98059 + 








~10-25% EM + VEGF + 
bFGF (+Serum) 
Expression of CD31, VE-Cad, 
Ang2, VEGFR2, vWF; Ac-
















~20% Collagen I; 
SFM+VEGF 
Expression of VE-Cad; Ac-
LDL uptake; MTF. 





Fibronectin EM (+ Serum; 
GMP grade)/ 
SFM + VEGF + 







~35-70% Matrigel; EM 
(GMP grade) 











~50% Collagen IV; 
EM+VEGF 
(+Serum) 
Expression of CD31, CD34, 
VE-Cad, vWF; Ac-LDL uptake; 
MTF. 
SMCs (Tan et al., 
2013a) 









~3% Collagen I; 
EM+VEGF + 
bFGF (+Serum) 
Expression of CD31, VE-Cad, 
vWF; Ac-LDL uptake; MTF. 





2.3.1. Embryoid body-mediated differentiation to endothelial/ vascular lineage 
When colonies of PSCs are suspended in hanging drop cultures or in ultra-low attachment 
plates, they form cell aggregates/ spheroids with mesodermal cells sandwiched between 
ectoderm-like cells in the core, and endodermal cells on the outer layer of the spheroids 
(Mummery et al., 2012). As these cell spheroids exhibit similarity to early postimplantation 
embryos and hence are termed as embryoid bodies (EBs). The cells in the EBs generally 
differentiate to progenies of all the three germ layers (Trounson, 2006). The pioneering study 
of EB differentiation of hESCs to endothelial cells reported isolation of CD31
+
 cells after 13 
days of differentiation; and demonstrated the expression of EC markers (CD34, CD31, VE-
CAD, VEGFR2) and formation of tube-like structures over Matrigel (Levenberg et al., 2002). 









 expression after differentiating EBs for 10 days 
(Wang et al., 2004). These endothelial progenitors were demonstrated to differentiate to 
mature endothelial phenotype after 7 days of culture under endothelial conditions. After these 
initial reports, several studies have demonstrated the spontaneous differentiation of hESCs 
through EB formation towards endothelial progenitors and ECs (Chen et al., 2007a; Cho et 
al., 2007; Ferreira et al., 2007; Levenberg et al., 2010; Li et al., 2008; Lu et al., 2007). 
However, these protocols suffer from low differentiation efficiency (ranging from 1-3% for 
ECs and ~10% for progenitors) and reproducibility. Low efficiency and reproducibility of 
these early differentiation protocols could be due to various reasons, that include 
heterogeneous sizes of EBs, presence of undefined components like serum, and differences in 
the conditions used for hESC culture. Hence, subsequent studies focused on improving the 
efficiency by inclusion of specific growth factors, transduction with angiogenic factors, 
elimination of serum in the differentiation milieu and/or generation of EBs of uniform and 
defined sizes.  
2.3.2. Optimization of media and growth factor conditions for EB-based differentiation 
Though spontaneous differentiation occurs within EBs, the culture conditions also play an 
important role in directing differentiation. To address the role of culture conditions, and to 
address the issues related with efficiency and reproducibility of EB-based differentiation 
protocols the use of serum-free media and mesodermal and/or vascular lineage inducing 
factors like bFGF, BMP4 and VEGF were investigated (James et al., 2010; Nakahara et al., 
2009; Rufaihah et al., 2007; Saeki et al., 2008). Culture of EBs in the presence of VEGF for 2 
weeks, was reported to express higher levels of endothelial markers compared to conditions 
lacking VEGF (Nourse et al., 2010). Goldman et al., demonstrated boost of BMP4 in early 




Similarly, inhibition of TGFβ was shown to increase the yield of endothelial cells (James et 
al., 2010).  
Protocols were developed using a variety of serum-free media that includes commercially 
available media like Stemdiff APEL (Stem Cell Technologies), Aggrewell media (Stem Cell 
Technologies), and StemPro-34 (Invitrogen). Stemdiff APEL medium requires a special 
mention as it is a chemically-defined media that is free of animal or human-derived products. 
APEL is an acronym for Albumin, Polyvinyl alcohol, Essential Lipids (Ng et al., 2008). This 
medium replaces animal and human derived proteins with synthetic chemicals and 
recombinant human proteins (albumin, insulin and transferrin). Because of the absence of 
undefined factors, this media could be used to assess the role of exogenously added growth 
factors and aid in the precise control of the differentiation microenvironment. Hence, using 
serum-free EB differentiation conditions and sequential application of specific growth factors 
and small molecules seem to aid in improved yield of vascular progenitors and ECs. 
2.3.3. Controlling the size of EBs 
To control the heterogeneity in the size of EBs, various methods were developed that includes 
the generation of spin-EBs, microwell EBs and micropatterned EBs. To generate spin-EBs of 
uniform and defined sizes, defined numbers of dissociated hESCs were seeded onto ultra-low 
attachment multiwell plates (e.g., Aggrewell Plates, Stem Cell Technologies) and centrifuged 
to aid the aggregation of dissociated hESCs into aggregates of uniform size (Burridge et al., 
2007; Ng et al., 2005b; Ungrin et al., 2008). The size of the EBs could be precisely controlled 
by varying the number of input cells in each well. Using the spin-EB approach, it was 
demonstrated that human EBs of 250-300µm in size are optimal for cardiogenic 
differentiation (Ungrin et al., 2008). While using mouse EBs, it has been demonstrated that 
smaller EBs (~150µm) favored endothelial lineage and larger EBs (~450µm) promoted 
cardiac differentiation (Hwang et al., 2009). Similarly, methods were developed to culture 
ESC colonies of defined sizes by using microwells/ micropatterns of defined size (Bauwens et 
al., 2008; Khademhosseini et al., 2006; Mohr et al., 2006; Mohr et al., 2010). These 
microwell/ micropattern cultured hESCs generated EBs of uniform and defined size 
depending on the size of the microwell.  
2.3.4. Co-culture mediated differentiation to endothelial/ vascular lineage 
Though various strategies to address the differentiation efficiency and variability of EB-based 
protocols have been reported, EB formation results in differentiation to all three germ layers. 
To circumvent the use of EB-based differentiation protocols, alternative models were 




promote vascular development. The murine feeder cells used for vascular induction include 
stromal cells (OP9, S17, MS-5, and M2-10B4) (Choi et al., 2009b; Hill et al., 2010; Oyamada 
et al., 2008; Sone et al., 2007; Vodyanik et al., 2005; Vodyanik and Slukvin, 2007; Yamahara 
et al., 2008), mouse embryonic fibroblasts (MEFs) (Wang et al., 2007) or mouse ECs 
(Kaufman et al., 2001). Among the various murine feeders, OP9 bone marrow stromal cells 
have been utilized most commonly. The use of OP9 stromal cell co-cultures for hematopoietic 
and endothelial cells from hESCs and hPSCs have been extensively characterized by 
Vodyanik and Slukvin (Choi et al., 2009b; Vodyanik et al., 2005; Vodyanik and Slukvin, 
2007). OP9 feeder layer system results in ~20% cells with CD34
+
 expression (Choi et al., 





 expression (Sone et al., 2007) capable of differentiation to ECs and 
vSMCs . Other studies using S17, M2-10B4 stromal cells, or MEFs as feeders have reported a 
yield of 5-10% CD34
+
 cells after 10-15 days of differentiation (Hill et al., 2010; Wang et al., 
2007). Towards avoiding the use of murine feeders and serum, Bai et al., used human foreskin 
derived fibroblasts (Hs27) as feeders in a serum-free medium and demonstrated the role of 




 cells) from hESCs(Bai et al., 
2010). They demonstrated that BMP4 supplementation at early stages promotes the induction 
of vascular progenitors, while TGFβ suppressed the induction potential of BMP4. Using Hs27 






Though the co-culture method eliminates the need for EB-based differentiation, it only 
enables production of not more than 20% vascular progenitors (CD34
+
 cells). Additionally, 
the presence of murine feeders is associated with the inclusion of undefined, animal-derived 
products and limits the ability to tune the culture milieu.  
2.3.5. Monolayer differentiation (feeder-free) to endothelial/ vascular lineage 
Differentiation protocols involving EB- and co-culture-based methods have aided in 
understanding the early stages of vascular commitment of hPSCs and the role of various 
growth factor combinations. However, significant scientific obstacles need to be resolved in 
terms of developing efficient differentiation strategies and removal animal-derived products 
in the culture milieu. Feeder-free differentiation of hPSCs is an attractive alternative to other 
differentiation strategies. In the monolayer differentiation strategy, the monolayer of hPSCs 
lacks the complex diffusion barriers present in EBs and the feeder cells present in co-culture 
model. Hence, theoretically it provides a platform to readily control the application of growth 




could be directly differentiated without the necessity for additional steps like replating and EB 
formation.  
Monolayer differentiation over collagen IV has been extensively studied using mouse ESCs 
(Blancas et al., 2008; Xiao et al., 2006; Yamashita et al., 2000; Zeng et al., 2006). A 
differentiation protocol using collagen IV as substrate was reported, wherein the hESCs were 
differentiated to ECs in the presence of VEGF and to vSMCs in the presence of PDGFbb 
(Gerecht-Nir et al., 2003). Similarly, Lagarkowa et al., developed a serum-free monolayer 





 cells with an efficiency of 50% after 6 days of differentiation (Lagarkova 
et al., 2008).  
Using Matrigel as substrate in serum-free conditions, a recent report indicates the 
differentiation of hESCs and iPSCs to CD34
+
 cells (~13-20%) by combined regulation of 
MEK/ERK and BMP4 signaling pathways (Park et al., 2010). Further the study demonstrates 
the role of MEK/ERK and BMP4 signaling in mesodermal induction; and bFGF and VEGF in 
induction of mesodermal cells to CD34
+
 cells capable of tri-lineage differentiation to ECs, 
vSMCs, and hematopoietic cells. Similarly, another study by Tan et al., reported the 




 cells) using Matrigel as 
substrate, chemically defined medium (Stemdiff APEL) and sequential modulation of Wnt/β-
catenin, BMP4 and VEGF signaling pathways (Tan et al., 2013a). Under chemically defined 





within a differentiation span of 4 days. 





 ECs (~80%) after 21 days of differentiation under serum-free conditions 
(Kane et al., 2010). Further they explored the role of microRNAs (miRs) in vascular 
differentiation. The same group also modified their protocol with the use of good 
manufacturing practice (GMP)-grade components in the differentiation system to obtain 
vascular cells under GMP-compliant conditions (Kaupisch et al., 2012). A recent report using 
mESCs, verified the role of various ECM substrates including gelatin, fibronectin, laminin, 
collagen I and collagen IV in endothelial differentiation using serum-free conditions (Blancas 
et al., 2011). Their results indicate the endothelial induction was maximum on fibronectin, 
while culture over gelatin, laminin and collagen I favored induction towards vSMCs.  Further, 




Using monolayer differentiation over various ECM substrates, many studies have indicated 
the ability to improve the endothelial differentiation ability, and the potential towards 






2.4. Vascular smooth muscle development and associated markers 
Formation of mature and functional microvascular network relies on the interaction between 
ECs and mural cells (Carmeliet and Conway, 2001; Jain, 2003). Mural cells are contractile 
and supportive cells that are associated with all vascular channels that play a role in vascular 
maturation, vascular remodeling and maintaining the vessel tone (Armulik et al., 2011). These 
mural cells found in the larger vessels (arteries and veins) are known as vascular smooth 
muscle cells (vSMCs) and those in association with the smaller channels (arterioles, 
capillaries, venules) are known as pericytes (Shepro and Morel, 1993). These vSMCs and/or 
pericytes share many morphological, molecular, and functional features and hence would be 
commonly referred to as vSMCs unless specified. 
In early embryogenesis and in adult life, newly formed endothelial vessels recruit mural cells 
resulting in a complex network of arteries, arterioles, capillaries, venules and veins (Coultas 
et al., 2005; Flamme et al., 1997) (Figure 11). Without the mural cells, the endothelial vessels 
undergo regression, and hence, the vSMCs play a crucial role in providing structural and 
functional support to the nascent endothelial vessels (Carmeliet, 2003; Jain, 2003) (Figure 
13).  
 
Figure 13. Blood vessel stabilization and regression. 
The nascent vessels formed either through vasculogenesis or angiogenesis is composed of ECs only. 
Under the influence of various factors secreted by ECs, mural cells (vSMCs/ pericytes) are recruited 
that cover the nascent endothelial tubes. The recruitment of mural cells and secretion of ECM stabilizes 
the endothelial tubes and also reduces the permeability of these vessels. On the other hand, without 
mural cell recruitment, the endothelial tubes remain nascent, fragile and leaky leading to rupture and 
bleeding which leads to reduced blood flow and vessel regression. Source: Adapted with permission 





vSMCs are heterogeneous group of cells derived from diverse embryological origins that 
include lateral plate mesoderm (secondary heart field, splanchnic mesoderm), paraxial 
mesoderm (somites) and neural crest (Majesky, 2007) (Figure 14, 15). Different vessels or 
different segments of the same vessel have been found to contain vSMCs of diverse 
embryonic origin (Majesky, 2007). More interestingly, the demarcation between the vSMCs 
of diverse origin is often sharp with little or no intermixing (Majesky, 2003). Additionally, the 
vSMCs from different origins exhibit lineage-specific response to the same stimulus. For 
instance, SMCs derived from neural crest and mesoderm display different growth and 
transcriptional responses to the stimulation with morphogenetic factors such as TGFβ1 
(Topouzis and Majesky, 1996). Hence, an understanding of the embryonic development of 
vSMCs and its precursors could aid in their differentiation from hESCs.  
 
Figure 14. Diverse developmental origin of vSMCs. 
The schematic illustrates the diverse origin of vSMCs. The vSMCs that line the aorta develop from 
three distinct embryonic lineages. The root of aorta (blue) develops from secondary heart field 
(derivative of lateral plate mesoderm). While the ascending aorta and the arch of aorta (red) develops 
from neural crest and the descending aorta (green) from paraxial mesoderm. The illustration also 
demonstrates the differentiation of human PSCs towards vSMCs of neuroectoderm (NE-SMC), lateral 
plate mesoderm (LM-SMC) and paraxial mesoderm (PM-SMC) origin and the associated differences in 
expression of MMP and TIMP. Source: Adapted with permission from (Cheung et al., 2012) 
 
2.4.1. Origin from lateral plate mesoderm 
Soon after gastrulation, the mesodermal cells segregate into paraxial, intermediate and lateral 
plate mesodermal subtypes. The lateral plate mesoderm gives rise to various derivatives that 
include somatic mesoderm and splanchnic mesoderm. The splanchnic mesoderm further gives 





Figure 15. Schematic illustration of diverse origin of vSMC development. 
The schematic illustrates the development of vSMCs from paraxial mesoderm, lateral plate mesoderm 
and neural crest-derived progenitors based on embryological and ESC differentiation studies. 
Derivatives of cardiac mesoderm, haemangioblast, somitic mesoderm and neural crest are indicated by 
red, blue, purple and green arrows respectively. Dotted arrows denote speculative differentiation 
pathways where there is still insufficient evidence at present. Source: Adapted with permission from 
(Cheung and Sinha, 2011) 
 
2.4.1.1. Proepicardial mesothelium 
Fate mapping studies have shown that vSMCs present in the walls of coronary arteries seem 
to arise from progenitors present in the proepicardial mesothelium (Majesky, 2007). Evidence 
suggests that precursors cells within the proepicardium give rise to epicardium, coronary 
endothelium and coronary SMCs (Mikawa and Gourdie, 1996). The coronary SMCs seem to 
arise through EMT of certain subset of epicardial cells. Mouse knock-in models have revealed 
that expression of Tbx18 and Wt1 marks the proepicardial progenitors that give rise to 
coronary SMCs (Cheung and Sinha, 2011). Similar to the proepicardial mesothelium evidence 
also suggest that vSMCs of the vasculature in the gut, lungs and liver, arise from mesothelial 




2.4.1.2. Secondary heart field   
Studies using lineage tracers in avian embryos and Isl1-cre transgenic mice have revealed the 
origin of vSMCs within the base of aorta and pulmonary trunk to a subset of progenitors 
within the secondary heart field (Moretti et al., 2006; Waldo et al., 2005). Islet-1 (Isl1) is a 
transcription factor expressed in the secondary heart field. vSMCs in the fetal heart co-
express Isl1 and smooth muscle myosin heavy chain (SM-MHC) suggesting the origin from 
secondary heart field (Moretti et al., 2006). Further using mouse ESCs they demonstrated that 
ESC-derived Isl1
+







were multipotent cardiac progenitors capable differentiating towards cardiac, endothelial and 
smooth muscle lineages. Similarly, certain other studies have shown that Nkx2.5
+
 population 




 subpopulation that gives rise to 




 subpopulation gives 
rise to ECs (Christoforou et al., 2008). Similarly, Bu et al., used a reporter gene targeting Isl1 
locus to track the differentiation of hESCs to Isl1
+
 cardiovascular progenitors resembling 
those derived from secondary heart field (Bu et al., 2009). These progenitors yielded 
subclones that gave rise to vSMCs, cardiomyocytes or ECs. Similarly, Cheung et al., 
demonstrated the differentiation of hESCs and iPSCs to vSMCs of lateral plate mesoderm 
origin (Cheung and Sinha, 2011). Using a 2 step induction consisting of treatment with bFGF, 
LY294002 and BMP4, followed by bFGF and BMP4, PSCs were differentiated towards 
VEGFR2 expressing lateral plate mesodermal cells which were further differentiated to 
vSMCs using PDGFbb and TGFβ1. These VEGFR2
+
 mesodermal cells also expressed Nkx2.5 
and Isl1 suggesting these progenitors could be similar to those from secondary heart field. 
2.4.1.3. Mesoangioblasts 
Mesoangioblasts refer to aorta-derived satellite-like cells that express markers related to 
myogenic and endothelial lineages and displays potential to differentiate into skeletal muscle, 
smooth muscle and other mesenchymal cell types (Majesky, 2007). However, the existence of 
such cell types is controversial. Evseenko et al., reported differentiation of hESCs  to 




 progenitors) in the 





 progenitors were shown to be unique in their ability to commit to all 
mesodermal lineages including hematopoietic, endothelial, smooth muscle, cardiomyocytes, 
and mesenchymal (bone, cartilage, fat, fibroblast) similar to mesoangioblasts (Figure 17).  
2.4.2. Origin from paraxial mesoderm (somitic mesoderm) 
The SMCs of the descending aorta seems to be “segmental” in terms of their origin, as they 




the paraxial mesoderm and consists of sclerotome, myotome and dermatome. The somite-
derived SMCs appear to arise from progenitors within the sclerotome. These paraxial 
mesoderm progenitors are reported to be marked by various markers that include MEOX1, 
PAX1, TCF1, TBX6, PDGFRα, and PDGFRβ (Cheung et al., 2012; Cheung and Sinha, 
2011). Cheung et al., demonstrated the differentiation of hESCs and iPSCs to vSMCs of 
paraxial mesoderm origin (Cheung and Sinha, 2011). Using a 2 step induction consisting of 
treatment with bFGF, LY294002 and BMP4, followed by bFGF and LY294002, PSCs were 
differentiated towards TCF15
+
 paraxial mesodermal cells which were further differentiated to 
vSMCs using PDGFbb and TGFβ1. These TCF15
+
 mesodermal cells also expressed paraxial 
mesoderm markers MEOX1 and PAX1 suggesting these progenitors could be similar to those 
from somatic mesoderm. Similarly, Tan et al., reported differentiation of hESCs to paraxial 
mesoderm progenitors marked by expression of PDGFRα that were negative for CD31 and 
VEGFR2 (Tan et al., 2013a). These PDGFRα+ paraxial mesoderm progenitors were 
demonstrated to differentiate towards vascular smooth muscle lineage. 
2.4.3. Origin from neural crest cells 
Lineage mapping studies in chick-quail and mouse embryos have demonstrated that migrating 
neural crest cells contribute to the origin of vSMCs in the ascending aorta, and the arterial 
branches arising from arch of aorta namely, ductus arteriosus, subclavian arteries, and 
common carotid arteries (Jiang et al., 2000; Majesky, 2007; Nakamura et al., 2006).  Most of 
the vSMCs/pericytes in the head and neck region seem to be derived from the neural crest 
(Armulik et al., 2011). 
Compared to vSMC derived from PSCs of mesodermal origin, protocols for directing PSCs to 
vSMCs through neural crest cells is poorly defined. A few protocols demonstrating the 
differentiation of human PSCs to neural crest stem cells have showed their smooth muscle 
differentiation potential. Lee et al., described a protocol to derive smooth muscle cells 
through a mesodermal phenotype derived from hESC-derived neural crest stem cells (Lee et 
al., 2007). In this protocol, hESCs were differentiated to CD75
+
 neural crest stem cells that 
were differentiated to CD73
+
 mesenchymal precursor cells, and subset of these cells 
expressing NCAM was sorted and differentiated to αSMA+ smooth muscle phenotype. Other 
protocols have demonstrated direct differentiation of vSMCs from hESCs-derived neural crest 
precursors. Colleoni et al., demonstrated the differentiation of hESC-derived neural crest 





cranial neural crest cells were demonstrated to differentiate towards smooth muscle 
phenotype in the presence of insulin-like growth factor-1 (IGF-1) and TGFβ1 (Zhou and 




neuroectoderm, lateral plate and paraxial mesoderm origin (Cheung and Sinha, 2011). Using 
bFGF and TGFβ inhibitor SB431542 PSCs were differentiated towards NESTIN and PAX6 
expressing neuroectodermal cells which were further differentiated to vSMCs using PDGFbb 
and TGFβ1.  
2.4.4. Origin through endothelial-mesenchymal transition 
Certain subsets of endocardial cells and ECs of the aorta and pulmonary arteries are reported 
to lose their endothelial phenotype and attain mesenchymal or smooth muscle-like 
characteristics through a process termed as endothelial-mesenchymal transition (EndMT) 
(Cheung and Sinha, 2011). Similar findings are reported in in-vitro ESC models wherein 
ESC-derived ECs are reported to transdifferentiate to vSMCs under the influence of PDGFbb 
and TGFβ1 (Hill et al., 2010; Marchetti et al., 2002). Many of the protocols demonstrate that 
hESC and iPSC-derived CD34
+
 cells differentiate to ECs and vSMCs depending on the 
culture conditions (Bai et al., 2010; Ferreira et al., 2007; Hill et al., 2010; Levenberg et al., 
2010; Li et al., 2009; Park et al., 2010). Though most of the CD34
+
 population that exhibit 
smooth muscle differentiation ability also co-express CD31 (an endothelial marker), bipotent 
differentiation potential has not been demonstrated at clonal level. EndMT of ECs to vSMCs 
has been reported to occur through SNAI1-mediated TGFβ1 signaling (Kokudo et al., 2008). 
In fact, such EndMT of ECs have been increasing implicated in cardiovascular pathologies 





2.5. In-vitro differentiation of PSCs to smooth muscle progenitors 
Various approaches to guide the differentiation of hESCs towards vSMC lineage involve one 
or combination of following methods: (1) EB-based differentiation (Ferreira et al., 2007; 
Levenberg et al., 2010; Vazao et al., 2011; Vo et al., 2010), (2) co-culture over murine/ 
human stromal cells like OP9 (Oyamada et al., 2008; Sone et al., 2007; Taura et al., 2009; 
Yamahara et al., 2008), MEFs (Bu et al., 2009), M2-10B4 (Hill et al., 2010), human foreskin 
fibroblasts (Lee et al., 2007), (3) culture of hESCs or iPSCs as monolayers over ECM 
proteins like Matrigel (Colleoni et al., 2010), and collagen IV (Oyamada et al., 2008; Sone et 
al., 2007; Taura et al., 2009; Wanjare et al., 2013; Xie et al., 2007; Yamahara et al., 2008), 
and/or (4) growth factor, cytokines or small molecule mediated differentiation in serum 
containing/ serum-free conditions (Bai et al., 2010; Cheung et al., 2012; Huang et al., 2006; 
Lee et al., 2007; Park et al., 2010; Tan et al., 2013a) (Figure 12, Table 4). These 
methodologies are similar to endothelial differentiation of PSCs discussed earlier.  
Most of these protocols rely on the use of serum and do not involve lineage-specific 
differentiation strategies (Huang et al., 2006; Vo et al., 2010; Xie et al., 2007). Certain other 







 cells) capable of differentiation towards endothelial and 
smooth muscle lineages (Bai et al., 2010; Ferreira et al., 2007; Hill et al., 2010; Levenberg et 







expressed by lateral mesodermal subsets, protocols utilizing these markers could be assumed 
to be yielding vSMCs of lateral plate mesoderm origin. vSMCs have also been demonstrated 
to be derived through a hESC/iPSC-derived mesenchymal stem cell (MSCs) intermediates 
(Bajpai et al., 2012; Guo et al., 2013). Recently, Cheung et al., reported differentiation of 
hPSCs to vSMCs through lateral plate mesoderm, paraxial mesoderm and neural crest 
progenitors (Cheung et al., 2012). Similarly, Tan et al., had recently demonstrated the 
differentiation of hESCs to vSMCs through paraxial mesoderm intermediates 
(PDGFRα+CD34-) (Tan et al., 2013a). Few protocols have demonstrated the derivation of 
vSMCs through neural crest progenitors (Colleoni et al., 2010; Lee et al., 2007; Zhou and 
Snead, 2008). Hence, the differentiation of PSCs towards vSMCs demonstrates the multi-
lineage origin of these cells observed during embryonic development. 
Various surface markers have been used to identify the progenitors that could be directed 
towards smooth muscle lineage. Various markers associated with these progenitors are 
highlighted by the schematic illustrations provided by Cheung and Sinha, Descamps and 
Emanueli, and Evseenko et al. (Cheung and Sinha, 2011; Descamps and Emanueli, 2012; 






Figure 16. Differentiation of ESCs towards vascular lineage progenitors and their associated 
markers. 
Schematic representation of cell surface marker expression during specification towards vascular 
lineage from ESCs. Source: Adapted with permission from (Descamps and Emanueli, 2012) 
 
 
Figure 17. Differentiation of hESCs towards mesenchymal and cardiovascular lineage 
progenitors and their associated markers. 
Schematic representation of the expression of various cell surface markers during specification towards 
mesenchymal and cardiovascular lineage from ESCs. The schema proposes a common progenitor for 
mesenchymal and cardiovascular lineages, and identifies the progenitor as mesenchymoangioblast. 





Table  4. Differentiation of human PSCs to vSMCs. 












Inducers for SMC 
differentiation 
from Progenitors 











- Collagen IV; DM 
+ PDGFbb 
(+Serum) 
Expression of αSMA, Calponin, 
MYH11. 
ECs (Gerecht-Nir 
et al., 2003; 
Vo et al., 
2010; Wanjare 





Serum + RA - - - - Expression of αSMA, SM22a, 
calponin, desmin, MYH11; 
contractility assays. 














~10% Gelatin; EM + 
PDGFbb (+ 
Serum) 
Expression of αSMA, Calponin, 
MYH11. 
ECs (Chen et al., 
2007b; 










- - - - Expression of αSMA, caldesmon, 
MYH11; Contractility assays. 





























(Lee et al., 
2010; Lee et 
al., 2007; 






Table  4. Differentiation of human PSCs to vSMCs. (Continued-1). 












Inducers for SMC 
differentiation 
from Progenitors 















~1% SFM + EGF + 
bFGF + NGF;  
+IGF-1 + TGFβ1 



















~10-15% Collagen IV, 
DM+ PDGFbb 
(+ Serum) 
Expression of αSMA, Calponin. ECs (Oyamada et 
al., 2008; 
Sone et al., 









SFM; BMP4 + 
bFGF + VEGF 







? Matrigel; SFM + 
VEGF + bFGF + 
DKK1 












SFM; BMP4 + 
VEGF + SCF + 
thrompbopoieti






- - Fibronectin; 
SMCM 
(+Serum) 
Expression of αSMA, Calponin, 
























Expression of smoothelin Cardiomyocyt
es, ECs 







KO serum + 
PD98059 + 








~10-25% EM + PDGFbb + 
bFGF (+Serum) 
Expression of αSMA, Calponin. ECs, 
Hematopoietic 
cells 






Table  4. Differentiation of human PSCs to vSMCs. (Continued-2). 












Inducers for SMC 
differentiation 
from Progenitors 







EB outgrowth Matrigel; SFM 

























~10% Fibronectin; DM 
(+ Serum) + 
PDGFbb + TGFβ1 
Expression of αSMA, SM22, 
Calponin, smoothelin, SM1; 
response to calcium signaling 
agonists 
SMCs (Hill et al., 
2010; Xiong 









CD34+, CD31+ MACS/ FACS 
(d10-12) 
~15-20% Collagen-I; SFM 
+ EGF + bFGF + 
PDGFbb  
Expression of αSMA, calponin, 
desmin, caldesmon. 
ECs (Bai et al., 
2010) 
hiPSCs EB outgrowth 
+ Cytokines  
+ Feeders 
MEF feeders; 






~6% B27+ VEGF + 
Ascorbic acid 
Expression of MYH11. Cardiomyocyt
es, ECs 




EB Serum CD34+ VEGFR2- MACS 
(10d) 
~2% Gelatin; SMC 
medium + 
PDGFbb + TGFβ1 
(+Serum) 
Expression of αSMA, calponin, 
SM22α, MYH11; contractility 
assays; angiocrines/ cytokine 
secretion assays. 














Expression of Calponin, 
PDGFRβ, NG2, CD146, CD90, 
CD73, Support tube formation by 
ECs. 






Table  4. Differentiation of human PSCs to vSMCs. (Continued-3). 












Inducers for SMC 
differentiation 
from Progenitors 




















- - Gelatin/ Collagen 
IV; SMC Medium 
+ TGFβ1 + 
heparin (+Serum) 
Expression of αSMA, Calponin, 
caldesmon, MYH11, SM22; 
Contractility assays.. 

















~90% SFM + PDGFbb + 
TGFβ1 
Expression of αSMA, Calponin, 
smoothelin, MYH11, SM22; 
contractility assays; Response to 
cytokines and calcium agonists; 
expression of ECM 




















SFM + PDGFbb + 
TGFβ1 
Expression of αSMA, Calponin, 
smoothelin, MYH11, SM22; 
contractility assays; Response to 
cytokines and calcium agonists; 
expression of ECM 

















SFM + PDGFbb + 
TGFβ1 
Expression of αSMA, Calponin, 
smoothelin, MYH11, SM22; 
contractility assays; Response to 
cytokines and calcium agonists; 
expression of ECM 
- (Cheung et al., 
2012) 
hESCs - - MSC 
intermediates 
- - SFM +  TGFβ1 Expression of αSMA, Calponin, 
caldesmon, MYH11, SM22α; 
Contractility assays; Support tube 
formation by ECs. 







Table  4. Differentiation of human PSCs to vSMCs. (Continued-4). 












Inducers for SMC 
differentiation 
from Progenitors 














CD34+ (CD31+/-) FACS  
(15d) 
~3-7% SMC medium + 
PDGFbb + TGFβ1 
(+ Serum) 
Expression of αSMA, SM22α; 
gene expression profiles. 

















~50% Collagen IV; 
EM+VEGF 
(+Serum) 
Expression of αSMA, calponin, 
SM22α, PDGFRβ. 

















SMC medium + 
PDGFbb + TGFβ1 
(+Serum) 
Expression of αSMA, calponin, 
PDGFRβ, CD105, caldesmon, 
NG2; Contractility studies. 
ECs (Marchand et 
al., 2013) 
 
Notes: CDM: animal component-free, chemically defined medium. DM: minimum essential medium + FBS. EM: standard endothelial media containing 
serum (2-5%), VEGF, bFGF and EGF. FACS: flow cytometry assisted cell sorting. KO serum: Knockout serum. MACS: magnetic assisted cell sorting. SFM: 




2.6. Isolation of endothelial/ vascular/ smooth muscle progenitors 
Strategies to isolate the endothelial and/or vascular progenitors from mixed differentiating 
PSC culture systems are needed to eliminate any contaminating PSCs and any other undesired 
cell populations, so as to minimize the risk of tumor formation and obtain a homogeneous cell 
population. A homogeneous cell population is also needed if global gene expression profiles 
of the differentiated cells needs to be investigated. Various cell isolations methods have been 
developed to purify the endothelial and/or vascular progenitors from differentiating cultures 
which include physical, genetic and non-genetic (antibody-mediated) methods. 
2.6.1. Physical methods  
Physical methods involve manually selecting the appropriate population of cells for further 
differentiation. These methods were commonly used in isolation of differentiating 
cardiomyocytes by manual dissection and dissociation of spontaneously contracting EBs. 
Similar methods have been reported to isolate vascualr progenitor populations. Gerecht et al., 
reported isolation of mesodermal cells using a 40µm strainer. They observed that the smaller 
cells that pass through the 40µm strainer had ability to differentiate to ECs and vSMCs upon 
induction with VEGF and PDGFbb respectively (Gerecht-Nir et al., 2003). Similarly, Kim et 
al., reported a 2-step enzymatic approach to isolate ECs from differentiating hESCs (Kim et 
al., 2007). Using gene expression, immunostaining and flow cytometry, they observed that the 
center regions of EB outgrowths had higher EC markers. The center regions of the EB 
outgrowths were detached from the outgrowth cells using trypsin followed by dissociation of 
the center region using cell dissociation buffer. Though the manual selection methods resulted 
in enrichment of ECs/ vSMCs, they were contaminated with other unknown cell populations 
and would require further purification steps. Additionally, these methods are labor intensive 
and subjective. 
2.6.2. Genetic (Promoter-based) isolation methods 
This method involves expression of a reporter gene under the control of a vascular lineage-
specific promoter. These methods have been used commonly in developmental biology to 
track the differentiation and migration of cells in-vivo. Marchetti et al., using plasmid 
containing enhanced green fluorescent protein (eGFP) or puromycin resistance gene under the 
control of Tie1 promoter, isolated ECs from differentiating mouse ESCs based on eGFP 
expression or resistance to puromycin (Marchetti et al., 2002). ECs were tracked in using the 
expression of Tie1 that is expressed by the cells of the endothelial lineage. Similarly Rufaihah 
et al., reported efficient differentiation of hESCs to ECs based on induction of VEGF 
expression using a adenoviral vector expressing VEGF gene (Rufaihah et al., 2007). James et 




containing eGFP and a genomic locus of human EC specific gene, VE-Cadherin (James et al., 
2010). This resulted in endothelial specific expression of eGFP. Using the VE-Cadherin 
mediated eGFP expression, they tracked the kinetics of emergence of endothelial cells within 
the differentiating hESCs EBs. Further, they used the VE-Cadherin mediated eGFP 
expression to screen a panel of small molecules that aid vascular development. Bu et al., used 
ISL1-β-geo bacterial artificial chromosome transgenic hESCs to genetically tag ISL1+ 
progenitors (Bu et al., 2009). Additionally, they employed a Cre/loxP system to mark ISL1 
expressing cells and their differentiated progeny to track the cells during the process of 
cardiac differentiation. Lineage tracking studies showed that ISL expressing cells 
differentiated into cells of the cardiovascular lineage including cardiomyocytes, ECs and 
vSMCs.  
The use of promoter-driven reporter genes enables identification, lineage tracking, and 
selection of vascular cells/ progenitors within the pool of differentiating ESCs and also 
tracking the cells in-vivo after transplantation in animal models. However, it is labor intensive 
and is associated with dangers related to genetic modification when these cells are intended 
for clinical therapy. 
2.6.3. Antibody-mediated selection methods 
Currently, the most commonly used method to isolate ECs, vSMCs or their progenitors rely 
on the use of antibodies against various cell surface antigens. Either fluorescent molecules or 
magnetic beads conjugated to antibodies against surface markers are used to isolate the cells 
using flow cytometry assisted cell sorting (FACS) or magnetic assisted cell sorting (MACS). 
Commonly used cell surface markers to identify endothelial or smooth muscle populations are 





2.7. Terminal differentiation to ECs and their characterization 
hESC and iPSC-derived endothelial progenitors are commonly sorted using MACS or FACS 
and differentiated to mature endothelial cells through culture in commercially available 
endothelial growth medium with or without additional supplementation with high 
concentrations of VEGF and bFGF. VEGF and bFGF are commonly used as endothelial 
inducing agents for their crucial role in angiogenesis (Cross and Claesson-Welsh, 2001). 
Commercially available endothelial growth medium typically consists of basal media and 
endothelial cytokine cocktail (2-5% FBS, VEGF, bFGF, EGF, IGF1, heparin, ascorbic acid, 
hydrocortisone and/or bovine pituitary extract). In addition to the growth medium and 
angiogenic growth factors, extracellular matrix also plays an important role. Commonly used 
matrix substrates for differentiation and culture of PSC-derived ECs include gelatin 
(Levenberg et al., 2010; Moon et al., 2011; Wang et al., 2007), fibronectin (Hill et al., 2010; 
Park et al., 2013; White et al., 2013) and collagen IV (Yamahara et al., 2008). 
2.7.1. Endothelial associated markers 
The PSC-derived ECs upon culture acquire a typical cobblestone morphology in-vitro. These 
ECs express CD31 (PECAM1), CD34, VEGFR2 (KDR/Flk1), VEGFR1 (Flt1), VE-Cadherin 
(CD144), endoglin (CD105), vascular cell adhesion protein (VCAM-1, CD106), endothelial 
nitric oxide synthase (eNOS), Tie-1, Tie-2 (tyrosine kinase with immunoglobulin-like and 
EGF-like domains) and vWF in a time-dependent manner (Kane et al., 2010). VEGFR2 and 
CD34 are regarded as the earliest marker to appear during the induction and development of 
endothelial phenotype (Vittet et al., 1996). On the other hand, VE-cadherin, Tie1 and vWF 
appear later and are regarded as markers of late or mature ECs. vWF and angiopoietin-2 are 
stored within cytoplasmic organelles that are visible through transmission electron 
microscopy as electron-dense striated structures termed as Wiebel-Palade bodies (Adams et 
al., 2013). These bodies also stain positive for vWF upon immune-gold staining. 
However, most of these markers are not endothelial specific and are expressed by other cells 
like hematopoietic stem cells. Hence, a panel of endothelial markers along with functional 
assays is needed to reliably characterize PSC-derived ECs. Additionally, functional assays 
indicate the maturation of ECs. 
2.7.2. In-vitro characterization of ECs 
In-vitro functional assays to characterize ECs include uptake of Dil (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindo-carbocyanine perchlorate) acetylated low density lipoprotein (Dil-Ac-LDL), 
ability to synthesize nitric oxide (NO), form tube-like structure over Matrigel (Glaser et al., 




activation with inflammatory cytokines like tumor necrosis factor-α (TNFα), ability to bind 
lectins, production of ECM, migratory response towards angiogenic signals and ability to 
regulate permeability (Glaser et al., 2011; Huang et al., 2013).  
2.7.2.1. Dil-Ac-LDL uptake assay 
Dil-Ac-LDL uptake assay relies on the phagocytosis of LDL molecules by endothelial cells. 
ECs lining the blood vessels take up LDL that is present in the bloodstream and plays a role 
in transport of lipoproteins and cholesterol (Glaser et al., 2011). LDL is phagocytized by other 
cells that include macrophages and vSMCs/ pericytes. However, the uptake of LDL is rapid in 
ECs and macrophages, and hence the assay relies on the ability of ECs to uptake Dil-Ac-LDL 
upon incubation for 4 hours (Voyta et al., 1984). Ability of hESC- and hiPSC-derived ECs to 
uptake Dil-Ac-LDL has been demonstrated by various reports (Bai et al., 2010; Levenberg et 
al., 2010; Park et al., 2010; Rufaihah et al., 2013a; Wang et al., 2007). 
2.7.2.2. Matrigel tube formation assay 
ECs and progenitors are well recognized in forming new blood vessels by the process of 
vasculogenesis and angiogenesis. Vasculogenesis is the formation of vascular networks de-
novo by ECs and progenitors, while angiogenesis is the formation of new vascular channels 
from existing vessels (Bai and Wang, 2008). The ability of ECs to forms cords and tube-like 
structures in-vitro upon culture over on a basement membrane matrix, Matrigel, derived from 
the Engelbreth-Holm-Swarm tumor. It is considered as a measure of vasculogenic and 
angiogenic potential of ECs (Glaser et al., 2011). Hence, Matrigel tube formation assay is one 
of the most commonly used assays to investigate angiogenesis and anti-angiogenesis 
(McGonigle and Shifrin, 2008). However, other cells like fibroblasts, MSCs also exhibit a 
response on Matrigel (Auerbach et al., 2003). The classic Matrigel tube formation assay 
involves seeding ECs directly over Matrigel in a 96/48/24 well tissue culture plate. However, 
the technique is limited by difficulty in imaging the vascular networks due to meniscus effect. 
To overcome this limitation, a novel slide/ 96 well plate angiogenesis product termed µ-
slide/plate angiogenesis (ibidi) is available, which uses a well within a well feature to produce 
a flat Matrigel interface resulting in a flat surface for imaging (Figure 18). 
The ability of hESC- and iPSC-derived ECs to form vascular tube-like structures has been 
demonstrated by various reports (Adams et al., 2013; Kane et al., 2010; Kurian et al., 2013; 
Sone et al., 2007; Tan et al., 2013a). Using Matrigel tube formation assay, the interactions 
between hESC-derived ECs and vSMCs have also been reported (Hill et al., 2010; Vo et al., 
2010). These studies have demonstrated the circumferential orientation of hESC-derived 




demonstrated the variation in tube length, tube thickness and branch points depending on the 
ratio of ECs to vSMCs. 
 
Figure 18. µ-slide angiogenesis (ibidi). 
µ-slide angiogenesis is a specialized slide with 15 wells. Cross-sectional view of each well shows the 
presence of two compartments within it. The smaller lower compartment holds the gel matrix, while 
the upper compartment holds the media. The specialized slide provides a flat gel surface for better 
visualization and photomicrography. Source: Adapted with permission from ibidi GmbH. 
 
2.7.2.3. NO and eNOS assay 
ECs regulate the blood flow and vascular tone through release of vasodilators (like NO, 
prostacyclin) and vasoconstrictors (like endothelin, platelet activating factor) (Glaser et al., 
2011). ECs among other cells synthesize NO by eNOS, and constitutively express NO and 
eNOS. Similar to primary ECs, hESC- and iPSCs-derived ECs constitutively express NO and 
eNOS (Wagner et al., 2010; White et al., 2013). eNOS expression has been reported to be 
absent in PSC-derived endothelial progenitors, while maturation of the progenitors to mature 
ECs was associated with marked cytoplasmic expression of eNOS (Kusuma et al., 2013). 
Costa et al., reported perinuclear localization of eNOS within golgi apparatus of hESC-
derived ECs when cultured under serum-free conditions, while transfer to serum-containing 
conditions resulted in a localization in the caveolae (Costa et al., 2013). 
2.7.2.4. Proinflammatory endothelial activation  
Inflammation is associated with recruitment of leukocytes to the site of inflammation. 
Leukocyte trafficking through the vessel wall involves the expression of various selectins, 
chemokines & integrins. In-vitro the endothelium could be activated with inflammatory 
cytokines like TNFα, IL1β, interferon-γ or microbial components like lipopolysaccharides 
(LPS). Activation of ECs leads to upregulation and expression of cell adhesion molecules like 




TNFα and LPS has been reported to induce the expression of adhesion molecules (E-selectin, 
ICAM1, VCAM-1) and secretion of proinflammatory cytokines (like monocyte chemotactic 
protein-1 (MCP1), IL8, RANTES) (Adams et al., 2013). 
2.7.2.5. ECM production by ECs 
Endothelial cells are separated from the vSMCs/ pericytes by a basement membrane that is 
composed of various ECM molecules that include collagen IV, laminin, fibronectin, entactin 
and heparin sulfate proteoglycans (Kusuma et al., 2012). Collagen IV is the most abundant 
form of ECM produced by ECs which aids in providing structural stability to the blood 
vessels (Anderson and Hinds, 2012; Glaser et al., 2011). Laminin especially, laminin-8 and -
10 isoforms are produced by the ECs, which play a role in maturation of vSMCs (Glaser et 
al., 2011).  
2.7.2.6. Wound healing assay 
Angiogenesis involves formation of new blood vessels from existing vascular channels. 
During the process of angiogenesis, the ECs sprout and migrate to angiogenic signals to form 
new blood vessels. Wound healing assay is one of various methods to assess migration of ECs 
in-vitro.  The assay involves creation of a wound by denuding a part of the endothelial 
monolayer, followed by observation of migration of the ECs into the wound/ denuded area 
over a period of time (Liang et al., 2007). These assays could also be used to study directional 
migration of cells in response to cellular, extracellular matrix and growth factors. The ability 
of hESC- and iPSC- derived ECs to migrate has been demonstrated using wound healing 
assays (Huang et al., 2013; Kane et al., 2010).  
2.7.2.7. Regulation of vascular permeability 
An important role of ECs is to maintain a tight dynamic barrier to regulate the transport of 
fluids, molecules and cells between the intraluminal and extraluminal compartments of the 
blood vessels. Monolayer of ECs are relatively impermeable to macromolecules (1-100kDa) 
with <1% flux (Glaser et al., 2011). To assess the barrier properties of ECs the flux of test 
compounds could be measured using electrical resistance across the monolayer of ECs termed 
as trans-endothelial electrical resistance (TEER). Alternatively, the permeation of 
fluorescently/ radioisotope labeled chemicals could be used to assess the movement of the 
chemicals across the endothelial monolayer. Adams et al., reported changes in permeability of 
human iPSC-derived ECs in response to histamine, VEGF, prostaglandin E2, spingosine-2-





2.7.2.8. Lectin binding 
The carbohydrates present on the surface of ECs act as ligands for various mammalian lectins. 
The L-fucose moieties present on endothelial surface bind to Ulex europaeus I (UEA-1) lectin 
and this is selective for all primate ECs (Gomez and Thorgeirsson, 1998). On the contrary, 
Griffonia simplicifoha lectin binds to ECs of murine origin and many other species except 
humans (Gomez and Thorgeirsson, 1998). Hill et al., demonstrated the binding of lectins 
Helix Pomatia, Griffonia simplicifolia and Ulex europaeus by hESC-derived ECs (Hill et al., 
2010).  
2.7.3. In-vivo characterization of ECs  
Therapeutic angiogenesis is a promising application of PSC-derived ECs for treatment of 
ischemia associated with peripheral arterial diseases, myocardial infarction, diabetic 
retinopathy and stroke. Most commonly hESC- and iPSC-derived ECs are assayed for their 
in-vivo functionality using Matrigel plug angiogenesis assay and hind limb ischemia model 
(Cho et al., 2007; Rufaihah et al., 2011; Yamahara et al., 2008). Other in-vivo functionality 
assays and therapeutic models include transplantation with various biomaterials, mouse 
ischemic retinal angiogenesis assay, incorporation into retinal vasculature of diabetic rats, 
myocardial ischemia model, stroke and vascularization in dermal wounds (Azhdari et al., 
2013; Kim et al., 2013; Kraehenbuehl et al., 2011; Levenberg et al., 2010; Li et al., 2009; Lu 
et al., 2007; Oyamada et al., 2008; Rufaihah et al., 2010; Wang et al., 2007).  
2.7.3.1. Matrigel plug angiogenesis assay 
Matrigel plug angiogenesis involves the injection of ECs with or without supporting stromal 
cells (vSMCs, fibroblasts, MSCs) encapsulated within Matrigel into subcutaneous depots of 
immunodeficient mice. Upon injection into the mice, the Matrigel undergoes gelation and 
forms a plug of extracellular matrix. Matrigel plug usually is harvested after 2 weeks for 
histological evaluation of blood vessel formation and integration with host circulation. hESC- 
and iPSC-derived ECs form human CD31
+
 positive capillaries with red blood cells within 
them, indicating the connectivity with host circulation (Ferreira et al., 2007; Rufaihah et al., 
2011). 
2.7.3.2. Hind limb ischemia model 
Murine hind limb ischemia model is a commonly used model to mimic peripheral arterial 
disease. The model involves induction of ischemia in one of the hind limbs through ligation 
of the femoral artery, followed by transplantation of the ECs into gastrocnemius muscle 
(Huang et al., 2009; Niiyama et al., 2009). Reperfusion of the ischemic hind limb through 




Doppler spectroscopy, bioluminescence imaging, and/or histology. The potential of hESC- 
and iPSC-derived ECs in association with mural cells to augment neovascularization and aid 
in reperfusion of the ischemic hind limbs have been demonstrated by various research groups 










2.8. Arterial-venous differentiation of endothelial cells 
The progenitors that give rise to endothelial cells form a primitive vascular plexus by the 
process of vasculogenesis. The endothelial progenitors (angioblasts) adjacent to the 
endodermal somites are directed towards arterial lineage and form the first artery (the dorsal 
aorta in zebrafish), while the endothelial progenitors adjacent to neural tube migrate dorsally 
and form the first vein (posterior cardinal vein in zebrafish) (Swift and Weinstein, 2009) 
(Figure 19). The angioblasts develop into arterial or venous ECs depending on the signals in 
the surrounding microenvironment. The plexus of arterial and venous ECs undergo a series of 
maturational events and give rise to functional blood vessels termed as arteries, arterioles, 
capillaries, venules and veins (Tan et al., 2013b). In general, the arteries arise from the heart 
and transport blood that is rich in oxygen to the peripheral tissues, while the veins terminate 
in the heart and transport oxygen-depleted blood from the peripheral tissues to the heart. The 
arteries are exposed to high hemodynamic forces, and hence are thick-walled with multiple 
layers of vSMCs. On the other hand, the veins are exposed to lower hemodynamic forces and 
are thin-walled with few layers of vSMCs. The veins also exhibit valves projecting into the 
lumen of the vascular channels to prevent the backflow of blood. Various phenotypic 
differences between arterial, venous and capillary ECs are highlighted in Figure 20. 
Two models have been proposed for the specification of arterial and venous identity. Atleast 
till late 1990s, the key factor involved in arterial-venous specification of ECs, was believed to 
be the exposure of ECs to blood flow and the accompanied mechanical forces (shear stress 
and pressure). Recent evidences however, show that the arterial-venous identity is specified 
well before the onset of circulation, leading to genetic or molecular-based mechanisms of 
specification.  
2.8.1. Mechanical determinants of arterial-venous identity 
As the arteries arise from the heart, they are exposed to significant hemodynamic forces shear 
stress and pressure. Due to the differences in flow speeds and lumen size, the various parts of 
the vascular bed is exposed to varying shear stress. The arteries and veins are exposed to 
varying blood pressure levels ranging from 100 mmHg in large arteries to 6-8 mmHg in large 
veins (Sato, 2013) (Figure 21). These large differences in the blood pressure between arteries 
and veins are found only in the adults, while in the embryonic vasculature the differences are 
significantly smaller in the range of 1-2 mmHg. Hence, the vascular channels adapt to 
differences in the hemodynamic forces by differences in their structure. The arteries are thick-






Figure 19. Role of endoderm and notochord in mammalian arterial-venous specification. 
VEGF secreted from endoderm results in de novo aggregation of angioblasts leading to formation of 
dorsal aorta and cardinal veins. In response to the Shh secreted by notochord, the developing somites 
(endoderm) secrete VEGF. The angioblasts in the immediately vicinity of somites are exposed to high 
concentrations of VEGF, resulting in commitment to arterial lineage and formation of dorsal aorta, 
while the angioblasts that are away from the somites and notochord commit towards venous phenotype 
resulting in formation of cardinal veins. Additionally, the notochord secretes BMP inhibitors (noggin 
and chordin) which results in an avascular midline zone. Source: Adapted with permission from 
(Coultas et al., 2005). 
 
Figure 20. ECs in arterial, venous and capillary systems. 
The illustration highlights the phenotypic differences among arterial, venous and capillary ECs. 




To investigate the role of hemodynamics in arterial-venous specification, “no-flow” models 
were developed. These “no-flow” in-vivo models indicate the downregulation of arterial 
markers in the arterial channels and no significant differences in the markers between arteries 
and veins (Sato, 2013). However, to understand whether the hemodynamic forces play a role 
in specification or in maintenance of arterial-venous identity needs further investigation.  
 
Figure 21. Differences in hemodynamic forces in various parts of the vascular system. 
The illustration represents the two types of hemodynamic forces, shear stress and blood pressure 
among various vascular beds. Shear stress is expressed as (dyn/cm2) and blood pressure as (mmHg). 
Source: Adapted with permission from (Sato, 2013) 
 
2.8.2. Genetic determinants of arterial-venous identity 
Investigations on the role of EphrinB2-EphB4 ligand receptor system in the development of 
nervous system by Wang et al., in 1998 showed that EphrinB2 was expressed only in the 
arterial system, and the expression of EphB4 was exactly complimentary to that of EphrinB2 
expression i.e., in the veins (Wang et al., 1998) (Figures 10 & 22). Additionally, this 
complimentary expression of EphrinB2 and EphB4 was found to be present even before the 
initiation of blood circulation (Adams et al., 1999; Wang et al., 1998). These findings lead to 
doubts on the mechanical specification theory of arterial-venous specification and further lead 
to rigorous molecular studies.  
Since the finding of complimentary expression of EphrinB2 and EphB4 within the arterial-
venous system, various arterial-venous markers have been identified. Arterial ECs are 




(Notch-1, Notch-4, Hey-1, Hey-2), Notch ligands (Delta-like 4 (Dll4), Jag-1 and Jag-2), 
neuropilin-1 (NRP1), chemokine receptor-4 (CXCR4), gap junction proteins (Connexin-37 
and Connexon-40); while the venous ECs express EphB4, COUP-TFII Lefty-1, Lefty-2, 
neuropilin-2 (NRP2) and apelin receptor (APJ receptor) (Aird, 2007b; Kume, 2010; Swift and 
Weinstein, 2009; Torres-Vazquez et al., 2003; Yamamizu and Yamashita, 2011). Most of the 
understanding about the molecular mechanisms of arterial-venous specification is based on 
studies in zebrafish and mice embryos, and a few studies using stem/progenitor cells. 
 
Figure 22. Pattern of EphrinB2 and EphB4 expression in the vascular system. 
(A) The schematic shows the distinct pattern of ephrinB2 and ephB4 expression in mouse embryo. The 
arterial system expresses ephrinB2, while the venous system EphB4 and both are co-expressed in the 
heart. (B) Formation of arterial-venous interaction in the yolk sac. (C) shows the cell-cell interactions 
between ECs (arterial, ea and venous, ev) and mesenchymal cells (m). Source: Adapted with permission 





2.8.2.1. Role of EphrinB2/EphB4 interaction in arterial-venous specification 
EphrinB2 and EphB4 were the first set of genes to be identified in the regulation of arterial-
venous specification of ECs. These genes encode for transmembrane proteins that belong to 
Eph-Ephrin subclass of tyrosine kinases. The Ephs represent the receptors and the Ephrins the 
ligand. Eph-Ephrin signaling occurs through cell-to-cell contact resulting in binding of the 
Ephrin ligand to the Eph receptors. The Eph-Ephrin signaling is bidirectional, wherein the 
forwards signaling represents Ephrin ligand to Eph receptor signaling, while reverse signaling 
represents Eph receptor to Ephrin ligand signaling.  
The role of molecular signals in arterial-venous specification was based on study by Wang et 
al., which showed that EphrinB2 was expressed only in the arterial system and EphB4 in the 
venous system (Wang et al., 1998). Additionally, this complimentary expression of EphrinB2 
and EphB4 was found to occur even before the initiation of blood circulation (Adams et al., 
1999; Wang et al., 1998). Though the expression of ephrinB2 is restricted to arterial system, 
mice knockouts for EphrinB2 exhibit defects in angiogenesis of both arterial and venous 
systems (Wang et al., 1998). Findings from ephrinB2 knockouts suggest that the reciprocal 
signaling between arterial and venous system is needed for the integrated development of 
both the systems. Though, the expression of ephrinB2 and EphB4 only labels the arterial and 
venous systems respectively, and they are not required for the arterial-venous specification of 
ECs during vasculogenesis. The various molecular pathways involved in the arterial-venous 
specification are discussed below and summarized in Figure 23. 
2.8.2.2. Role of VEGF in arterial-venous specification 
VEGF family of proteins plays a fundamental role in the vascular development through 
endothelial commitment, differentiation, proliferation, survival and migration. In mammals, 
VEGF family is composed of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth 
factor (PlGF) (Hirashima, 2009). VEGF-A acts through various receptor tyrosine kinases that 
include VEGFR2 (also known as flk1), VEGFR1 (also known as flt1), VEGFR3 (also known 
as flt4), and NRP1. VEGF-A exists as three isoforms; VEGF120, VEGF164 and VEGF188 in 
mice; and VEGF121, VEGF165 and VEGF185 in humans. Expression of the VEGF receptors and 
co-receptors also show differences in their expression patterns. The VEGFR1 and VEGFR2 
are expressed in all vascular ECs, VEGFR3 is mainly expressed in lymphatic ECs (but is an 
early marker for venous commitment), NRP1 in arterial ECs, and NRP2 in venous and 
lymphatic ECs (Herzog et al., 2001; Swift and Weinstein, 2009).  
Selective expression of single isoforms of VEGF in transgenic mice, showed impaired arterial 




displayed normal arterial development (Ng et al., 2001). Similarly, loss of VEGF164 
expression was associated with downregulation of EphrinB2 expression (Ng et al., 2001). 
These findings suggest the role of VEGF164 in arterial differentiation and VEGF188 in venous 
development.  
 
Figure 23. Signaling pathways involved in endothelial phenotype specification. 
(a) Shh signaling induces VEGF which interacts with VEGFR2 and NRP1 resulting in activation of 
Notch-Dll4 downstream pathways to activate expression of arterial phenotype. (b) In contrast, in 
venous fated ECs, the presence of COUP-TFII suppress the expression of NRP1 and Notch-Dll4 
pathways resulting in upregulation of genes related to venous phenotype. (c) Transcription factor 
Sox18 in co-operation with COUP-TFII activates the expression of Prox1 resulting in lymphatic 
endothelial phenotype. Source: Adapted with permission from (Tan et al., 2013b). 
 
In Zebrafish embryos, injection of morpholinos targeted against vegf results in significant 
downregulation of arterial ephrinB2 expression and arterial commitment; and upregulation of 
venous marker vegfr3 (Swift and Weinstein, 2009).  Similarly, sonic hedgehog (shh) deficient 
embryos display strong downregulation of arterial ephrinB2 expression that could be rescued 
by injection of vegf mRNA (Atkins et al., 2011). vegf expression by somites is dependent on 
shh signals form the notochord (Swift and Weinstein, 2009). The somites in shh
-/-
 embryos or 
cyclopamine-treated embryos fail to express vegf that could be rescued by injection of shh 
mRNA (Lawson et al., 2002). However, injection of vegf mRNA does not rescue the arterial 
differentiation observed in Notch-deficient embryos. Instead the injection of Notch 
intracellular domain (NICD) into vegf morpholino-injected embryos, rescues the ephrinB2 
expression and arterial differentiation (Lawson et al., 2002). These results indicate that VEGF 




hierarchical manner of arterial differentiation involves the expression of Shh by the notochord 
inducing the expression of vegf in the adjacent somite, which in turn induces Notch signaling 
in the adjacent ECs resulting in arterial specification and suppression of venous fate (Swift 
and Weinstein, 2009) (Figures 19 & 23).  
The diffusion of VEGF expressed by somites towards the developing vascular channels 
results in a VEGF gradient. In zebrafish embryos, the vascular channel developing into dorsal 
aorta is exposed to higher levels of VEGF, while the blood vessel developing into posterior 
cardinal vein is exposed to lower levels of VEGF (Atkins et al., 2011) (Figure 19). This 
indicates the gradient effect of VEGF in arterial-venous specification of ECs, with higher 
levels favoring arterial fate. Binding of VEGF to its receptors like VEGFR2 results in 
activation of several targets that include phospholipase Cγ1 (PLCγ1), which in turn activates 
mitogen-activated protein kinase (MEK) and extracellular signal-regulated kinase (ERK) 
signaling pathways (Atkins et al., 2011; Swift and Weinstein, 2009). Further, in zebrafish 
embryos the activated form of ERK (phosphorylated form) is preferentially expressed in 
angioblasts fated towards arterial phenotype in early stages of vascular development; and is 
localized to arterial ECs in later stages of vascular development (Swift and Weinstein, 2009).  
2.8.2.3. Role of Notch in arterial-venous specification 
Notch family is composed of 4 receptors (Notch1-4) and 6 ligands (Dll1-4, Jag1-2). 
Activation of Notch results in cleavage of the NICD which translocates to the nucleus where 
it upregulates various target genes.  In mice, the ephrinB2
+
 arterial ECs specifically express 
Notch1, Notch4, Dll4, Jag1, and Jag2 (Swift and Weinstein, 2009). Mice lacking Notch1 
display defects in vascular remodeling (especially axial vessels), reduced size of dorsal aorta 
and embryonic lethality, while Notch4 knockouts display no major vascular manifestations. 
However, Notch1/Notch4 double knockout mice show abnormal development of axial vessels 
that is severe than Notch1 mutants (Krebs et al., 2000). In zebrafish embryos, inhibition of 
Notch signaling by injection of a dominant negative Su(H) (suppressor of hairless) leads to 
downregulation of arterial markers (ephrinB2) and corresponding ectopic expression of 
venous markers (ephB4 and flt4) (Lawson et al., 2001). On the other hand, forced expression 
of NICD results in downregulation of venous markers (Lawson et al., 2001). Similarly, mice 
heterozygous & homozygous for Dll4 exhibit severe vascular malformations, downregulation 
of arterial markers (ephrinB2, Connexin 37, Connexin 40) and upregulation of ephB4 
expression indicative of failure in arterial specification (Duarte et al., 2004). All these 
findings indicate the role of Notch signaling in induction of arterial specification and 




2.8.2.4. Role of Hedgehog in arterial-venous specification 
Hedgehog (Hh) belongs to a family of secreted morphogens that includes sonic hedgehog 
(shh) and Indian hedgehog (ihh). Hh signaling occurs through interaction with a 
transmembrane receptor (Patched) that leads to patched-mediated inhibition of a 
transmembrane protein called Smoothened (smo) which leads to activation of target genes 
(Swift and Weinstein, 2009). The developing endoderm (proximal to the developing vascular 
network) expresses shh and the receptor for shh signal (patched-1) is expressed in ECs (Swift 
and Weinstein, 2009). In mice, shh induces expression of vegf and angiopoietins which in turn 
induces the development of coronary vessels (Pola et al., 2001). Inhibition of shh signaling 
using cyclopamine in mouse embryos results in underdeveloped vessels in the yolk sac and 
downregulation of vegf and Notch1 (Pola et al., 2001). Further, mouse embryos lacking shh or 
those treated with cyclopamine, exhibit development of a single large axial vessel instead of a 
pair and the vessel shows expression of venous markers instead of arterial markers (Lawson 
et al., 2002). Similarly, zebrafish embryos injected with vegf anti-sense morpholinos exhibit 
downregulation of arterial specific markers like ephrinB2 (Lawson et al., 2002). On the 
otherhand, injection of vegf mRNA into zebrafish embryos that lacks activity of shh, rescues 
arterial specification (Lawson et al., 2002).  These findings indicate that shh acts upstream of 
vegf and Notch in regulating in arterial specification (Figure 23). 
2.8.2.5. Role of COUP-TFII in arterial-venous specification 
Chicken ovalbumin upstream-transcription factor II (COUP-TFII) is an orphan nuclear 
receptor specifically expressed in venous ECs and is a genetic determinant of venous 
specification (Atkins et al., 2011). Unlike arterial specification, the molecular mechanisms 
into venous specification are poorly understood. Exposure to low concentrations of VEGF 
seems to be a negative regulator of arterial specification. Phosphatidylinosito-3-kinase/Akt 
pathway and retinoic acid is hypothesized to induce COUP-TFII which leads suppression of 
Notch and Nrp1 signaling, expression of EphB4, Nrp2, Vegfr3 and induction of a venous 
phenotype (You et al., 2005). In endothelial specific COUP-TFII knockout mice, the vessels 
are thin and dilated; and the venous ECs express arterial markers (Nrp1, Jag1, Notch1, Hey1, 
and EphrinB2) suggesting suppression of Notch1 and Nrp1 signaling (You et al., 2005). 
Further, endothelial specific overexpression of COUP-TFII in mouse embryos results in 
downregulation of Jag1 in aortic ECs (You et al., 2005).  Hence, it seems that COUP-TFII 
expression in venous fated ECs leads to suppression of Notch and Nrp1 signaling, and hence 




2.8.3. Arterial-venous differentiation of ECs derived from PSCs 
Subculture of mouse ESC-derived Vegfr2+ mesodermal cells on collagen IV coated plates in 
the presence of high concentrations of VEGF (50ng/ml) yielded ECs with upregulation of 
arterial markers like Dll4, Notch4, EphrinB2, and Nrp1; while in the presence of low 
concentrations of VEGF (10ng/ml) the ECs displayed upregulation of venous marker COUP-
TFII (Lanner et al., 2007). Further inhibition of Notch signaling resulted in downregulation of 
arterial markers and upregulation of venous markers implying the role of Notch signaling in 
arterialization of ECs. Similarly, directed differentiation of mouse ESCs and iPSCs-derived 
Vegfr2+ mesodermal cells to arterial, venous and lymphatic ECs by modulation of the 
concentration VEGF and cAMP was reported (Narazaki et al., 2008). However, in their study 
high concentration of VEGF (50-100ng/ml) resulted in venous ECs, and supplementation 
with cAMP in addition to VEGF was needed for arterial differentiation (Narazaki et al., 2008; 
Yurugi-Kobayashi et al., 2006). Aranguren et al., reported high concentration of VEGF 
(100ng/ml) induced arterial differentiation of human bone marrow-derived multipotent adult 
progenitor cells (Aranguren et al., 2007). Further, the arterial induction was reported to be 
enhanced by supplementation with Dll4 and Shh, while blockade of Notch and/or Shh led to 
attenuation of arterial differentiation and upregulation of venous markers similar to data from 
animal studies (Aranguren et al., 2007). Similarly, Rufaihah et al., demonstrated high 
concentration of VEGF (50ng/ml) in the presence of cAMP aided differentiation of human 
iPSCs-derived EBs towards ECs of arterial phenotype; and low concentration of VEGF 
(10ng/ml) resulted in venous differentiation (Rufaihah et al., 2013a). Interestingly, the role of 
VEGF and Notch signaling in arterial-venous specification was reported using human bone 
marrow-derived MSCs (Zhang et al., 2008b). Endothelial differentiation of MSCs in the 
presence of high concentration of VEGF (100ng/ml) resulted in upregulation of arterial 
markers and low concentration (50ng/ml) resulted in upregulation venous markers. Further 
the upregulation of arterial markers were abrogated upon inhibition of Notch signaling.  
In contrast to these studies, certain studies have analyzed the expression of arterial, venous 
and lymphatic markers in the pool of PSC-derived ECs. Glaser et al., analyzed mouse ESC-
derived ECs differentiated in the presence of VEGF (50ng/ml) and serum for proportion of 
ECs expressing arterial, venous and lymphatic markers (Glaser et al., 2011). Almost 60% of 
the mouse ESC-derived ECs expressed venous marker EphB4, while only 20% of the cells 
expressed arterial markers Notch1 and Dll4. Based on these observations the authors 
hypothesized that venous specification is the default differentiation pathway similar to early 
embryonic development. In another study from the same group, reported ~60% of mouse 
ESC-derived ECs expressed arterial markers (EphrinB2, Notch1, Dll4) and almost 90% of 




arterial and venous markers (Hatano et al., 2013). Kurian et al., recently reported conversion 
of fibroblasts to ECs through a plastic intermediate state, and these ECs exhibited expression 
of arterial, venous and lymphatic markers (Kurian et al., 2013). 
In aggregate, studies in mouse and human in-vitro models indicate the dose-dependent effect 









2.9. Terminal differentiation to vSMCs and their characterization 
Early reports on differentiation of hESCs to vSMCs employed a direct differentiation to 
vSMC bypassing identification/ purification of a defined progenitor stage (Gerecht-Nir et al., 
2003; Huang et al., 2006; Vo et al., 2010; Xie et al., 2007). Currently, hESC and iPSC-
derived smooth muscle progenitor cells are commonly sorted using MACS or FACS and 
differentiated to mature vSMCs through culture in the presence of FBS or commercially 
available smooth muscle growth medium with or without additional supplementation with 
retinoic acid,  PDGFbb and/or TGFβ1 (Cheung and Sinha, 2011). Commercially available 
smooth muscle growth medium typically consists of basal media and smooth muscle cytokine 
cocktail (2-5% FBS, bFGF, EGF, IGF1, heparin, ascorbic acid, and/or hydrocortisone). 
Alternative media used is DMEM supplemented with 10% FBS. In addition to the growth 
medium and growth factors, extracellular matrix also plays an important role. Commonly 
used matrix substrates for differentiation and culture of PSC-derived vSMCs include gelatin 
(Levenberg et al., 2010), fibronectin (Hill et al., 2010; Lu et al., 2007) and collagen IV 
(Oyamada et al., 2008; Vo et al., 2010; Yamahara et al., 2008). 
2.9.1. Smooth muscle associated markers 
To isolate the smooth muscle progenitors various markers have been reported in the literature 
(Table 4, Figures 15-17), however the commonly employed markers are VEGFR2, CD34, 
PDGFRs, and ISL1. vSMC usually display a typical spindle-shaped morphology similar to 
fibroblasts and MSCs. vSMCs exist as contractile and synthetic phenotypes with the ability to 
switch phenotypes. The contractile vSMCs have a spindle-shaped morphology while the 
synthetic vSMCs are short and exhibit epitheloid morphology (Kane et al., 2011). As the 
synthetic phenotype is associated with modulation of ECM, it displays higher growth and 
migratory activities. The contractile phenotype being associated with contractile role contains 
large quantities of contractile filaments, while the synthetic phenotype has organelles 
associated with protein synthesis (Hao et al., 2003). 
PSC-derived vSMCs are defined by expression of intracellular contractile proteins like α-
smooth muscle actin (αSMA), calponin (CNN1), smoothelin (SMTN), transgelin 
(TAGLN/SM22a), smooth muscle myosin heavy chain (MYH11/ SM1a), calmodulin 
(CALM), and h-caldesmon (Cheung and Sinha, 2011; Descamps and Emanueli, 2012). αSMA 
is considered as the most early marker of smooth muscle differentiation, while CNN1, 
desmin, TAGLN are considered as intermediate and MYH11, SMTN are late stage markers of 
differentiation towards smooth muscle lineage. αSMA is the most commonly used marker for 
defining differentiation towards smooth muscle lineage (Kane et al., 2011). It is also the most 




content (Fatigati and Murphy, 1984). Among the various SMC marker, MYH11 and SMTN 
are considered as the best markers of mature vSMCs. Although these markers are present in 
vSMCs, they are not definitive for vSMCs as they are also expressed in other cell types like 
myofibroblasts, skeletal muscle, cardiac muscle and visceral smooth muscle cells (Owens et 
al., 2004; Shepro and Morel, 1993). Vascular and visceral SMCs are very closely related and 
could be distinguished using spice variants of myosin heavy chain, and smoothelin (Cheung 
and Sinha, 2011).  
In addition to the expression of intracellular contractile proteins, various cell surface 
associated markers are used to identify, sort and characterize progenitors and mature SMCs/ 
pericytes (Wang et al., 2012b). These markers include PDGFRα, PDGFRβ, NG2 (neuroglial 
2), CD90, CD73, CD105, CD146, CD13 and alkaline phosphatase (Armulik et al., 2011; 
Bergers and Song, 2005; Dar et al., 2012; Wang et al., 2012b). Other markers identified to 
mark the vSMCs/pericytes include RGS5 (regulator of G protein signaling 5), SUR2 (ATP-
binding cassette, subfamily C), Kir6.1 (potassium inwardly rectifying channel), endosialin, 
DLK1 (delta-like 1 homolog) (Armulik et al., 2011). However, these additional markers need 
validation. PDGFRβ is tyrosine kinase receptor, expressed by developing vSMCs (Hellstrom 
et al., 1999). Its expression by the developing vSMCs is extremely crucial for their 
recruitment onto developing nascent endothelial channels resulting in stabilization and 
maturation of the vascular networks. NG2 is a chondroitin sulfate proteoglycan (also referred 
to as high molecular weight melanoma associated antigen) is especially expressed in pericytes 
(Bergers and Song, 2005).  
Both the intracellular and surface markers of developing and mature vSMCs are not specific 
to vSMCs, and hence a panel of smooth muscle markers along with functional assays are 
needed to reliably characterize vSMCs derived from PSCs. 
2.9.2. Characterization using functionality assays 
Functional assays to characterize vSMCs include contractility assays, ability to support 
endothelial vessels in-vitro and in-vivo, and synthesis of ECM.  
2.9.2.1. Contractility assays 
vSMCs maintain the tone of blood vessels and control the flow of blood through their ability 
to contract. In-vitro equivalent of inducing contraction of vSMCs involve stimulation with 
agonists that include carbachol, histamine, bradykinin, angiotensin II norepinephrine, 
oxytocin, serotonin, endothelin, ATP and potassium chloride (Vazao et al., 2011). The assay 
typically involves stimulation with the agonist (most commonly carbachol) followed by time-




Additionally, relaxation of the cells is induced with atropine before inducing carbachol for 
negative control experiments. The change in area of the cells is used as a measure to quantify 
the amount of contraction (Marchand et al., 2013; Vo et al., 2010). Alternatively, flux of 
intracellular calcium (Ca
2+
) is also used to quantify the contractility of PSC-derived vSMCs 
(Cheung et al., 2012; Hill et al., 2010; Vazao et al., 2011). 
2.9.2.2. Support maturation of endothelial vessels 
Formation of mature and functional microvascular network relies on the interaction between 
ECs and mural cells. Without the mural cells, the nascent endothelial vessels would undergo 
regression (Jain, 2003). Hence, the vSMCs play a crucial role in providing structural and 
functional support to the nascent endothelial vessels.  
In-vitro tubulogenesis of ECs using Matrigel tube formation is used to investigate the 
supportive role of PSC-derived vSMCs in-vitro (Hill et al., 2010; Kim et al., 2013; Marchand 
et al., 2013; Vo et al., 2010). These studies have demonstrated the circumferential orientation 
of PSC-derived vSMCs over cords/ tubes formed by PSC-derived ECs. Additionally, these 
studies have demonstrated the variation in tube length, tube thickness and branch points 
depending on the ratio of ECs to vSMCs. In general, vSMCs supported formation of longer 
and thicker vascular tubes with less complex networks. 
For in-vivo functional assessments, the PSC-derived vSMCs are co-implanted along with 
PSC-derived ECs. Subcutaneous injection of the two cells encapsulated within Matrigel and 
other biomaterials has been reported by various groups. Co-implantations have demonstrated 
higher density of vascular structures with host connectivity in the presence of vSMCs have 
been demonstrated (Ferreira et al., 2007; Kim et al., 2013; Kusuma et al., 2013; Levenberg et 
al., 2010; Lu et al., 2007). Similarly using cranial window models, formation of stable, 
perfused vascular networks by PSC-derived ECs in the presence of PSC-derived vSMCs have 
been demonstrated (Samuel et al., 2013; Wang et al., 2007). Further the supportive role of 
vSMCs in neovascularization have been demonstrated in hindlimb ischemia (Yamahara et al., 
2008), myocardial infarction (Kraehenbuehl et al., 2011) and dermal wound models (Kim et 
al., 2013). 
2.9.2.3. Synthesis of ECM proteins 
To support the formation of mature vascular networks, vSMCs secrete various ECM 
molecules around the nascent endothelial channels. The expression of collagen and 
fibronectin has been investigated using hESC-derived vSMCs (Vo et al., 2010). vSMCs 
demonstrate upregulation of collagen and fibronectin. However, the effects on other matrix 




2.10. Engineering vascularized tissue equivalents 
Tissue engineering provides a great platform to build functional tissues and organs to build, 
replace or repair lost, damaged or diseased tissues and also provides a platform for designing 
in-vitro test systems. Although considerable advancement has taken place in the field of tissue 
engineering in the past few decades, success has been limited to thin, avascular tissues like 
cartilage, cornea and skin that depend on nutrient and oxygen supply by diffusion (Novosel et 
al., 2011; Tian and George, 2011). Due to the limited success in engineering complex tissues, 
development and testing of pharmaceutical products are limited to use of conventional 
monolayer cell culture systems and/or animal experiments.  
 
Figure 24. Schematic representation of graft nutrition after transplantation. 
The schematic illustrates the three different mechanisms of nutrient supply to a graft after 
transplantation, which includes diffusion (imbibition), neovascularization, and inosculation. Imbibition 
is a passive diffusion of nutrients from the host and hence is has a limited range, while 
neovascularization is an active process involving migration of new blood vessels from the host into the 
graft. But neovascularization is a slow process taking upto 15 days depending on the thickness of the 
graft. On the other hand, inosculation is process of anastomosis of pre-existing graft vasculature with 
the host vasculature resulting rapid supply of nutrition within 4 days. Source: Adapted with permission 
from (Tremblay et al., 2005) 
 
Fabrication of complex tissues needs delivery of nutrients and oxygen through perfusion, 
rather than diffusion alone. To enable the perfusion of thick, complex tissues a network of 
blood vessel system within the tissue constructs are needed. Young et al., described three 




(2) neovascularization and (3) inosculation (Montano et al., 2010; Young et al., 1996) (Figure 
24). Diffusion of the nutrients through the tissue construct is an inefficient process limited to 
a maximum distance of 200µm (Novosel et al., 2011). Neovascularization is the formation of 
new blood vessels through the process of vasculogenesis and/or angiogenesis. But, this 
process takes time and hence, is not the mechanism by which the graft survives during the 
initial days after implantation. Inosculation is the anastomosis of preexisting graft vasculature 
with the host vessels. The process of inosculation occurs rapidly, and would result in early 
supply of nutrients to the graft after implantation.  
To vascularize engineered tissue several possible approaches have been explored over the 
past few decades. These approaches include (1) vascularization using (a) angiogenic factors 
and adhesion molecules, (b) incorporation of ECs and mural cells, (c) biomaterials or 
decellularized matrices; and (2) prevascularization by formation of de novo vascular channels 
before implantation (Figure 25). 
2.10.1. Neovascularization using angiogenic factors and adhesion molecules 
Vascularization of acellular or cellular tissue constructs could be aided by incorporation of 
angiogenic factors and adhesion molecules. Adhesion molecules like RGD, REDV, YIGSR 
sequences are commonly used with synthetic biomaterials to aid adhesion, recruitment, 
migration and differentiation of cells (Novosel et al., 2011). The angiogenic factors are aimed 
to activate the endothelial progenitors or ECs to migrate, proliferate and assemble to form a 
vascular network within the tissue construct.  
VEGF and bFGF are the commonly growth factors used for upregulating the angiogenic 
process (Kaully et al., 2009; Novosel et al., 2011). Other angiogenic factors investigated 
include PDGF, TGFβ, hepatocyte growth factor and angiopoietins (Novosel et al., 2011). 
Hence, various scaffolds have been designed to incorporate and release various growth 
factor(s). Administration of single growth factor is generally insufficient, as several growth 
factor combinations are involved in the process of formation and maturation of vascular 
network. Hence, a cocktail of growth factors are needed that needs to be delivered in a spatial 
and temporal manner. Additionally, these growth factors generally suffer from very short-
half-lives and hence require scaffolds capable of controlled-release of growth factors to 
enable local delivery for a prolonged period of time (Kaully et al., 2009). Further controlling 






Figure 25. Common strategies for vascularization in tissue engineering. 
Common strategies for engineering vascularized tissues include the delivery of (A) angiogenic factors 
like VEGF, bFGF, gene vectors, small molecules; (B) vascular cells like ECs, vSMCs, MSCs, 
fibroblasts; (C) biomaterials ranging from natural, synthetic to hybrid materials, (D) prefabricated/ 
prevascularized constructs; and (E) combination of one or more of the above methods. Source: 
Adapted with permission from (Phelps and Garcia, 2010) 
 
Dual factor release system for temporal delivery of VEGF and PDGFbb was demonstrated to 




maturation with pericytes under the control of PDGFbb (Carmeliet and Conway, 2001; 
Richardson et al., 2001). Similarly, incorporation and dual delivery of VEGF and bFGF 
within collagen-heparin and fibrin scaffolds was demonstrated to enhance the formation of 
mature vascular structures in-vivo (Hall, 2007; Nillesen et al., 2007). Recently, multifactor 
delivery was demonstrated using co-immobilization of VEGF and angiopoietin-1 as well as 
VEGF, IGF1 and stromal cell-derived factor-1 facilitated rapid and functional 
neovascularization compared to any individual factor (Sun et al., 2011). Another alternative 
method to deliver growth factors is to use genetically modified cells that overexpress these 
angiogenic factors (Novosel et al., 2011). hESC-derived endothelial progenitors expressing 
VEGF under the influence of adenoviral vector was reported to aid regeneration of infarct 
region in a rat myocardial infarct model (Rufaihah et al., 2010). Similarly, bone substitutes 
seeded with MSCs overexpressing VEGF was demonstrated to enhance angiogenesis and 
osteogenesis (Geiger et al., 2007). 
2.10.2. Scaffolds for enhancing neovascularization 
Advantage of using scaffolds primarily lies in providing the initial encapsulation of the donor 
cells that provides physical, chemical or mechanical cues that gradually preconditions the 
cells to the local biological environment upon implantation. Delivery of progenitors/ cells 
encapsulated within biomaterials with controlled release of pro-angiogenic factors may 
provide the ideal microenvironment for neovascularization (Kraehenbuehl et al., 2009; Saif et 
al., 2010). Though significant advancements have been achieved in the past decade, there are 
only a few studies that employ a biomaterial-based generation of in-vitro or in-vivo 
vascularized grafts using human PSC-derived vascular cells. 
2.10.2.1. Natural biomaterials 
Natural biomaterials offer several advantages as they provide both physical and chemical cues 
for cell adhesion, proliferation, migration and differentiation (Tian and George, 2011). 
Further they are biocompatible, biodegradable and biologically active. Various biological 
materials are available, but only those relevant to fabrication of vascularized tissues would be 
discussed below. Though natural biomaterials offer promising biological properties, they 
generally degrade rapidly, can cause immune reaction (except collagen), have batch-to-batch 
variation and may harbor infectious agents (Tian and George, 2011). To overcome these 
issues, the natural biomaterials are used in combination with synthetic biomaterials. 
Collagen 
Collagen is the most abundant protein present in the mammalian extracellular matrix. It has 




degrades faster. The degradation kinetics, pore size and mechanical properties of collagen 
scaffolds could be controlled by conjugation with various polymers. Collagen and hybrid 
collagen scaffolds promote angiogenesis as evidenced by the ability of various ECs to form 
functional vascularized tissue upon implantation into subcutaneous tissues of mouse. 
Collagen is commonly used in combination with fibronectin to fabricate vascularized tissues. 
Human umbilical vein endothelial cells (HUVECs) and murine fibroblasts encapsulated 
within collagen-fibronectin gels formed functional vessels integrated with the host 
vasculature and was durable for 1 year in-vivo (Koike et al., 2004). In-vivo the ECs formed 
long, branching vascular channels stabilized by recruitment of murine fibroblasts as pericytes. 
Similarly, hESC-derived ECs and murine fibroblasts encapsulated within collagen-fibronectin 
gels and implanted into cranial windows in severe combined immunodeficient (SCID) mice 
integrated with mouse vasculature and were functional for 150 days (Wang et al., 2007). 
Further, the microvessels derived from hESC-derived ECs without pericytes failed to 
anastomose with host vasculature and regressed within 7 days, underscoring the role of mural 
cells in maturation and stabilization of endothelial microvessels. In another study, hESC-
derived ECs encapsulated within collagen-Matrigel gel constructs and cultured in-vitro for 5 
days upon transplantation into infarcted nude rat hearts formed vascular networks that 
integrated with host vasculature (Nourse et al., 2010). Human iPSC-derived ECs and 
supporting perivascular cells (MSCs or iPSC-derived mesenchymal cells) encapsulated within 
collagen-fibronectin gels and transplanted into cranial windows or dorsal skin chamber 
models, formed functional, perfused blood vessels (Samuel et al., 2013). 
Fibrin 
Fibrin is a natural polymer of the monomer fibrinogen and is formed during the final phases 
of coagulation cascade. Fibrin-based materials are biocompatible, and biodegradable. It can 
be easily obtained from patient’s blood, and hence eliminating the issues related to xenogenic 
products, foreign body reaction and disease transmission (Aper et al., 2007). Using this 
advantage, Aper et al., demonstrated fabrication of autologous blood vessels using endothelial 
progenitor cells and fibrin obtained from patient’s peripheral blood (Aper et al., 2007). Fibrin 
and its degradation products support cellular attachment, cellular proliferation, angiogenesis 
and tissue repair (Ahmed et al., 2008; Shaikh et al., 2008). As a natural polymer involved in 
healing, fibrin has excellent biological properties for vascular tissue engineering (Chen et al., 
2009; Lesman et al., 2011). Additionally, fibrinogen/ fibrin acts as a growth factor sink by 
providing binding sites for angiogenic factors VEGF and bFGF, and further protects them 
proteolytic degradation (Sahni et al., 2000; Sahni and Francis, 2000; Sahni et al., 2006). 
Hence, use of fibrin-based scaffolds for vascularization holds a great promise. However, 




(Dikovsky et al., 2006). Stiffness of the fibrin hydrogels could be controlled by using fibrin in 
conjugation with collagen or synthetic polymers like polyglycolic acids (PGA), poly-L-lactic 
acid (PLLA), polylactic-glycolic acid (PLGA) or crosslinking with synthetic polymers like 
polyethylene glycol (PEG) (Dikovsky et al., 2006; Gonen-Wadmany et al., 2011; Lesman et 
al., 2011; Natesan et al., 2011). Similarly, the degradation rates could also be modulated using 
enzyme inhibitors like aprotinin (Wozniak, 2003). Additionally, the porosity of fibrin gels 
could also be modulated by varying the concentration of fibrinogen, with higher 
concentrations yielding gels with lower porosity and higher stiffness. 
One of the well documented methods of controlling the limitations of fibrin scaffolds is 
through crosslinking the fibrin with PEG (PEGylation) and this has been employed for 
various tissue engineering applications. PEGylation has been reported to introduce the ability 
to photopolymerize, improve the degradation rates and structural properties like porosity and 
mechanical strength (Zhang et al., 2006; Zhu, 2010). Additionally, PEG is biocompatible, 
non-immunogenic and is resistant to protein adsorption (Zhu, 2010). On the other hand, 
crosslinking could be detrimental to biological activity of fibrin due to certain alterations to 
the protein during the process of PEGylation (Barker et al., 2001). However, certain other 
studies have found no effect on the biofunctionalilty of fibrin in PEG-fibrin hydrogels (Zhang 
et al., 2008a; Zhang et al., 2006). The contradicting findings may be due to differences in the 
PEGylation process.  
Excellent pro-angiogenic properties has led to fibrin-based gels been extensively used for 
fabrication of vascularized tissue equivalents for skin (Lugo et al., 2011; Montano et al., 
2010), bone (Steffens et al., 2009), adipose tissue (Borges et al., 2006; Frerich et al., 2001; 
Natesan et al., 2012; Natesan et al., 2011), skeletal muscle (Lesman et al., 2011) and 
cardiovascular (Birla et al., 2005; Plotkin et al., 2014) applications. Using fibrin, an in-vitro 
3D-model for assessing the permeability of capillary networks was recently reported 
(Grainger and Putnam, 2011).  
HUVECs or endothelial progenitor cells encapsulated with fibrin-based tissue constructs 
cultured in-vitro for a week aided the formation of patent capillary network that upon 
transplantation into mouse anastomosed with mouse blood vessels within 1-4 days (Chen et 
al., 2009; Chen et al., 2010). Similarly, in-vitro triculture of ECs, fibroblasts and skeletal 
myoblasts within fibrin gels alone or in combination with synthetic PLLA/PLGA sponges 
resulted in formation of network of vessels within 7 days (Lesman et al., 2011). Further, the 
maturity levels of the vessel networks were dependent on the concentration of fibrinogen. 
Although the utility of fibrin gels in aiding vascularization has been extensively studied, no 





Matrigel is a basement membrane extracted from Engelbreth-Holm-Swarm mouse sarcoma 
cells (Tian and George, 2011). It is most extensively used extracellular matrix especially for 
assaying angiogenesis and vasculogenesis both in-vitro and in-vivo. ECs including human 
PSC-derived ECs form tube-like structures when seeded over Matrigel, and also form 
perfused vascular structures when injected subcutaneously (Ferreira et al., 2007; Rufaihah et 
al., 2011). However, from a clinical stand point, use of Matrigel is limited by its xenogenic 
and tumor-origin, and batch variability (Tian and George, 2011). 
Hyaluronic acid hydrogels 
Hyaluronic acid (HA) is a glycosaminoglycan made of nonsulfated linear polysaccharide of 
(1-β-4)D-glucuronic acid and (1-β-3)N-acetyl-D-glucosamine. HA has been reported to aid 
EC attachment, proliferation, migration and sprouting through surface receptors CD44 and 
CD168 (Yee et al., 2011). Using HA hydrogels, Gerecht and colleagues, developed a 3D in-
vitro vascularized construct to study the events during the process of vascular morphogenesis 
(Hanjaya-Putra et al., 2011).  
Decellularized matrices 
Engineering the natural architecture of the vascular tree in-vitro and rebuilding the vascular 
networks within is challenging. Decellularization of mammalian tissues, a naturally-derived 
3D-architecture of the vascular system could be obtained. Decellularized matrix exposes the 
ECM and also maintains its 3D architecture like that of vasculature that could be repopulated 
with desired ECs and/or mural cells to rebuild the vascular tree in-vitro (Novosel et al., 2011). 
Additionally, the process of decellularization removes most, if not all, antigens that might 
invoke a host-immune response. For instance, in-vitro vascularized heart and liver-like tissues 
were reported utilizing the intact geometry of the vasculature after decellularization of rat 
heart and porcine jejunal segment with ECs (Linke et al., 2007; Ott et al., 2008).  
2.10.2.2. Synthetic biomaterials 
Numerous synthetic biomaterials have been investigated for tissue engineering purposes, but 
the most essential features to consider while designing or choosing a suitable scaffold for 
vascularization include (1) ability to aid attachment, proliferation and migration of ECs, (2) 
adequate porosity for vessel infiltration, and (3) sufficient pore interconnectivity to allow for 
the branching and anastomoses of microvascular channels. Synthetic biomaterials are 
advantageous in terms of the ability to tune their mechanical properties, degradation rates, 
pore size, and pore interconnectivity. Additionally, they can be reproduced consistently and 




surface ligands for cell attachment and fate of degradation products. Many synthetic 
biomaterials have been used for fabrication vascularized tissue equivalents, but the most 
commonly used include PEG and PLGA-based hydrogels. In addition to conventional 
methods of engineering vascularized constructs, microfabrication techniques like rapid 
prototyping and solid free form techniques are used to engineer scaffolds with required 
vascular tree architecture (reviewed by Kaully et al., (Kaully et al., 2009) and Novosel et al., 
(Novosel et al., 2011)). However, the challenges include the micron-scale of the vessels that 
vary from few nanometers to few micrometers, and biological qualities for adequate adhesion, 
proliferation and growth of cells within the architecture. 
Polyethylene glycol (PEG) 
PEG is an inert hydrophilic polyether that is biocompatible and approved by US Food Drug 
and Administration (FDA) for clinical use (Barker et al., 2001). PEG has an extremely simple 
structure (HO(CH2CH2O)nCH2CH2OH) that is either linear or branched with hydroxyl ends 
that could be functionalized through conjugation with other polymers, drugs, peptides and 
proteins (Banerjee et al., 2012). Due to the hydrophilic nature of PEG, it attracts water 
molecules forming hydrogels that is resistant to protein adsorption and cell attachment (Tian 
and George, 2011). However, for purpose of vascularization applications, PEG must be 
modified to enhance cell attachment, migration and endothelial sprouting. The most common 
chemical approach for conjugating PEG with proteins or peptide sequences involves addition 
of an electrophilic functional group to the hydroxyl ends. The electrophilic functional group is 
used to couple with amine (-NH2) groups present in proteins/ peptides, and the process is 
termed as PEGylation (Banerjee et al., 2012). For the purpose of engineering vascularized 
tissue equivalents, PEG is commonly conjugated with fibrinogen resulting in PEGylated-
Fibrinogen that could be used to encapsulate ECs or other cells. Two commonly reported 
PEG-Fibrin gels for vascularization use PEG molecules functionalized using diacrylate or 
succinimidyl groups (Gonen-Wadmany et al., 2011; Seetharaman et al., 2011). In the former, 
bifunctional PEG-diacrylate is conjugated with fibrinogen using a complex process and the 
PEG-fibrin hydrogel is formed by photopolymerization using UV light exposure in the 
presence of a photoinitiator (Irgacure) (Almany and Seliktar, 2005; Gonen-Wadmany et al., 
2011). While in the later, bifunctional PEG-succinimidylglutarate is conjugated to fibrinogen 
by a simple process of incubation wherein the electrophilic groups at both ends of PEG react 
with amine groups present in fibrinogen at 37
0
C to produce stable amide linkages (Natesan et 
al., 2011; Seetharaman et al., 2011). PEG-fibrin hydrogel is formed using thrombin-assisted 




Seliktar and colleagues, demonstrated that PEG-fibrin hydrogels aided the recovery of cardiac 
function and cardiac neovascularization in a myocardial infarct model (Plotkin et al., 2014; 
Rufaihah et al., 2013b). Additionally, they demonstrated the ability to modulate the matrix 
stiffness by varying the concentration of PEG and its effect on cardiac recovery (Plotkin et al., 
2014). Further, they have demonstrated the use of PEG-fibrin hydrogel as a delivery system 
for controlled release of VEGF (Rufaihah et al., 2013b). Same group  using PEG-Collagen 
hydrogels demonstrated in-vitro capillary morphogenesis of ECs and fibroblasts (Singh et al., 
2013). Similarly, Suggs and colleagues developed a PEG-Fibrin hydrogel for various cell 
delivery applications. They demonstrated differentiation of bone marrow and adipose-derived 
MSCs encapsulated within PEG-fibrin gels towards ECs without the need for additional 
growth factor supplementation (Natesan et al., 2011; Zhang et al., 2010). Further, using PEG-
Fibrin hydrogels they developed wound dressing for cell delivery with antimicrobial and 
angiogenic properties (Seetharaman et al., 2011; Zhang et al., 2006). Similarly Kraehenbuehl 
et al., developed an injectable MMP-responsive PEG hydrogels for dual delivery of pro-
angiogenic and pro-survival factor, thymosinβ4 and hESC-derived vascular cells for 
restoration of cardiac function in a rat myocardial infarct model (Kraehenbuehl et al., 2011).  
Polylactic-glycolic acid (PLGA) 
Polylactic-glycolic acid (PLGA) is a co-polymer of polylactic acid and polyglycolic acid. It is 
one of the most commonly used synthetic biomaterial in tissue engineering applications. 
Upon transplantation in-vivo, the polymer degrades to non-toxic naturally occurring 
compounds (glycolic acid and lactic acid) by hydrolysis and hence is biodegradable and 
biocompatible. Other advantages include tunable degradation rates and mechanical properties, 
ability to absorb proteins, and ability to functionalize using peptide sequences. PLGA is 
commonly used as a composite in combination with PLLA. The degradation rate of the 
polymer could be controlled by varying the molecular weight of the polymers and their ratios. 
The PLGA component of the composite polymer (PLGA/PLLA) degrades quickly and allows 
cellular ingrowth, while the PLLA degrades slowly providing mechanical strength.  
PLGA/PLLA composite is commonly used in combination with natural biomaterials like 
collagen, fibronectin, Matrigel for fabrication of 3D vascularized tissue constructs. hESC-
derived ECs encapsulated within a PLGA/PLLA + Matrigel formed perfused CD31
+
 vascular 
channels upon subcutaneous implantation into SCID mice (Levenberg et al., 2010; Levenberg 
et al., 2002). Similarly, implantation of a triculture of hESC-derived cardiomyocytes, ECs and 
fibroblasts within PLGA/PLLA porous scaffolds into rat heart demonstrated formation of 
perfused donor (human) and host (rat)-derived vasculature (Lesman et al., 2010). A 




construct using hESC-derived ECs and mouse myoblasts that resulted in stable vascular 
structures surrounded by myoblasts (Levenberg et al., 2005). Further, addition of embryonic 
fibroblasts to the system resulted in dramatic increase in vascularization. Another study 
utilized co-seeding of ECs and MSCs encapsulated within collagen-fibronectin gel into PLGA 
to engineer vascularized bone graft in-vivo that integrated with host vasculature (Tsigkou et 
al., 2010). Hence, hybrid scaffolds of PLGA/PLLA along with natural biomaterials are a 
promising option for engineering vascularized scaffolds. 
2.10.3. Engineering prevascularized tissue equivalents 
Since long term survival of the cells within engineered tissue equivalents depends on 
adequate nutrient and oxygen supply, rapid establishment of vascular channels immediately 
after implantation is critical. Implantation of vascular cells encapsulated within biomaterials 
has shown promising results in establishment of vascular supply by process of vasculogenesis 
and neovascularization. However, this process takes atleast 7-15 days depending on the 
thickness of the construct (Tremblay et al., 2005). During this period of neovascularization, 
the cells in the center of the scaffold are dependent on mass transport (diffusion) which leads 
to a central zone of apoptosis (Johnson et al., 2011; Tsigkou et al., 2010). Hence, the ideal 
approach to provide rapid supply of nutrients would be to transplant tissue constructs with 
preformed vasculature that would anastomose with the host vasculature. This process of 
anastomoses of host and graft vasculature is termed as inosculation. In addition to clinical 
use, establishment of 3D prevascularized tissue equivalents would aid in development and 
testing of pharmaceutical products which otherwise are limited to use of conventional 
monolayer cell culture systems and/or animal experiments.  
2.10.3.1. Role of preformed vascular network 
Preformed vascular channels are believed to play a fundamental role of rapid establishment of 
nutrient supply to the tissue construct. In addition to this fundamental role, the preformed 
vascular channels also play passive and active roles in the success of the tissue construct after 
implantation. Vascularization of the implanted tissue equivalents (graft) could occur by (1) a 
simple anastomoses of the graft and host vessels, (2) ingrowth of host vasculature into the 
graft (internal inosculation), (3) outgrowth of graft vasculature (external inosculation) (Figure 
26), and/or (4) recruitment of host derived-endothelial progenitors in the process of 
neovascularization. To determine how the vascularization of a transplanted full-thickness skin 
graft occurs, Capla et al., transferred grafts between transgenic tie2/lacZ mice and wild-type 
FVB/N mice (Capla et al., 2006). To differentiate the host and donor-derived ECs they 
employed lacZ expression under the control of endothelial specific tie2 promoter. Their 




periphery of the graft on day 3 towards center of the graft through day 21. In parallel to the 
regression of graft vascular channels, ingrowth of the host vasculature was found to replace 
the regressing vessels. Additionally, bone marrow-derived endothelial progenitor cells were 
recruited and contributed to ~20% of the host ECs that invaded the graft. Hence, it seems that 
the prevascularization of tissue equivalents plays a passive role in the process of 
neovascularization by providing an outline for the ingrowth of new host-derived blood 
vessels. This process of ingrowth of host vasculature into the channels formed by regressing 
graft vasculature is termed as internal inosculation (Figure 26). 
 
Figure 26. Schematic representation of internal and external inosculation. 
The schematic illustrates the process of internal and external inosculation. The grey circular region 
represents the graft with its vasculature (blue network) surrounded by host vasculature (red network). 
Implantation of a graft with preformed vasculature could aid in vascularization of the graft by two 
processes: internal and external inosculation. In the process of internal inosculation the graft 
vasculature regresses, and is followed by invasion of host microvasculature into the graft. In external 
inosculation, the graft vasculature grows out into the host tissue and anastomoses with host vasculature. 
In parallel, the graft vasculature undergoes sprouting angiogenesis within the graft leading to increased 
density of the graft microvasculature. Source: Adapted with permission from (Laschke et al., 2009) 
 
Recent studies demonstrate that preformed vascular channels play an active role in the 




within GFP-transgenic mice into dorsal skinfold chamber of wild-type recipient mice 
(Laschke et al., 2008). They observed that GFP
+
 microvessels grew out of the graft into the 
surrounding host tissue and interconnected with GFP
-
 host vasculature. Further, they observed 
that the graft vasculature instead of regressing contributed to more vasculature by means of 
sprouting angiogenesis. This process of outgrowth of graft vasculature into the host tissue and 
anastomoses external to the graft is termed as external inosculation (Figure 26). Similarly, 
Shepherd et al., using prevascularized collagen gels demonstrated that anastomoses of graft 
and host vasculature predominantly occurred through external inosculation; and internal 
inosculation was restricted to the periphery of the graft (Shepherd et al., 2004).  
The contradicting results demonstrate that the role of preformed vascular channels in the 
process of neovasculariazation is yet to be understood. However, the role of preformed 
vascular channels seems to be more than providing a framework for the ingression of host 
vasculature.  
2.10.3.2. Approaches to prevascularize tissue equivalents 
Tissue equivalents could be prevascularized in-vitro by seeding/ encapsulating ECs or 
endothelial progenitor cells with or without supporting mural cells (like vSMCs, fibroblasts, 
MSCs) within a suitable biomaterial. This approach is termed as in-vitro prevascularization. 
Secondly, a tissue construct could be prevascularized in-vivo by using body as a natural 
bioreactor and is termed as in-vivo prevascularization approach to engineering the 
microcirculation (Figure 27). 
In-vitro prevascularization 
To prevascularize tissue equivalents in-vitro angiogenic cells are seeded/ encapsulated within 
a 3D angiogenic matrix. This approach utilizes the ability of ECs and endothelial progenitors 
to self-assemble into microvascular networks. After the cells form a preliminary 
microvascular network, the in-vitro prevascularized tissue equivalent could either be used for 
in-vivo implantation or for in-vitro studies.  
In one of the earliest attempts, Black et al., co-cultured keratinocytes, HUVECs, and dermal 
fibroblasts in a chitosan-collagen-chondroitin sulfate sponge to engineer the first 
endothelialized human tissue engineered skin equivalent (Black et al., 1998). Further, they 
demonstrated that the endothelialized skin equivalent accelerated graft revascularization by 
means of inosculation. Later the same group developed a human endothelialized skin 
equivalent by co-culturing keratinocytes, fibroblasts and HUVECs in a collagen sponge and 
demonstrated the rapid vascularization of the endothelialized skin equivalent in less than 4 




al., developed vascularized skeletal muscle constructs in-vitro by co-culturing mouse 
myoblasts, embryonic fibroblasts and HUVECs/ hESC-derived ECs. They demonstrated that 
ECs organized into CD31
+
 vascular channels in between the skeletal myoblasts. Further, in 
the presence of embryonic fibroblasts the ECs formed more vascular structures underscoring 
the role of mural cells. The vascular channels within in-vitro vascularized skeletal muscle 
constructs were stable for 1 month.  
Chen et al., reported fabrication of fibrin-based in-vitro prevascularized tissue constructs by 
co-culturing HUVECs or endothelial progenitor cells with fibroblasts (Chen et al., 2009). 
Further, they demonstrated that prevascularization aided rapid vascularization by anastomosis 
with host vasculature within 1-4 days compared to non-prevascularized tissue constructs (8-
14 days) (Chen et al., 2009; Chen et al., 2010). Further, the density of fibroblasts was 
demonstrated to play a role in establishing anastomoses with higher densities favoring rapid 
anastomoses (Chen et al., 2010). The optimal concentration and superior angiogenic 
properties of fibrin over collagen was demonstrated by Montano et al. (Montano et al., 2010). 
3D culture of human microvascular ECs within fibrin (fibrinogen: 10-11mg/ml) resulted in 
formation of capillary networks, while the ECs remained as spherical aggregates in collagen 
matrices. Using the fibrin gels, they recapitulated the early stages of capillary morphogenesis 
i.e., (1) aggregation of single ECs into solid cords, (2) deposition of basement membrane, (3) 
formation of intracellular vacuoles through pinocytosis (pinocytotic vesicles), (4) formation 
of intracellular lumen by fusion of the intracellular vacuoles, and (5) formation of patent 
vascular channels by fusion of intracellular vacuoles of adjacent ECs (Figure 28). Further, the 
rudimentary vascular channels underwent maturation by recruitment of mural cells upon 
implantation into a mouse. 
Grainger and Putnam developed 3D in-vitro vascularized tissue equivalents using HUVECs 
supported by fibroblasts, adipose derived-stem cells or MSCs in a fibrin gel (Grainger and 
Putnam, 2011). Further, they developed a novel 3D in-vitro model to assess the permeability 







Figure 27. Approaches to prevascularize tissue constructs. 
Tissue engineering constructs could be prevascularized in-vitro which upon implantation could 
inosculate with the host circulation (a). Alternatively, the tissue constructs could be vascularized in-
vivo involving extrinsic and intrinsic vascularization approaches. In the extrinsic approach, the tissue 
construct is vascularized by host vasculature outside of the construct (b); while in the intrinsic 
approach, the host vasculature is included within the tissue to be constructed (c). Source: Adapted with 






Figure 28. Schematic illustration of early morphogenetic events in formation of lumenized 
endothelial channels.  
The schematic illustrates the early events in capillary morphogenesis i.e., (1) aggregation of single ECs 
into solid cords mediated by junctional complexes, (2) deposition of early basement membrane and 
formation of intracellular vacuoles through pinocytosis (pinocytotic vesicles), (3) formation of 
intracellular lumen by fusion of the intracellular vacuoles, and (4) formation of patent vascular 
channels by fusion of intracellular vacuoles of adjacent ECs. Source: Adapted with permission from 






In-vivo prevascularization of tissue constructs utilizes the inherent angiogenic capacity of 
body, and could be achieved by two ways termed as extrinsic and intrinsic vascularization 
(Lokmic and Mitchell, 2008; Novosel et al., 2011) (Figure 27). Both the approaches involve 
a preliminary implantation of a non-vascularized construct into the host body, when 
vascularization of the construct occur de novo. After vascularization, the construct is 
harvested and reimplanted in the region of need. This methodology could be used to 
prevascularize large scaffolds but is limited by the need for multiple surgeries and donor-site 
morbidity.  
Extrinsic vascularization 
This method of in-vivo prevascularization involves the ingrowth of host vasculature into the 
implanted construct. It involves implantation of a cellular/ acellular porous scaffold into 
vascularized areas like adipose tissue, kidney capsule, and subdermis (Lokmic and Mitchell, 
2008). Ingrowth of blood vessels into the porous scaffold vascularizes the construct.  
Intrinsic vascularization 
This approach is based on the provision of an artery or vein as a source of new blood vessels. 
Tissue construct to be vascularized is implanted within a chamber along with pedicle flap or 
an arteriovenous loop, which results in spontaneous angiogenic sprouting from the pedicle or 
loop. Then the vascularized construct with the feeder vessel is harvested and implanted into 
the site of need. This approach is commonly used to engineer vascularized bone grafts (Wang 
et al., 2010). In a landmark study, this methodology was used to fabricate a custom-made 
vascularized mandible by implantation of a titanium mesh filled with autologous bone chips 
and BMP4 in the latissimus dorsi muscle (Warnke et al., 2004). Hence, using this approach 
individually tailored, large 3D tissue constructs could be fabricated. However, the 













Rationale and study design 




3. Rationale and study design 
 
This doctoral study was designed to address the following objectives: 
1. Develop protocols to efficiently differentiate hESCs to endothelial lineage through 
efficient commitment to primitive streak (PS), lateral plate mesoderm, endothelial 
progenitors and ECs. 
2. Investigate the commitment of endothelial progenitors to arterial and venous endothelial 
phenotypes. 
3. Develop protocols to efficiently differentiate hESCs to vascular smooth muscle lineage 
through efficient commitment to PS, paraxial mesoderm and vSMCs. 
4. To engineer in-vitro 3D vascularized tissue equivalents using hESC-derived vascular 
progenies in a suitable biomaterial. 
5. Reduce the use of xenogeneic products throughout the process of differentiating hESCs to 
progenitors and terminally differentiated ECs and vSMCs; and fabrication of vascularized 
tissue equivalents. 
These objectives were approached in a phased manner as summarized below and in Figure 
29.  
Phase 1: Differentiation of hESCs to PS through modulation of Wnt/β-Catenin signaling 
pathway using an inhibitor of glycogen synthase kinase-3 (GSK3) under feeder- and serum-
free conditions (Chapter 4). 
Phase 2: Differentiation of PS to lateral plate mesoderm and endothelial lineage through 
modulation of mesoderm and vascular lineage inducing factors that include bFGF, BMP4, 
and VEGF under feeder- and serum-free conditions (Chapter 4). 
Phase 3: Differentiation of hESC-derived endothelial progenitors to ECs, in particular arterial 
and venous phenotypes under feeder- and serum-free conditions (Chapter 5). 
Phase 4: Differentiation of PS to paraxial mesoderm intermediates through modulation of 
mesoderm and vascular lineage inducing factors that include bFGF and VEGF under feeder- 
and serum-free conditions (Chapter 6). 
Phase 5: Differentiation of hESC-derived paraxial mesoderm intermediates to vSMCs under 




Phase 6: Engineer in-vitro 3D vascularized tissue equivalents using hESC-derived arterial 
ECs and -vSMCs using PEG-Fibrin as a scaffold material under serum-free conditions 
(Chapter 6). 
 
Figure 29. Schematic representation of the study design. 
The schematic summarizes the findings demonstrated in this study. Refer to the text for detailed 
explanations. Briefly, the study aims to develop protocols to efficiently differentiate hESCs towards 
primitive streak-like cells that could be further directed towards lateral plate and paraxial mesoderm 
subtypes. Further, the differentiation of lateral plate mesoderm to endothelial progenitors that could be 
differentiated to venous and arterial endothelial phenotypes is studied. Similarly, the differentiation of 
paraxial mesoderm intermediates to vSMCs is investigated. Further, the utility of hESC-derived arterial 
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4. Efficient differentiation of hESCs to endothelial progenitors under feeder-
free, chemically-defined conditions 
 
4.1. Introduction 
Efficient differentiation of pluripotent stem cells (PSCs) that include human embryonic stem 
cells (hESCs) and induced pluripotent stem cells (iPSCs) towards specific lineages is a critical 
step towards obtaining sufficient amounts of clinically relevant cell populations for cell 
therapy, drug screening and developing models to study human development or disease. Since 
the pioneering report of Levenberg et al., (Levenberg et al., 2002) several protocols to 
differentiate hPSCs towards endothelial lineage have been reported till date (Kane et al., 
2011). These protocols involve: (1) embryoid body-based differentiation, (2) co-culture of 
hPSCs over murine stromal cells, , (3) culture of hESCs or iPSCs as monolayers over 
extracellular matrix proteins like Matrigel, and collagen IV, and/or (4) growth factor, 
cytokines or small molecule mediated differentiation in serum containing/ serum-free 
conditions (Figure 12). However, these protocols are either inefficient or involve the use of 
xenogeneic (animal-derived) products such as fetal bovine serum (FBS), murine feeder cells 
and/or extracellular matrix. These xenogeneic components limit the clinical translation 
potential of these cells owing to the potential risk of transmission of animal pathogens and 
xenogeneic rejection (Kaupisch et al., 2012). Additionally, undefined nature of serum limits 
the ability to tune the cellular microenvironment. Hence, major challenges in the current 
differentiation models for endothelial differentiation include elimination of xenogeneic 
products and developing strategies for efficient differentiation. 
Vascular cells that include the endothelial progenitor cells are derived from the mesoderm 
lineage. Formation of three germ layers including mesoderm begins with the formation of PS.  
The formation of PS is considered as the central structural marker for mesodermal and 
endodermal precursors (Tam and Beddington, 1987). The mesoderm further differentiates 
into paraxial, intermediate and lateral mesodermal subtypes (Figures 3-5). Embryologically, 
the endothelial lineage develops from the lateral mesoderm, while the vSMCs have diverse 
origins that include the lateral plate mesoderm, paraxial mesoderm and neuroectoderm. 
Hence, efficient differentiation of hESCs to vascular cells may also require the efficient 
differentiation towards specific mesodermal subtypes. Since, the formation of PS is the first 
event that marks the generation of mesodermal lineages, efficient differentiation towards PS 





4.2. Objectives  
To efficiently differentiate hESCs to endothelial progenitors with minimal use of xenogeneic 
products.  
4.3. Materials and Methods 
4.3.1. Culture of hESCs under feeder-free and serum-free conditions 
For feeder- and serum-free culture, H1- and H9- hESCs (WiCell Research Institute, Madison, 
WI) were cultured in chemically-defined medium (mTeSR™1; Stemcell Technologies) on 
growth factor reduced Matrigel (BD Biosciences)-coated plates (Nunc). Briefly, 70-80% 
confluent hESCs were passaged after treatment with 1mg/ml dispase (Invitrogen) for 5 min at 
37
0
C. The hESC colonies were dispersed into small clumps and re-plated onto Matrigel-
coated plates.  
4.3.2. Directed Differentiation of hESCs under chemically-defined conditions 
To achieve the objective of minimal use of xenogeneic products, hESCs were differentiated 
under feeder-free and chemically-defined conditions as follows. hESCs cultured as described 
above were passaged using dispase, dispersed into small clusters (~300-500 cells per colony) 
and seeded onto 4µg/cm
2
 human plasma fibronectin (GIBCO) coated plates. These hESC 
colonies were maintained in mTeSR™1 for 24 hours, after which the cells were gently 
washed with DMEM:F12 (Invitrogen) and differentiated in chemically-defined, serum-free, 
animal component-free basal medium (STEMdiff™ APEL™, Stemcell Technologies) 
supplemented with appropriate factors as depicted in Figures 32, 35-37. Briefly, to induce 
hESCs towards PS, the hESCs were exposed to glycogen synthase kinase-3 inhibitor (GSKi;  
CHIR99021, 5µM, Stemgent) for 24 hours as previously reported (Tan et al., 2013a). 
Following induction of PS, mesodermal and endothelial induction was carried out in the 
presence of basic fibroblast growth factor (bFGF; 50ng/ml; R&D systems) for 24 hours 
followed by 72 hours of bone morphogenic protein-4 (BMP4; 25ng/ml; R&D systems) and/or 
vascular endothelial growth factor-A (VEGF; 50ng/ml; GIBCO). For validating the 
mesodermal differentiation potential of PS, hESCs after 24 hour treatment with CHIR99021 
was treated with bFGF (50ng/ml) with or without FGF receptor inhibitor (PD173074; 0.1µM) 
as illustrated in Figure 35. Similarly, validation of endodermal differentiation potential of PS 
was verified by induction with Activin A (50ng/ml) with or without Activin and TGF-β 




4.3.3. RNA extraction and real-time PCR 
Total cellular RNA was isolated from harvested cells using RNeasy Plus Mini kit (Qiagen) 
and reverse transcribed using iScript™ cDNA synthesis kit (BioRad) according to 
manufacturer’s instructions. Real-time PCR was performed in triplicates using Fast SYBR 
Green PCR master mix (Applied Biosystems) and Stepone Plus real-time PCR system 
(Applied Biosystems) as per manufacturer’s instructions. Real-time PCR reaction mixtures 
were denatured at 94
o
C for 20s and cycled for 40 cycles at 95
o
C for 3s, 60
o
C for 30s, followed 
by melt curve stage. Based on our previous studies (Rufaihah et al., 2010; Rufaihah et al., 
2007) and others (Hill et al., 2010; Vo et al., 2010), we had chosen β-ACTIN as the internal 
control. The expression levels of specific genes were quantified by normalization against 
corresponding internal control gene β-ACTIN and expressed as the fold change relative to 
control sample (undifferentiated hESCs). Details of related primer sequences used in this 
study are presented in Appendix I. The results are presented as mean ± standard deviations of 
two or more independent experiments. 
4.3.4. Flow cytometry analysis 
hESCs and differentiated cells were harvested using accutase, resuspended in FACS buffer 
(1xPBS/ 0.5% BSA) and incubated with FcR blocking agent (1:10; Miltenyi Biotec) for 10 
minutes at 4
o
C to block non-specific binding of antibodies. For labeling of cell surface 
antigens (VEGFR2, CD34, CD31), the cells were incubated with the antibodies for 10 
minutes at 4
o
C. The details of the antibodies used are presented in Appendix II. After labeling 
with appropriate antibodies, the cells were washed thrice with FACS buffer to remove 
unbound antibodies and resuspended in FACS buffer for analysis and/or sorting. The labeled 
cells were analyzed for surface-marker expression using Dako Cytomation CyAn ADP. The 
flow cytometry data was further analyzed using FlowJo v7.6.5 (TreeStar). 
4.3.5. Immunocytochemistry 
hESCs and differentiated cells were fixed with 4% paraformaldehyde (Sigma) for 20 minutes 
at room temperature. The fixed cells were permeabilized using PBS/ 0.1% TritonX-100 
(Sigma) for 10 minutes, washed thrice with PBS/0.05% Tween-20 (Sigma) and blocked with 
PBS/5% goat serum for 60 minutes to block non-specific binding. Subsequently, the cells 
were labeled with appropriate primary antibodies (OCT4, SSEA4, TRA-1-60, TRA-1-81, 
Alkaline phosphatase, BRACHYURY, β-Catenin; details of these antibodies are listed in 
Appendix III) at 4
o
C overnight. After thorough washing, the cells were fluorescently labeled 
using appropriate secondary antibodies (listed in Appendix III) for 60 minutes. For nuclear 




Sigma) for 3 minutes. After washing thrice, the cells were observed using fluorescence 
microscope (Olympus IX70). 
4.3.6. Statistical Analysis 
All real time RT-PCR experiments were performed in duplicates with duplicate readings 
each. Student’s t-test was performed to determine significance using Microsoft Excel Data 
Analysis ToolPak. 
4.4. Results 
To study the specification of hESCs towards mesodermal subtypes, H1-hESC line was used 
and the robustness of the protocol verified using H9-hESCs. The pluripotency status of H1-
hESCs maintained on Matrigel and mTeSR1 were confirmed by immunocytochemical 
staining for expression of OCT4, SSEA4, TRA-1-60, TRA-1-81 and Alkaline Phosphatase 
(AP) (Figure 30). One day prior to differentiation, hESCs were passaged onto human plasma 
fibronectin coated plates. The pluripotent status of hESCs cultured upon fibronectin for 24 
hours was confirmed by RT-PCR and immunocytochemical staining. Real time RT-PCR 
analysis revealed the hESCs cultured upon Matrigel and fibronectin had similar expression 
levels of pluripotent genes (OCT4, SOX2, NANOG) (Figure 31). Further, the hESCs cultured 
over fibronectin also expressed OCT4, SSEA4, TRA-1-60, TRA-1-81 and AP (Figure 31). 
Hence, the hESCs grown over fibronectin for 24 hours maintained pluripotent status. 
4.4.1. Temporal emergence of primitive streak (PS) 
During gastrulation in early embryogenesis, the mesoderm that gives rise to cells of the 
vascular lineage arises through an epithelial-mesenchymal transition of epiblast cells in the 
region of PS. Hence, we believe that efficient differentiation of hESCs to endothelial lineage 
depends on effective commitment of hESCs towards PS-like stage. Canonical Wnt pathway is 
one of various signaling pathways implicated in playing a critical role in the formation of PS. 
For differentiation towards PS, we adopted our previously published protocol (Tan et al., 
2013a), using inhibition of glycogen synthase kinase-3 (GSKi) with CHIR99021 (5µM) under 
feeder-free, chemically-defined conditions. Since Matrigel is of animal-origin, and we aimed 
to reduce the use of xenogenic products, we modified our previous protocol by replacing 
Matrigel with human plasma fibronectin. During the induction of PS in hESCs, we observed 
that GSKi induced a marked decrease in pluripotency gene SOX2 within 24 hours, followed 
by OCT4 and NANOG; and the neuroectoderm-associated genes (PAX6, SOX1) (Figure 32). 
In contrast to the downregulation of neuroectodermal genes, the PS-related genes 
(BRACHYURY, MIXL1) were upregulated synchronously along with anterior PS genes 




of PS-related genes was accompanied by steady upregulation of gene involved in epithelial-
mesenchymal transition (SNAI1). The expression of BRACHYURY and OCT4 after 24 hours 
of GSKi was confirmed by immunofluorescence (Figure 33). As the cells migrate out of the 
colony by day 2, OCT4 was downregulated with persistent expression of BRACHYURY in 
the migrating cells. Further, the hESCs treated with CHIR99021 displayed nuclear 
accumulation of β-catenin as the cells differentiated; while the β-catenin was localized to the 
cell periphery in hESCs and no-GSKi control cells (Figure 34).  
We further analyzed the expression of ectoderm, mesoderm and endoderm related transcripts. 
In the absence of GSKi, upregulation of neuroectodermal genes (PAX6 and SOX1) around 3
rd
 
day of differentiation indicates the probable neuroectodermal induction (Figure 32). On the 
other hand, under the influence of GSKi, the expression levels of these neuroectodermal 
genes remained downregulated throughout the time-course of differentiation, suggesting a 
non-ectodermal differentiation (Figure 32). With prolonged treatment of hESCs with GSKi, 
only genes indicative of paraxial mesoderm (PDGFRα, PDGFRβ) and endoderm (CXCR4) 
were upregulated, while that of lateral plate mesoderm (VEGFR2) was downregulated 
(Figure 32). These findings suggest that prolonged GSKi treatment possibly favors 
differentiation towards paraxial mesoderm and endoderm fate.  
Collectively, these findings suggest that treatment of hESCs with GSKi is unable to maintain 
pluripotency, and instead triggers differentiation towards a non-ectodermal lineage. Further, 
short-term treatment (24 hours) of hESCs with GSKi results in emergence of PS-like cells. 
4.4.2. hESC-derived PS-like cells have potential to commit towards mesoderm and 
endoderm 
Cells of the PS have the ability to commit to mesoderm and endodermal progenies depending 
on the balance between bFGF, Activin and BMP4 signaling (Huber et al., 1998; Pick et al., 
2007; Tan et al., 2013a). We next sought to ascertain the bipotential differentiation capacity 
of PS towards mesoderm and endoderm. During embryonic development, FGF signaling is 
involved in specification, migration and patterning of mesoderm (Ciruna and Rossant, 2001). 
Hence, commitment of mesodermal lineage was investigated after exposure to bFGF. After 
24-hour treatment of hESCs with CHIR99021, mesodermal induction was carried out using 
bFGF (50ng/ml) with or without FGF receptor inhibitor (PD173074; 0.1µM) as illustrated in 
Figure 35. During early stages of induction towards mesoderm, mesodermal subsets could be 
identified by expression of VEGFR2 and PDGFR receptors.(Tan et al., 2013a; Yamashita et 
al., 2000; Zhang et al., 2008c). Real-time PCR analysis revealed that induction of GSKi 




PDGFRβ transcripts accompanied by steady downregulation of PS (BRACHYURY, MIXL1) 
and endoderm-related transcripts (FOXA2, GSC, CXCR4) (Figure 35). On the other hand, 
absence of bFGF or presence of FGF inhibitor resulted in marked downregulation of PS, 
endoderm, lateral plate mesoderm and EMT-related transcripts; and upregulation paraxial 
mesoderm-related transcripts (PDGFRα, PDGFRβ). These findings indicate the commitment 
of hESC-derived PS-like cells towards mesoderm subtypes.  
Activation of Nodal pathway using high concentrations of Activin A in mouse and human 
ESCs induces specification of PS towards endoderm fate (D'Amour et al., 2005; D'Amour et 
al., 2006; Kubo et al., 2004; Vallier et al., 2009). Hence, endodermal differentiation was 
induced using Activin A (50ng/ml) with or without Activin and TGF-β signaling inhibitor 
SB431542 (10µM) as illustrated in Figure 36. Treatment of GSKi treated-hESCs with 
Activin A resulted in marked upregulation of endoderm genes (FOXA2, GSC, CXCR4) and 
downregulation of PS, EMT and mesoderm-related transcripts (Figure 36). To confirm the 
involvement of Activin/Nodal signaling in the commitment to endoderm fate, the GSKi 
treated-hESCs were treated with Activin A and SB431542 (a selective inhibitor of TGFβ type 
I activin receptor-like kinases). The upregulation of endodermal genes and the 
downregulation of mesodermal genes were abolished in the absence of Activin A and in the 
presence of SB431542 (Figure 36).  
Collectively, these observations demonstrate the potential of hESCs differentiated to PS under 
the influence of GSK-3 inhibition (for 24 hours) to commit towards mesoderm or endoderm 
depending on the culture milieu provided. 
4.4.3. Synergistic differentiation to endothelial progenitor cells using BMP and VEGF 
signaling 
Inhibition of GSK-3 followed by bFGF exposure drives the hESCs towards lateral plate 
mesoderm as evidenced by the upregulation of VEGFR2 and downregulation of PS and 
endoderm-related genes (Figure 35).  We next sought to investigate the potential of these 
lateral plate mesoderm cells to commit towards endothelial lineage. Earlier studies have 
reported the ability of BMP4 and VEGF in the induction of hESCs to endothelial and smooth 
muscle lineages (Bai et al., 2010; Ferreira et al., 2007; Hill et al., 2010; Levenberg et al., 
2010; Tan et al., 2013a). The kinetics of differentiation towards endothelial lineage was 
monitored using VEGFR2 (an early marker for lateral plate mesoderm-derived progenitors), 
CD34 (early marker for progenitors with potential to differentiate towards endothelial 
lineage), and CD31 (pan-endothelial lineage marker). Differentiation was performed in a step-
wise approach wherein the hESCs exposed to CHIR99021 and bFGF for 24 hours each, were 




PCR analysis (Figure 37) revealed BMP4 (Gi.F.B) supplementation resulted in modest 
upregulation of VEGFR2 and a marked upregulation of PDGFRβ, but had minimal effect on 
the expression levels of CD34 and CD31. On the contrary, treatment with VEGF (Gi.F.V) 
resulted in modest increase in the transcript levels of CD34, CD31, VEGFR2 and PDGFRβ. 
While combined modulation with BMP4 and VEGF (Gi.F.BV) resulted in marked 
upregulation of all the three markers related to lateral plate mesoderm and endothelial lineage 
(VEGFR2, CD34, CD31) and downregulation of paraxial mesoderm-related transcript 
(PDGFRβ) (Figure 36).  
In accordance with the real-time RT-PCR data, time-course flow cytometry analysis (Figure 
38, 39) revealed the gradual emergence of VEGFR2
+
 population with BMP4 supplementation 
(G.F.B), but only a small subset of this population co-express CD34. While addition of VEGF 
(G.F.V) results in gradual appearance of CD34
+
 cells that co-express VEGFR2 and CD31 and 
account for ~54% of the differentiated cells by the 5
th
 day of differentiation. Combined 












 day of differentiation respectively (Figure 38, 39).  




 population starting from 3
rd
 day of differentiation 
under the influence of BMP4 and/or VEGF demonstrate the emergence of lateral plate 
mesoderm. In all the three differentiation conditions, time-course flow cytometry plots also 
reveal the temporal emergence of VEGFR2
+
 population that gradually attain CD34 and CD31 
positivity (Figure 38, 39). These findings suggest the role of BMP4 in induction of lateral 
plate mesoderm progenitors (VEGFR2
+
 cells) followed by initiation towards endothelial 
lineage by VEGF. Additionally, we verified the robustness of the protocol using H9-hESCs 
which also yielded ~90% of cells positive for VEGFR2, CD34 and CD31 (Figure 40). In 
conclusion, BMP4 synergizes the endothelial induction potential of VEGF resulting in a 
robust protocol that yields ~90-95% of endothelial progenitor cells co-expressing VEGFR2, 
CD34 and CD31.  
4.5. Discussion 
The in-vitro differentiation of hESCs in most cases recapitulates the sequential stages of 
development observed in embryological studies. In the developing embryo, the cells of the 
hematopoietic and cardio-vascular lineage arise from subpopulations of mesoderm in a 
defined temporal sequence. Hence, the development of successful human hESC-based 
therapies would require an understanding of the complex signaling pathways controlling the 
lineage commitment during embryonic development to establish robust, efficient, and 




devised, most of these involve spontaneous and/or single-step approaches under undefined 
conditions, and/or require long-term culture resulting in low yields of the desired cell 
population (Descamps and Emanueli, 2012; Kane et al., 2011). We previously developed a 
directed differentiation of hESCs over Matrigel, to efficiently generate lateral plate and 
paraxial plate mesoderm derivatives through short term inhibition of GSK-3 (Tan et al., 
2013a). In the present study we modified the differentiation microenvironment using human 
plasma fibronectin as substrate instead of Matrigel, and investigated the sequence, timing and 
combination of growth factors needed to efficiently drive the differentiation towards 
endothelial lineage. In the current approach, a step-wise modulation of Wnt-βcatenin, FGF, 
BMP and VEGF signaling pathways led to sequential and efficient induction of hESCs 
towards PS, lateral plate mesoderm and endothelial progenitors.  
Mesoderm induction starts with formation of primitive streak (PS) from the epiblast which 
gives rise to the progenitors related to cells of the mesoderm and endoderm germ layers. In 
this part of the study, we demonstrate that short-term inhibition of GSK-3 efficiently drives 
the differentiation of hESCs towards a PS/mesendoderm-like state. Inhibition of GSK-3 leads 
to stabilization, accumulation and translocation of β-catenin to the nucleus. In the nucleus, the 
β-catenin binds to members of T-cell factors (TCF) family of transcription factors and 
activates the target genes (Kimelman, 2006; Sokol, 2011b). Among the different PS-related 
genes, BRACHYURY is reported as a direct target of Wnt-βcatenin pathway (Arnold et al., 
2000; Yamaguchi et al., 1999). The concurrent upregulation of BRACHYURY and other PS-
related genes (MIXL1, FOXA2, GSC) within 24 hours of GSKi and their subsequent 
downregulation is indicative of the transient and temporal emergence of PS observed during 
early embryogenesis. Furthermore, these short-term GSKi treated cells show evidence of 
commitment towards mesoderm upon induction with bFGF and towards endoderm in 
response to Activin A. The rapid induction of PS in response to GSKi is comparable to the in-
vivo events described in the study by Kemler et al., (Kemler et al., 2004). In transgenic mouse 
models constitutive expression of stabilized β-catenin induces premature EMT of epiblasts to 
mesodermal progenitors (Kemler et al., 2004). Hence, we demonstrate that these hESC-
derived PS/mesendoderm-like cells have the bipotent differentiation towards mesoderm or 
endoderm depending on the culture milieu.  
The role of Wnt/β-catenin signaling in mouse and human ESCs has been controversial due to 
contradictory findings. Studies have reported the activation of Wnt/β-catenin signaling 
maintains pluripotency of both mouse and human ESCs (Hao et al., 2006; Miyabayashi et al., 
2007; Ogawa et al., 2006; Sato et al., 2004; Singla et al., 2006; Takao et al., 2007; ten Berge 




inhibitors induces differentiation of ESCs towards PS, mesoderm and endoderm (Bone et al., 
2011b; Davidson et al., 2012; Nakanishi et al., 2009a; Tan et al., 2013a). These controversial 
observations may be due to differences in dose and duration of Wnt activation, differences in 
differentiation methods, and presence of serum or other factors like bFGF in the 
differentiation medium. In one of the studies, it has been observed that Wnt3a maintains 
pluripotency of hESCs wherein MEF-conditioned media was used as differentiation media 
(Dravid et al., 2005).  It could be argued that the presence of anti-differentiation factors like 
bFGF in the conditioned media could aid in the pluripotency in-spite of Wnt signaling. In 
support of this argument are studies that demonstrate Wnt signaling aids pluripotency of 
hESCs under the influence of FGF signaling, while aids differentiation in the absence of FGF 
signaling (Cai et al., 2007; Ding et al., 2010b). However, this was contradicted by another 
study that uses mTeSR1 as differentiation media that is known to contain high concentrations 
of bFGF (Bone et al., 2011a). In this study, the authors demonstrate the differentiation 
towards endoderm upon inhibition of GSK-3. In the present study, we demonstrate activation 
of Wnt/β-catenin signaling using CHIR99021 in feeder-free, chemically-defined conditions 
without the addition/ presence of additional growth factors/ cytokines drives the 
differentiation of hESCs towards PS. 
Previous studies (Bai et al., 2010; Ferreira et al., 2007; Hill et al., 2010; Park et al., 2010; Tan 




 cells could serve as 
endothelial progenitors. Under serum-free conditions, bFGF, BMP4 and VEGF have been 
reported to facilitate the differentiation of hESCs towards endothelial lineage (Bai et al., 
2010). Similar to the findings of Bai et al., (Bai et al., 2010) we found that BMP4 alone is not 




 cells, while VEGF alone or in combination 
with BMP4 causes a significant increase in the commitment to endothelial lineage. However, 





cells, while we could achieve around 90-95% of the cells being positive for CD34 and CD31. 
This could be due to efficient induction of hESCs towards PS and mesoderm before 
stimulation with BMP4 and VEGF. Currently available protocols to differentiate hESC and 
hiPSCs towards endothelial lineage generally requires 10-15 days of differentiation to achieve 
a modest 2-40% of cells committed to endothelial lineage (Kane et al., 2011). In contrast, our 
findings suggest a robust commitment (90-95%) towards endothelial lineage within a 
differentiation span of 5 days compared to those previously reported (Bai et al., 2010; Ferreira 
et al., 2007; Hill et al., 2010; James et al., 2010; Levenberg et al., 2010; Park et al., 2010). 





1. Monolayer differentiation of hESCs instead of EB/co-culture methods. In EB method of 
differentiation, the addition of growth factors would result in a gradient effect within the 
differentiating EBs which in turn could have dose-dependent effect and reduce the 
differentiation efficiency or reduce the abi;lity to tune/ precisely control the 
differentiation. 
2. hESCs were differentiated immediately (24 hours) after seeding, instead of waiting of the 
hESC colonies to grow larger. When the hESC colonies are small, they are more 
uniformly spread and remain almost as a monolayer of cells. In this state, the addition of 
growth factors/ small molecules could theoretically result in equal induction of all the 
cells. 
3. The differentiation of hESCs was carried out based on a developmental biology approach 
wherein the differentiation through various developmental stages like PS, mesoderm 
(lateral plate/ paraxial), endoderm and endothelial lineages were closely monitored. 
4. Differentiation of hESCs under chemically defined conditions could be a reason which 
allows for fine tuning of the differentiation microenvironment.  
In conclusion, we dissected the early signaling pathways leading to a novel, step-wise 
differentiation approach to efficiently drive the commitment of hESCs towards endothelial 
lineage. The ability to generate endothelial progenitors efficiently may provide opportunities 
to study endothelial commitment using hESCs as an in-vitro model. Additionally, efficient 
generation of endothelial progenitors under defined conditions could pave way towards 








Figure 30. Analysis of pluripotency status of hESCs cultured over Matrigel. 
Top left photomicrograph shows the compact, well defined morphology of hESC colony upon culture 
over Matrigel and mTeSR1. Immunofluorescence micrographs show the expression of pluripotency 








Figure 31. Analysis of pluripotency status of hESCs cultured over fibronectin. 
(a) Photomicrograph shows the compact, well defined morphology of hESC colony upon culture over 
fibronectin and mTeSR1 for 24 hours. (b) Real time RT-PCR comparison of expression of pluripotency 
genes (OCT4, SOX2, NANOG) by the hESCs cultured over Matrigel and fibronectin. The plots show no 
significant difference in the gene expression between the cells grown on Matrigel and fibronectin. For 
gene expression plots, the levels of expression were normalized to corresponding β-ACTIN values and 
are shown as relative to that of undifferentiated hESCs cultured over Matrigel.  (c) 
Immunofluorescence micrographs show the expression of pluripotency markers OCT4, SSEA4, TRA-








Figure 32. Time course analysis of expression of genes associated with pluripotency and early 
differentiation of hESCs in response to inhibition of GSK-3. 
(a) Schematic representation of differentiation of hESCs with or without the inhibition of GSK-3 using 
CHIR99021 (±GSKi). (b) Real time RT-PCR analysis of gene expression kinetics of markers 
associated with pluripotency and neuroectoderm, primitive streak (PS/ mesendoderm), epithelial-
mesenchymal transition (EMT), anterior PS/ endoderm, and mesodermal subsets after differentiation of 
hESCs with (■) or without (■) GSKi. For all gene expression plots, the levels of expression were 
normalized to corresponding β-ACTIN values and are shown as relative to that of undifferentiated 
hESCs. The expression levels of OCT4, SOX2, NANOG, PAX6, SOX1 and VEGFR2 were log-
normalized to reveal the amount of downregulation in relation to undifferentiated hESCs. Error bars: 






Figure 33. Immunocytochemical analysis of expression of BRACHYURY and OCT4 in response 
to inhibition of GSK-3. 
Immunofluorescence micrographs display the expression of OCT4 and BRACHYURY after 
differentiation with or without GSKi. (green-OCT4; red-BRACHYURY; blue-nuclear stain DAPI). 







Figure 34. Immunocytochemical analysis of expression of β-Catenin in response to inhibition of 
GSK-3. 
Immunofluorescence micrographs display the expression of OCT4 and BRACHYURY after 
differentiation with or without GSKi. (green-OCT4; red-BRACHYURY; blue-nuclear stain DAPI). 







Figure 35. Time course analysis of early differentiation of hESCs towards mesoderm lineage. 
(a) Schematic representation of differentiation of hESCs towards mesoderm using bFGF (Gi.F.F) after 24 
hours of treatment with CHIR99021 (+GSKi). Condition without bFGF (Gi.-.-) and the one with bFGF+FGF 
receptor inhibitor PD173074 (Gi.FFi.FFi) were used as controls.  (b) Representative photomicrographs 
display the change in the morphology of the hESC colonies under different differentiation conditions after 2 
and 3 days of differentiation.  The cells can be seen spreading and migrating away from the center of the 
colony similar to early migratory events observed in early embryonic development. (c) mRNA expression 
kinetics of markers associated with PS, anterior PS/ endoderm, mesodermal subsets and EMT after 
differentiation of hESCs under the three different conditions.  For all gene expression plots, levels of 
expression were log normalized to corresponding β-ACTIN values and are shown as relative to that of 
undifferentiated hESCs. Scale bars: 500µm. Error bars: s.d. (n≥2). *p<0.05. **p<0.01. p values represent the 





Figure 36. Time course analysis of early differentiation of hESCs towards endoderm lineage. 
(a) Schematic representation of differentiation of hESCs towards endoderm using Activin A (Gi.A.A) after 
24 hours of treatment with CHIR99021 (+GSKi). Condition without Activin A (Gi.-.-) and the one with 
Activin+TGFβ inhibitor SB431542 (Gi.ASb.ASb) were used as controls.  (b) Representative 
photomicrographs display the change in the morphology of the hESC colonies under different differentiation 
conditions after 2 and 3 days of differentiation.  The cells can be seen spreading and migrating away from 
the center of the colony similar to early migratory events observed in early embryonic development. (c) 
mRNA expression kinetics of markers associated with PS, anterior PS/ endoderm, mesodermal subsets and 
EMT after differentiation of hESCs under the three different conditions.  For all gene expression plots, the 
levels of expression were log normalized to corresponding β-ACTIN values and are shown as relative to that 
of undifferentiated hESCs. Scale bars: 500µm. Error bars: s.d. (n≥2). *p<0.05. **p<0.01. p values represent 





Figure 37. Time course analysis of differentiation of hESCs towards endothelial lineage. 
(a) Schematic representation of differentiation of H1-hESCs towards endothelial progenitors by 
sequential treatment with CHIR99021 (+GSKi) and bFGF for 24 hours each followed by exposure to 
BMP4 and/or VEGF. (b) Kinetics of expression of VEGFR2 (an early marker for lateral plate 
mesoderm-derived progenitors), CD34 (early marker for progenitors with potential to differentiate 
towards endothelial lineage), and CD31 (pan-endothelial lineage marker) upon induction with BMP4 
(Gi.F.B), VEGF (Gi.F.V) and BMP4 + VEGF (Gi.F.BV) over a differentiation period of 5 days. (c) 
Time course expression kinetics of pluripotency genes (OCT4, SOX2, NANOG) over 5 days of 
differentiation among the three differentiation conditions. For gene expression plots in (b), the levels of 
expression were normalized to corresponding β-ACTIN values and are shown as relative to that of 
undifferentiated hESCs; while for those in (c) the expression levels were log-normalized to reveal the 
amount of downregulation in relation to undifferentiated hESCs. Error bars: s.d. (n≥2).  *p<0.05. 






Figure 38. Flow cytometry analysis CD34 and VEGFR2 expression upon differentiation of hESCs 
towards endothelial lineage. 
Representative flow cytometry overlays display the kinetics of co-expression of VEGFR2 and CD34 
over 5 day period of differentiation of H1-hESCs, in the presence of BMP4 and/or VEGF after initial 







Figure 39. Flow cytometry analysis CD34 and CD31 expression upon differentiation of hESCs 
towards endothelial lineage. 
(a) Representative flow cytometry overlays display the kinetics of co-expression of CD34 and CD31 over 5 day 
period of differentiation of H1-hESCs, in the presence of BMP4 and/or VEGF after initial treatment with GSKi 
and bFGF for 24 hours each. (b) Graphical representation comparing the percentage of CD31+, CD34+, and 
VEGFR2+ cells after 5 days of differentiation in the presence of BMP4 and/or VEGF. Error bars: s.d. of 2 
independent experiments. Error bars: s.d. (n=3). *p<0.05. **p<0.01. p values represent the levels of significance 









Figure 40. Flow cytometry validation of differentiation of H9-hESCs towards endothelial lineage. 
Representative flow cytometry overlays display the co-expression of VEGFR2 and CD34, CD31 and 
CD34 after 5 days of differentiation of H9-hESCs, in the presence of BMP4 and/or VEGF, after initial 
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5. Differentiation of hESC-derived endothelial progenitors to arterial and 
venous endothelial cells 
 
5.1. Introduction 
Endothelial cells (ECs) are a unique population of cells that share many common 
morphological and functional features, and yet present significant heterogeneity in different 
vessels and organs. The vascular system in a broad sense consists of a complex network of 
arteries and veins. These arteries and veins share certain features and have several 
morphological, molecular and functional differences (Aird, 2007b; Dyer and Patterson, 2010; 
Kume, 2010; Swift and Weinstein, 2009; Torres-Vazquez et al., 2003). Although, arterial and 
venous ECs share certain common molecular signatures like the expression of pan-endothelial 
markers (CD31, VE-Cad, and vWF), they do possess certain distinct molecular profiles 
(Torres-Vazquez et al., 2003). Such molecular distinction seems to occur quite early in the 
development even before the onset of blood flow; while other factors like hemodynamic 
stress, oxygen tension and interplay of various signaling cues such as VEGF, Notch, and 
COUP-TFII also play a significant role (Aird, 2007b; Kume, 2010; Swift and Weinstein, 
2009; Torres-Vazquez et al., 2003).  
Arterial ECs are characterized by expression of high levels of Ephrin-B2, DLL4, Hey-1, Hey-
2, NRP1, NOTCH-1, NOTCH-4, CXCR4, JAG-1 and JAG-2; while the venous ECs express 
EphB4, Lefty-1, Lefty-2, NRP2 and COUP-TFII (Aird, 2007b; Kume, 2010; Swift and 
Weinstein, 2009; Torres-Vazquez et al., 2003). Previous studies have reported differentiation 
of hPSCs towards mature and functional ECs (Ferreira et al., 2007; Hill et al., 2010; James et 
al., 2010; Kane et al., 2010; Kaupisch et al., 2012; Levenberg et al., 2010; Li et al., 2009; 
Margariti et al., 2012; Rufaihah et al., 2011; Tan et al., 2013a; White et al., 2013), but very 
limited data is available on how these stem cells could be coaxed into arterial or venous ECs. 
Recent studies have observed the heterogenous expression of arterial and venous markers 
within the pool of PSC-derived ECs (Hatano et al., 2013; Margariti et al., 2012; Samuel et al., 
2013). Limited reports using mouse ESCs (Lanner et al., 2007; Yurugi-Kobayashi et al., 
2006), mouse iPSCs (Narazaki et al., 2008) and human iPSCs (Rufaihah et al., 2013a) have 
shown the specification towards arterial or venous fate by modulation of VEGF, Notch and/or 






To efficiently differentiate hESC-derived endothelial progenitors to arterial and venous ECs 
under feeder- and serum-free conditions. 
5.3. Materials and Methods 
5.3.1. Differentiation of endothelial progenitors (CD34+CD31+ cells) to endothelial 
subtypes in feeder-free, serum-free conditions 
After 5 days of differentiation in STEMdiff™ APEL™, CD34+CD31+ cells were isolated by 
flow cytometry assisted sorting (FACS), and plated onto 2µg/cm
2
 human plasma fibronectin 
coated plates (12,000 cells per cm
2
) and cultured in endothelial serum-free medium (ESFM, 
Invitrogen) with medium changes every 2-3 days (Figure 41). For differentiation towards 
venous endothelial cells, the medium was supplemented with 10ng/ml EGF (R&D Systems), 
20ng/ml bFGF (R&D Systems) (Figure 41). While, arterial differentiation was induced using 
10ng/ml EGF, 20ng/ml bFGF, and 10ng/ml VEGF (GIBCO) (Figure 41). The resulting 
endothelial cells were passaged using accutase (Invitrogen) when 70-80% confluent and 
characterized after 3 to 5 passages. 
5.1.1. RNA extraction and real-time PCR 
Total cellular RNA was isolated, reverse transcribed and quantitated using real-time PCR as 
described previously under Section 4.3.3. 
5.1.2. Flow cytomerty analysis and sorting 
Flow cytometry analysis of differentiated cells for cell surface antigens (CD34, CD31, VE-
Cad, NRP1, DLL4, CXCR4, NRP2, EphB4) were performed and analyzed as previously 
described under Section 4.3.4.  
5.1.3. Immunocytochemistry 
Immunocytochemical staining of differentiated cells for appropriate primary antibodies 
(CD31, VE-Cad, vWF) were performed and documented as previously described under 
Section 4.3.5. 
5.1.4. Acetylated-low density lipoprotein uptake assay 
To demonstrate the ability of ECs to phagocytize low-density lipoprotein (LDL), hESC-
derived arterial and venous ECs, were incubated with 10µg/ml of Dil-acetylated-LDL (Dil-




counterstained with Hoescht 33258 (Sigma) and observed using fluorescence microscope 
(Olympus IX70). 
5.1.5. Matrigel tube formation assay 
Ability of the ECs to form vascular tube-like structures over Matrigel™ was analyzed as 
previously described (Tan et al., 2013a). Briefly, 7.5x10
3
 ECs were seeded onto each well of 
ibidi µ-angiogenesis slides that is coated with 10µl of Matrigel. After incubation for 18h, the 
vascular tube-like structures were labeled with 1µM Calcein-AM (Sigma) as per 
manufacturer’s instructions and visualized using fluorescence microscope (Olympus IX70). 
5.1.6. Annexin V-Propidium Iodide (PI) apoptosis assay 
Analysis of live cells and apoptotic cells were performed using Alexa Fluor® 488 Annexin 
V/Dead Cell Apoptosis Kit (Molecular Probes). Briefly, after 24 hour exposure to varying 
concentrations of VEGF, the cells in the culture supernatant and culture plate were collected, 
washed and resuspended in 1x annexin-binding buffer. Then, the cells were incubated with 
Alexa Fluor® 488 annexin V and PI for 15 minutes at room temperature as per 
manufacturer’s instructions. After the incubation period, the cells were analyzed immediately 
using Dako Cytomation CyAn ADP and FlowJo v7.6.5. 
5.1.7. Wound closure assay 
Monolayers of H1-hESC derived arterial and venous ECs were scraped with a 200µl pipette 
tip to create a “wound” as described previously (Liang et al., 2007). Following the creation of 
the wound, the cells were washed with PBS to remove debris and floating cells. The cells 
were incubated for a period of 24 hours at 37
0
C in endothelial serum-free media 
supplemented with EGF (10ng/ml) and bFGF (20ng/ml). The Art-ECs were not supplemented 
with VEGF to eliminate the bias that could be created otherwise. Photomicrographs of the 
same field were acquired every 3 hours starting from 0 hours to 24 hours. The closure of the 
wound by migration of the cells was analyzed using TScratch program (Geback et al., 2009), 
available from www.cse-lab.ethz.ch/software.html. The results are tabulated as mean ± 
standard deviations of three independent experiments. 
5.1.8. Human angiogenesis antibody array 
Human Angiogenesis Proteome Profiler™ antibody array (R&D Systems) was used to survey 
the levels of 55 different angiocrines secreted by H1-hESC derived Art-ECs and Ven-ECs 
into culture supernatants. Arterial and venous ECs were seeded onto fibronectin coated plates 




 in their respective media. After 24 hours, the media was 




for 24 hours. After the incubation the culture supernatants were collected and stored at -80
0
C. 
Total protein concentration within cell-free culture supernatants were quantified using Micro 
BCA™ Protein Assay Kit (Thermoscientific) as per manufacturer’s instructions. Cell culture 
supernatant containing 200µg of protein was used for the antibody array as per 
manufacturer’s instructions. The membranes were developed using 10 minute exposure to X-
ray film. The array data was quantified by densitometry analysis using Image J (NIH, USA). 
The various angiocrines in the protein blot are listed in Appendix IV. 
5.1.9. Statistical Analysis 
All real time RT-PCR and angiogenesis antibody array experiments were performed in 
duplicates with duplicate readings each. Student’s t-test was performed to determine 
significance using Microsoft Excel Data Analysis ToolPak. For angiogenesis antibody arrays, 
the density of each protein blot was quantified by a densitometry analysis using Image J 
software. The pixel densities corresponding to the negative control spots within each array 
was used as controls to normalize the density corresponding to each protein spot. These pixel 
density values were used as relative pixel density measurements to compare the expression 
levels of the proteins between different blots. 
5.4. Results 
To study the specification towards arterial and venous endothelial subtypes, H1-hESC line 
was used and the robustness of the protocol verified using H9-hESCs. 
5.4.1. Differentiation of hESCs to endothelial progenitors 
hESCs were differentiated to endothelial progenitors expressing VEGFR2, CD34 and CD31 
using sequential modulation of Wnt/β-catenin, FGF, BMP and VEGF signaling pathways as 
described under Section 4.4.3. Briefly, differentiation was performed in a step-wise approach 
wherein the hESCs exposed to CHIR99021 and bFGF for 24 hours each, were treated with 
BMP4 (25ng/ml) and VEGF (50ng/ml) as illustrated in Figure 41. This sequential 
differentiation of H1- and H9-hESCs resulted in 90-95% of the cells co-expressing VEGFR2, 
CD34 and CD31 (Figure 38-40). These cells expressing CD34 and CD31 would be termed as 
endothelial progenitors.  
5.4.2. Terminal differentiation of CD34+CD31+ endothelial progenitors to arterial and 
venous endothelial cells under serum-free conditions 
Under serum-containing conditions, high concentrations (50ng/ml) of VEGF have been 
reported to aid arterial differentiation, while lower concentrations (10ng/ml) aid venous 




However, such dose-dependent role of VEGF under serum-free conditions is not reported so 
far. Differentiation of mouse ESCs and human iPSCs towards arterial and venous ECs have 
been reported. However, differentiation of arterial-venous specification of hESCs has not 




endothelial progenitors obtained after 5 days of 
differentiation were sorted using FACS and further differentiated towards endothelial 
subtypes in serum-free conditions, using commercially available endothelial serum-free 
medium (ESFM, GIBCO). Serum-containing endothelial medium typically requires the 
supplementation with bFGF, EGF and VEGF but the serum-free endothelial medium as per 
manufacturer’s instructions, requires supplementation with bFGF and EGF only. Hence we 




cells in ESFM supplemented with 
bFGF (20ng/ml) and EGF (10ng/ml) for 3-6 passages (Figure 41). Differentiation under these 
conditions yielded 98-99% CD34, CD31 and VE-CAD positive ECs (Figure 41). Real-time 
PCR analysis demonstrated upregulation of all transcripts associated with endothelial lineage 
(CD31, VE-CAD, VEGFR-2, CD34, vWF, GATA2, eNOS, TIE2) (Figure 42). Additionally, 
immunocytochemistry revealed the characteristic membrane expression of CD31 and VE-
CAD, and cytoplasmic expression of vWF (Figure 43). Further analysis into the arterial and 
venous phenotype markers showed almost 85-90% of the cells to be positive for venous 
markers (NRP2, COUP-TFII) while only ~7% of the cells expressed NRP1 and DLL4, and 





cells towards venous endothelial phenotype and these would be referred to Ven-
ECs. Expression of arterial markers by a minor subset of the differentiated cells might 
indicate either presence of arterial phenotype or co-expression of arterial markers. 
VEGF has been reported as critical for vascular patterning governing the specification 
towards arterial phenotype through a cascade of signaling events involving Shh, Notch, Dll4 
and Ephrin-B2 (Coultas et al., 2005; Lawson et al., 2001; Lawson et al., 2002; Yamamizu et 
al., 2010).  Similar studies on mouse ESCs (Lanner et al., 2007; Yamamizu et al., 2010), 
human adult progenitors (Aranguren et al., 2007) and human iPSCs (Rufaihah et al., 2013a) 





 cells had the potential to commit towards arterial phenotype, we additionally 





 cells were exposed to high concentrations of VEGF (50ng/ml), some of the 
cells underwent apoptosis (Figure 44). To ascertain the effect of VEGF, we analyzed 
apoptotic cell death using Annexin-V/ dead cell apoptosis kit. Titration of VEGF 
concentration using Annexin V-PI staining revealed the occurrence of cellular apoptosis in a 
dose-dependent manner with the optimal concentration around 5-10ng/ml VEGF (Figure 44). 














 ECs (Figure 41). Flow 
cytometry analysis showed that these ECs were also positive for arterial markers (NRP1, 
DLL4, CXCR4) and only 5-6% of the cells positive for venous markers (NRP2, EPH-B4) 
(Figure 41). When compared to Ven-ECs, the cells differentiated under the influence of 
VEGF, displayed significantly higher levels of CD31, vWF, eNOS and Tie2 transcripts 
(Figure 42). Real-time PCR analysis also revealed that these cells had significantly higher 
levels of arterial-related transcripts (NRP1, EPHRIN-B2, DLL4, NOTCH1, CXCR4) and lower 
levels of venous endothelial-related transcripts (NRP2, EPH-B4, COUP-TFII) (Figure 42). 
The expression profile of the cells differentiated under the influence of low concentrations of 




 cells towards arterial endothelial phenotype 
and these would be referred to as Art-ECs.  




 cells towards arterial and venous phenotype 
under serum-free conditions with or without VEGF was validated using H1- and H9-hESCs, 
and both these cell lines yielded similar results (Figure 42). The in-vitro functionality of 
hESC-derived Art-ECs and Ven-ECs was assessed by their ability for uptake of acetylated 
low-density lipoprotein (LDL) uptake, a characteristic of mature ECs and by their ability to 
self-organize into cord-like structures over Matrigel. Both the Art-ECs and Ven-ECs were 
functional in terms of their ability for LDL uptake and formation of cord-like structures over 





 endothelial progenitors to arterial and venous ECs under feeder- 
and serum-free conditions. Moreover, under serum-free conditions low concentrations of 
VEGF drives arterial differentiation, while the absence of VEGF drives commitment towards 
venous phenotype. 
5.4.3. Intrinsic differences in cell migration and angiocrine secretory profile of hESC-
derived arterial and venous ECs  
ECs interact with the local micro-environment and support tissue regeneration after injury 
through revascularization of the newly healed tissue and expression of various trophic growth 
factors, known as angiocrine factors (Ding et al., 2010a). To revascualrize the regenerating 
tissue, ECs proliferate and migrate from pre-existing blood vessels. To assess cell migration, 
in-vitro wound closing assays were performed over a period of 24 hours. Compared to Ven-
ECs, the Art-ECs displayed faster closure of the wound area resulting in a complete wound 
closure by Art-ECs in ~15 hours in contrast to ~24 hours taken by Ven-ECs (Figure 45).  
ECs pertaining to distinct vascular beds have recently been reported to express diverse 
signatures of angiocrine factors (Nolan et al., 2013). However, the distinct expression of 




angiocrine factors secreted by hESC-derived endothelial phenotypes, we used angiogenesis 
antibody array of 55 different proteins related to angiogenesis, inflammation, and 
extracellular matrix.  Both arterial and venous ECs showed similar protein secretion profiles 
with certain dissimilarities (Figure 46, 47). Both Art-ECs and Ven-ECs displayed marked 
induction of endothelin-1, insulin-like growth factor-binding protein-2 (IGFBP-2), monocyte 
chemoattractant protein-1 (MCP-1), pentraxin-3, serpin-E1, and tissue inhibitor of matrix 
metalloproateinase-1 (TIMP-1). However, the media conditioned by Art-ECs had 
significantly higher levels of IGFBP-1, interleukin-8 (IL-8), matrix metalloproteinase-8 
(MMP-8), platelet-derived growth factor-AA (PDGF-AA) and thrombospondin-1 (TSP-1) 
compared to that of Ven-ECs (Figure 46). On the contrary, the conditioned media of Ven-
ECs had significantly higher levels of activin-A, IGFBP-3, interleukin-1β (IL-1β), and 
placenta-derived growth factor (PlGF) compared to Art-ECs (Figure 46). These results 
emphasize the existence of functional differences between the two endothelial phenotypes in 
addition to the differences in their molecular expression profiles. 
 
5.5. Discussion 
In this part of the study, we demonstrate for the first time the differentiation of hESCs 
towards arterial and venous ECs under feeder- and serum-free conditions. Inhibition of GSK-
3 followed by stepwise stimulation with bFGF, BMP4 and VEGF led to robust differentiation 









progenitors were differentiated to ECs of arterial and venous phenotype under serum-free 
conditions by modulating the concentration of VEGF. Further, we validated the differences 
between the two endothelial phenotypes at molecular and functional levels.  
In the last few decades, our understanding regarding heterogeneity among various endothelial 
phenotypes in terms of their function, molecular signatures and the underlying pathways 
controlling their specification has increased tremendously (Aird, 2007a; Coultas et al., 2005; 
Kume, 2010; Lanner et al., 2007; Lawson et al., 2001; Lawson et al., 2002; Nolan et al., 2013; 
Swift and Weinstein, 2009; Torres-Vazquez et al., 2003; Yamamizu et al., 2010). Distinction 
of arterial and venous endothelial phenotypes seems to occur quite early in the development, 
wherein VEGF, Shh, and Notch signaling has been suggested to play a crucial role (Lawson 
et al., 2001; Lawson et al., 2002). Current understanding on the specification of arterial and 
venous endothelial phenotypes is based predominantly on animal studies. In-vitro studies 
using mouse PSCs (Lanner et al., 2007; Narazaki et al., 2008) indicate the expression of 
arterial markers like Dll4, EphrinB2 and Notch4 in response to high concentrations of VEGF 




COUP-TFII. Additionally, the VEGF-mediated arterialization was reported to be further 
enhanced by the addition of adrenomedullin (Narazaki et al., 2008; Yurugi-Kobayashi et al., 
2006) and these effects were blocked in the absence of Notch signaling (Lanner et al., 2007; 
Yurugi-Kobayashi et al., 2006). These findings from in-vitro models correlate with the 
findings of in-vivo animal models highlighting the coordinated activation of VEGF-Notch 
signaling in arterial specification.  
Towards obtaining data from human models, several groups have used human stem cells to 
study the early developmental events in the specification of endothelial lineage. Though 
tremendous amounts of information have been obtained from these in-vitro human models, 
the heterogeneity of ECs has been investigated by very few studies. Kurian et al., (Kurian et 
al., 2013) reported conversion of fibroblasts to ECs through a plastic intermediate state, 
wherein they found the pool of ECs as being heterogeneous in terms of expression of arterial, 
venous and lymphatic markers. Similarly, Samuel et al., (Samuel et al., 2013) reported 
differentiation of human iPSCs to NRP1 (an arterial marker) expressing progenitors which 
further differentiated to ECs expressing markers related to both arterial and venous 
phenotypes. These studies indicate the expression of arterial and venous endothelial markers 
by a pool of differentiated ECs, however distinct specification towards either phenotype is not 
investigated. Only two studies using human adult progenitors (Aranguren et al., 2007) and 
human iPSCs (Rufaihah et al., 2013a) have elucidated the arterial-venous specification of 
human progenitor/ stem cells till date. Aranguren et al., (Aranguren et al., 2007) reported high 
concentration of VEGF (100ng/ml) induced arterial differentiation of human bone marrow-
derived multipotent adult progenitor cells. Further, the arterial induction was reported to be 
enhanced by supplementation with Dll4 and Shh, while blockade of Notch and/or Shh led to 
attenuation of arterial differentiation and upregulation of venous markers. Similarly, Rufaihah 
et al., (Rufaihah et al., 2013a) using human iPSCs model demonstrated the arterial 
differentiation by high VEGF concentration coupled with cAMP and induction of venous 
specification under low concentrations of VEGF. In aggregate, all the above studies in mouse 
and human in-vitro models indicate the dose-dependent effect of VEGF in arterial-venous 
specification of endothelial cells. However, all these studies were performed under serum-
containing conditions.  
Inclusion of xenogeneic products (like Matrigel, FBS, murine stromal cells) in the culture 
milieu could influence the differentiation outcome and limit the ability to tune the 
microenvironment due to the presence of unknown/ poorly defined factors (Kaupisch et al., 
2012). Additionally, these xenogeneic components could limit the clinical translation 




rejection (Kaupisch et al., 2012). Towards eliminating or reducing the use of xenogeneic 
products, we have developed a novel feeder- and serum-free protocol for differentiation of 
hESCs to endothelial subtypes. Under serum-free conditions, we found higher concentrations 
of VEGF (25-100ng/ml) causes apoptosis of the cells, while at lower concentrations 
(10ng/ml) directs arterial phenotype and its absence favors venous fate. This is in contrast to 
the findings previously reported under serum-containing conditions. The contradictory results 
could be due the presence of serum in the culture milieu. The novel insights into the arterial-
venous specification under serum-free conditions would provide clues for developing 
clinically competent vascular cells in the future. In addition, access to robust differentiation of 
hESCs to arterial and venous ECs under defined conditions could provide a potential human 













progenitors to venous and arterial endothelial cells under serum-free conditions. 





cells by sequential treatment with CHIR99021 (+GSKi), bFGF, followed by combined treatment with 




 cells were sorted using flow cytometry after 5 
days of differentiation and further differentiated towards venous ECs (hESC-Ven-ECs) and arterial 
ECs (hESC-Art-ECs). (c) Representative flow cytometry histogram overlays represent the expression 
of pan-endothelial markers, arterial markers and venous markers among H1-hESC derived Ven-ECs 





Figure 42. RT-PCR analysis of terminal differentiation of CD34+CD31+ endothelial progenitors 
to venous and arterial endothelial cells under serum-free conditions. 
mRNA profiles of pan-endothelial (a), arterial (b), and venous (c) endothelial related transcripts (e) 
among Art-ECs and Ven-ECs derived from H1- and H9-hESCs. For gene expression plots, the levels of 
expression were normalized to corresponding β-ACTIN values and are represented as relative to that of 







Figure 43. Immunocytochemical analysis of expression of endothelial markers by hESC-derived 
venous and arterial endothelial cells. 
Representative photomicrographs of ECs differentiated under venous (a) and arterial (b) differentiation 
conditions. Photomicrographs show the cobblestone morphology of ECs under phase contrast 
microscopy, and immunofluorescence images demonstrate the expression of endothelial markers 
CD31, VE-Cadherin, and vWF; uptake of Dil-acetylated low density lipoprotein (Dil-Ac-LDL) and 






Figure 44. Effect of VEGF on endothelial cells. 
(a) Representative photomicrographs of endothelial cells after 24 hour exposure to increasing 
concentrations of VEGF reveal the apoptosis of cells at higher VEGF concentrations. (b) 
Representative flow cytometry plots displaying the Annexin V/ PI staining to quantify the apoptotic 









Figure 45. Assessment of cell migration using in-vitro wound 
healing assay. 
(a) Representative serial phase contrast photomicrographs of H1-
hESC derived Ven-ECs and Art-ECs after wound creation. The 
serial photomicrographs taken every 3 hours demonstrate the 
migration of the ECs across the scratch wound. (b) Graphical 
representation of the comparison of the percentage of wound 
coverage over period of time among the two endothelial phenotypes. 






Figure 46. Angiocrine secretory profile of hESC-derived arterial and venous ECs using 
angiogenesis antibody array. 
(a) Representative scans of angiogenesis antibody arrays demonstrating the secretion of various 
angiocrine factors by arterial and venous ECs. Array images are obtained from 10-minute exposure of 
X-ray film. (b) Graphical representation of the relative amounts of selected angiocrine factors that 
show significant difference among the arterial and venous ECs. The bars represent relative amounts of 
factors secreted based on densitometric analysis of relative pixel density of the blots. Figure 46 
provides the complete densitometric analysis of all the 55 angiocrine factors analyzed using antibody 








Figure 47. Survey of secretory profile of 55 angiocrines by hESC-derived arterial and venous ECs using angiogenesis antibody array. 
Graphical representation of the relative amounts of 55 angiocrine factors secreted by H1-hESC derived Art-ECs and Ven-ECs analyzed using angiogenesis antibody array. 












Differentiation of hESCs to 
vascular smooth muscle cells 










Formation of mature and functional microvascular network relies on the interaction between 
ECs and vSMCs. In early embryogenesis and in adult life, newly formed endothelial vessels 
recruit mural cells (pericytes and vSMCs) resulting in a complex network of arteries, 
arterioles, capillaries, venules and veins (Coultas et al., 2005; Flamme et al., 1997). These 
vSMCs and/or pericytes are heterogeneous group of cells derived from diverse embryological 
origins ranging from lateral plate mesoderm (secondary heart field, splanchnic mesoderm), 
paraxial mesoderm (somites) and neural crest (Majesky, 2007). Various approaches to guide 
the differentiation of PSCs towards vSMC lineage involves one or combination of following 
methods: (1) EB-based differentiation (Ferreira et al., 2007; Levenberg et al., 2010; Vazao et 
al., 2011; Vo et al., 2010), (2) co-culture over murine/ human stromal cells like OP9 
(Oyamada et al., 2008; Sone et al., 2007; Taura et al., 2009; Yamahara et al., 2008), MEFs 
(Bu et al., 2009), M2-10B4 (Hill et al., 2010), human foreskin fibroblasts (Lee et al., 2007), 
(3) culture of hESCs or iPSCs as monolayers over ECM proteins like Matrigel (Colleoni et 
al., 2010), and collagen IV (Oyamada et al., 2008; Sone et al., 2007; Taura et al., 2009; 
Wanjare et al., 2013; Xie et al., 2007; Yamahara et al., 2008), and/or (4) growth factor, 
cytokines or small molecule mediated differentiation in serum containing/ serum-free 
conditions (Bai et al., 2010; Cheung et al., 2012; Huang et al., 2006; Lee et al., 2007; Park et 
al., 2010; Tan et al., 2013a) (Figure 12, 15-17, Table 4). Most of these protocols rely on use 
of serum and do not involve lineage-specific differentiation strategies. Recently, Cheung et 
al., using serum-free media and specific lineage restriction methods reported differentiation of 
hPSCs were differentiated to lateral plate mesoderm, paraxial mesoderm and neural crest 
progenitor-derived vSMCs (Cheung et al., 2012). Similarly, Tan et al., had recently 
demonstrated the differentiation of hESCs to vSMCs through paraxial mesoderm progenitors 
(PDGFRα+CD34-) (Tan et al., 2013a). In this study, the hESCs were differentiated to paraxial 
mesoderm intermediates in chemically-defined media conditions using Matrigel as substrate 
and sequential modulation of Wnt/β-catenin, BMP and VEGF signaling pathways. Further, 
these paraxial mesoderm intermediates were sorted and differentiated into vSMCs under the 
influence of platelet-derived growth factor-BB (PDGFbb) and serum.  
Using human plasma fibronectin as substrate and chemically defined medium (Stemdiff 
APEL medium), we developed a feeder-free, and chemically-defined differentiation system 




further investigated the differentiation towards paraxial mesoderm intermediates followed by 
differentiation towards vSMCs. 
6.2. Objective 
To differentiate hESCs to paraxial mesoderm intermediates and vSMCs with minimal use of 
xenogeneic products. 
6.3. Materials and Methods 
6.3.1. Culture of hESCs under feeder-free and serum-free conditions 
H1- and H9- hESCs were cultured as perviosly described under Section 4.3.1.  
6.3.2. Directed Differentiation of hESCs to paraxial mesoderm intermediates under 
chemically-defined conditions 
hESCs were passaged using dispase, dispersed into small clusters (~300-500 cells per colony) 
and seeded onto 4µg/cm
2
 human plasma fibronectin (GIBCO) coated plates. These hESC 
colonies were maintained in mTeSR™1 for 24 hours, after which the cells were gently 
washed with DMEM:F12 (Invitrogen) and differentiated in chemically-defined, serum-free, 
animal component-free basal medium (STEMdiff™ APEL™, Stemcell Technologies) 
supplemented with appropriate factors as depicted in (Figure 48). Briefly, to induce hESCs 
towards PS, the hESCs were exposed to glycogen synthase kinase-3 inhibitor (CHIR99021, 
5µM, Stemgent) for 24 hours. Following induction of PS, mesodermal and vascular induction 
was carried out in the presence of bFGF (50ng/ml; R&D systems) for 24 hours followed by 
72 hours of VEGF (50ng/ml; GIBCO). 
6.3.3. Differentiation of paraxial mesoderm intermediates (CD34-CD31-PDGFRβ- cells) 
to vSMCs in feeder-free, serum-free conditions 
After 5 days of differentiation in STEMdiff™ APEL™, CD34-CD31-PDGFRβ- cells were 
isolated by flow cytometry assisted sorting (FACS), and plated onto 2µg/cm
2
 human plasma 
fibronectin coated plates (12,000 cells per cm
2
) and cultured in serum-free medium (SFM) 
with media changes every 2-3 days. The SFM consists of Opti-MEM (GIBCO, Invitrogen) 
supplemented with insulin, transferrin, selenium (ITS) supplement (GIBCO, Invitrogen), 
0.1mM β-mercaptoethanol (Sigma), 1% (5mg/ml) bovine serum albumin (Sigma). For 
differentiation towards vSMCs, the SFM was further supplemented with EGF (10ng/ml), 
bFGF (20ng/ml) and PDGFbb (GIBCO; 10ng/ml). The vSMCs were passaged using accutase 




6.3.4. RNA extraction and real-time PCR 
Total cellular RNA was isolated, reverse transcribed and quantitated using real-time PCR as 
described previously under Section 4.3.3. 
6.3.5. Flow cytomerty analysis and sorting 
Flow cytometry analysis of differentiated cells for cell surface antigens (VEGFR2, CD34, 
CD31, PDGFRβ, NG2, CD73, CD90, CD105) were performed and analyzed as previously 
described under Section 4.3.4.  
For intracellular antigens, the cells were harvested, fixed and permeabilized using BD 
Cytofix/Cytoperm™ fixation/permeabilization solution for 20 minutes at 4oC as per 
manufacturer’s instructions. After fixation/permeabilization, the cells were washed and non-
specific staining blocked with PBS/5% goat serum (30 minutes). Subsequently, the cells were 
labeled with appropriate primary antibodies (αSMA, CNN1, MYH11; details of the 
antibodies listed in Appendix III) diluted in BD Perm/Wash™ staining buffer for 15 minutes 
at 4
o
C, washed and fluorescently labeled using appropriate secondary antibodies (listed in 
Appendix III) for 15 minutes at 4
o
C. After washing thrice, the cells were resuspended in 
FACS buffer for analysis. 
The labeled cells were analyzed for surface marker and intracellular protein expression using 
Dako Cytomation CyAn ADP.  For sorting paraxial mesoderm intermediates, the cells labeled 
with surface markers were sorted using a Dako Cytomation MoFlo high speed flow 
cytometer. The flow cytometry data was further analyzed using FlowJo v7.6.5 (TreeStar). 
6.3.6. Immunocytochemistry 
Immunocytochemical staining of differentiated cells for appropriate primary antibodies 
(αSMA, CNN1; details listed in Appendix III) were performed and documented as previously 
described under Section 4.3.5. 
6.3.7. Contractility assays 
Agonist-induced contraction of the hESC-differentiated cells was assessed as previously 




PDGFRβ+ progenitor cells differentiated under smooth muscle inducing conditions for 3-6 
passages were stimulated with 10
-5
M carbachol (Sigma) in Opti-MEM for 30 minutes. In a 
separate experiment, the cells were treated with muscarinic antagonist 10
-4
 atropine (Sigma) 
in Opti-MEM for 1 hour before induction with carbachol. The cells were visualized using 




6.3.8. Human angiogenesis antibody array 
Human Angiogenesis Proteome Profiler™ antibody array (R&D Systems) was used to survey 
the levels of 55 different angiocrines secreted by H1-hESC derived vSMCs into culture 





. After 24 hours, the media was changed to SFM without any additional 
supplements and incubated for 24 hours. After the incubation the culture supernatants were 
collected and stored at -80
0
C. Total protein concentration within cell-free culture supernatants 
were quantified using Micro BCA™ Protein Assay Kit (Thermoscientific) as per 
manufacturer’s instructions. Cell culture supernatant containing 200µg of protein was used 
for the antibody array as per manufacturer’s instructions. The membranes were developed 
using 10 minute exposure to X-ray film. The array data was quantified by densitometry 
analysis using Image J (NIH, USA). The various angiocrines in the protein blot are listed in 
Appendix IV. 
6.3.9. Statistical Analysis 
All real time RT-PCR and angiogenesis antibody array experiments were performed in 
duplicates with duplicate readings each. Student’s t-test was performed to determine 
significance using Microsoft Excel Data Analysis ToolPak. For angiogenesis antibody arrays, 
the density of each protein blot was quantified by a densitometry analysis using Image J 
software. The pixel densities corresponding to the negative control spots within each array 
was used as controls to normalize the density corresponding to each protein spot. These pixel 
density values were used as relative pixel density measurements to compare the expression 
levels of the proteins between different blots. 
6.4. Results 
6.4.1. Directed Differentiation of hESCs to paraxial mesoderm intermediates under 
chemically-defined conditions 
A variety of markers have been used to identify/ track the progenitors that give rise to 
vSMCs, including CD34, CD31, VEGFR2, PDGFRα, PDGFRβ, NKX2.5, ISL1, TCF15, and 
p75 (Cheung and Sinha, 2011). In early embryonic development, PDGFRα, PDGFRβ, and 
TCF15 indicate commitment towards paraxial mesoderm (Cheung et al., 2012; Sakurai et al., 
2006; Sakurai et al., 2012; Takakura et al., 1997; Yang et al., 2008b); and PDGF receptors are 
associated with progenitors for cardiac, smooth muscle, and mesenchymal lineages (Evseenko 
et al., 2010). We utilized paraxial mesoderm marker PDGFRβ in association with lateral plate 
mesoderm markers (VEGFR2, CD34, CD31) to track the commitment towards paraxial 




conditions as previously mentioned in Section 4.3 and 4.4. Briefly, the hESCs were 
differentiated by sequential modulation of Wnt/β-catenin using CHIR99021 followed by FGF 
and VEGF signaling pathways (Figure 48). This step-wise modulation resulted in ~55% of 
the differentiated cells positive for VEGFR2, CD34, and CD31 after 5 days of differentiation 
(Figure 48). Analysis of CD34, CD31 and PDGFRβ expression showed that almost 35% of 
the differentiated cells were positive for PDGFRβ, but this subset was negative for CD34 and 
CD31 (Figure 48). Further, almost 96% of CD34 and CD31 negative population expressed 
PDGFRβ, while only ~8% of CD34 and CD31 positive cells expressed PDGFRβ (Figure 49). 
Expression of PDGFRβ (paraxial mesoderm marker) and simultaneous absence in the 
expression of lateral plate mesoderm markers (VEGFR2, CD34, CD31) among the subset of 
differentiated cells is indicative of potential commitment of the subpopulation towards 
paraxial mesoderm.  
6.4.2. Terminal differentiation of PDGFRβ+CD34-CD31- paraxial mesoderm 
intermediates towards vascular smooth muscle lineage under serum-free conditions 
During early embryonic development, paraxial mesoderm is a potential source of vSMCs. 
During vasculogenesis and angiogenesis, PDGFbb induces the differentiation of mesenchymal 
progenitors towards vSMC lineage (Flamme et al., 1997; Jain, 2003). To terminally 
differentiate hESC-derived paraxial mesoderm progenitor population towards vascular 
smooth muscle lineage, the PDGFRβ+CD34-CD31- was FACS sorted after 5 days of 
differentiation. The sorted population was seeded onto fibronectin coated plates and cultured 
in SFM supplemented with EGF, bFGF and PDGFbb (Figure 50). Within one passage, the 
PDGFRβ+CD34-CD31- cells attained a spindle-shaped morphology and were observed for 
over 10 passages (Figure 50). These cells were characterized for vSMC phenotype by real 
time RT-PCR, flow cytometry and immunocytochemistry after 3-6 passages.  
Real time RT-PCR analysis showed the PDGFRβ+CD34-CD31- cells expressed early SMC 
markers (αSMA, CNN1, TAGLN), late SMC markers (MYH11, SMTN) and PDGFRβ (Figure 
50). On the other hand, these cells showed down-regulation of endothelial-associated genes 
(CD34, CD31, VE-CAD). Flow cytometry analysis for cell surface marker expression profile 
displayed that the PDGFRβ+CD34-CD31- cells were negative for CD34 and CD31, while 
~65% of the cells were positive for PDGFRβ (Figure 51). Analysis of pericyte markers 
showed that ~96% of the cells were positive for pericyte marker, NG2 with ~62% of the cells 
double positive for PDGFRβ and NG2 (Figure 51). Analysis of mesenchymal/ perivascular 
markers showed that almost all of the cells were positive for CD73 and CD105, while only 
~32% of the cells were positive for CD90 (Figure 51). Flow cytometry analysis of SMC-




markers (αSMA, CNN1) and late SMC marker (MYH11) (Figure 51). Immunocytochemical 
analysis also displayed the cytoplasmic, filamentous expression of αSMA and CNN1 (Figure 
51). Expression of perivascular markers at mRNA and protein levels indicates the terminal 
differentiation to vSMC phenotype and these cells would be referred to as H1-vSMCs.  
6.4.3. In-vitro functionality of H1-vSMCs 
vSMCs/ pericytes are heterogeneous group of mesenchymal cells that exhibit phenotypes 
ranging from contractile to synthetic phenotype. The in-vitro functionality of H1-vSMCs in 
terms of their ability to contract was investigated upon stimulation with cholinergic 
(muscarinic) agonist, carbachol and muscarinic antagonist atropine. Stimulation of H1-
vSMCs with 30 minute exposure to carbachol showed marked contraction of most of the cells 
that was abolished by preincubation with atropine (Figure 52).  
To investigate the synthetic function of these H1-vSMCs, the production of extracellular 
matrix components (Collagen IV, fibronectin, laminin) and various proteinases was analyzed. 
Immunohistochemical staining revealed that H1-vSMCs produce their own extracellular 
matrix proteins fibronectin, laminin and traces of collagen IV (Figure 52). Further, culture 
supernatants of H1-vSMCs were screened for matrix metalloproteinase (MMPs; MMP8, 
MMP9), ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs), 
serpins (serine protease inhibitors; serpin-B5, E1, F1) and tissue inhibitor of 
metalloproteinases (TIMP; TIMP1, TIMP4) using angiogenesis protein array.  Protein blots of 
the culture supernatants displayed the secretion of MMP9, Serpin-E1, Serpin-F1 and TIMP-1 
(Figure 53, 54). H1-vSMCs, in comparison to H1-Art-ECs and H1-Ven-ECs, display higher 
levels of secretion of Serpin-E1, Serpin-F1 and TIMP1; and in comparison to H1-Art-ECs, 
secrete significantly lower levels of MMP9 (Figure 55).  
Analysis angiogenesis protein array also revealed the secretion of various angiocrine and pro-
inflammatory factors by H1-vSMCs that include Activin A, angiogenin, endostatin, IGFBP (-
1,2,3), IL-8, monocyte chemoattractant protein (MCP-1), PDGFaa, pentraxin 3, urokinase 
type-plasminogen activator (uPA), and VEGF (Figure 53, 54). Levels of secretion of most of 
these factors are significantly higher compared to H1-Art-ECs and H1-Ven-ECs (Figure 55). 
Further, the H1-vSMCs secreted significantly high amounts of angiogenic factors that include 
activin A, angiogenin, IGFBP (1-3), IL-8, VEGF, and uPA. However, the H1-vSMCs also 
secreted significantly high amounts of certain anti-angiogenic factors that include Serpin F1, 
thrombospondin-1 (TSP-1), and TIMP1. Hence, the various angiocrines factors secreted by 
H1-vSMCs might provide a balanced angiogenic and anti-angiogenic signals for H1-Art-ECs 





In this part of the study, we developed a feeder- and serum-free differentiation system to 
efficiently generate origin-specific vSMCs from hESCs. Inhibition of GSK-3 followed by 
stepwise stimulation with bFGF and VEGF led to robust differentiation of H1-hESCs towards 
two distinct population, PDGFRβ-CD34+CD31+ (lateral plate mesoderm/ endothelial 
progenitors) and PDGFRβ+CD34-CD31- (paraxial mesoderm intermediates). The 
PDGFRβ+CD34-CD31- cells were further differentiated to vSMCs under serum-free 
conditions. The H1-vSMCs were characterized for expression of vSMC-related markers, 
secretion of ECM proteins and their ability to contract upon stimulation with cholinergic 
(muscarinic) agonist, carbachol and muscarinic antagonist atropine.  Further, the expression 
profile of angiocrine factors were surveyed and compared with those of H1-hESC derived 
arterial and venous ECs. 
vSMCs are a heterogeneous group of vascular cells derived from diverse developmental 
origins that include lateral plate mesoderm, paraxial mesoderm and neural crest (Majesky, 
2007). Interestingly, vSMCs derived from different origins are reported to display distinct 
functional properties. For instance, SMCs derived from neural crest and mesoderm display 
different growth and transcriptional responses to the stimulation with morphogenetic factors 
such as TGFβ1 (Topouzis and Majesky, 1996). Similarly, hPSC-derived vSMCs of different 
origin exhibit differences in activation of MMPs & TIMPs in response to IL-1β (Cheung et 
al., 2012).  Protocols to differentiate hESCs towards vSMCs initially relied on differentiation 
towards spindle-shaped cells that express vSMC-related markers without due consideration 
for their diverse developmental origin (Huang et al., 2006; Vo et al., 2010; Xie et al., 2007). 
Developmental insights, lead to protocols demonstrating the differentiation of hESCs towards 






 cells) capable of 
differentiation towards endothelial and smooth muscle lineages (Bai et al., 2010; Ferreira et 







 is expressed by lateral mesodermal subsets, protocols 
utilizing these markers could be assumed to be yielding vSMCs of lateral plate mesoderm 
origin. Similarly, certain groups have reported the differentiation towards vSMCs through a 
hESC/iPSC-derived mesenchymal stem cell (MSCs) intermediates (Bajpai et al., 2012; Guo et 
al., 2013). Recently, Cheung et al., reported differentiation of hPSCs to vSMCs through 
lateral plate mesoderm, paraxial mesoderm and neural crest progenitors (Cheung et al., 2012). 
Similarly, Tan et al., had recently demonstrated the differentiation of hESCs to vSMCs 
through paraxial mesoderm intermediates (PDGFRα+CD34-) (Tan et al., 2013a). Hence, the 
recent studies based on PSCs, highlight the focus towards developing protocols for lineage-




In the current study, we modified our earlier protocol to differentiate hESCs to paraxial 
mesoderm and then to vSMCs (Tan et al., 2013a). We replaced Matrigel used in the previous 
study with human plasma fibronectin with the aim of reducing the use of xenogeneic 
products. Secondly, we used PDGFRβ instead of PDGFRα to track paraxial mesoderm 
intermediates, as studies in mouse embryos have demonstrated the selective expression of 
PDGFRβ by developing vSMCs; and the expression of PDGFRβ by the developing vSMCs 
was crucial for their recruitment onto the embryonic blood vessels (Hellstrom et al., 1999). 
Further, PDGFbb is well documented to induce the differentiation of vascular progenitors 
towards smooth muscle lineage (Cheung et al., 2012). For the cells to respond to PDGFbb, 
they should express the receptors for the same i.e., PDGFRβ. Hence, we believe that it is 
more prudent to track cells that express PDGFRβ, than the α-subtype (though the cells might 
express both the subtypes).   
Differentiation of the PDGFRβ+ cells in the presence of PDGFbb under serum-free conditions 
yielded cells with spindle-shaped morphology reminiscent of the mesenchymal cells like 
vSMCs, fibroblasts, and MSCs. However, gene expression, flow cytometry and 
immunocytochemical studies revealed the expression of various vSMC-related markers 
indicating the commitment to vSMC phenotype. Mature vSMCs are specialized type of 
vascular cells that can perform both synthetic function (to support blood vessels) and 
contractile function (to regulate vessel hemodynamics) (Majesky, 2003). Further, the vSMCs 
interact with the ECs to stabilize the nascent endothelial channels through cytokine 
interactions and production of ECM (Carmeliet, 2005; Jain, 2003). Hence, engineering 
functional vascular networks requires the presence of both the synthetic and contractile 
phenotypes. In this study, immunocytochemical evidence shows that hESC-vSMCs secrete 
ECM proteins fibronectin, laminin and traces of collagen IV. Similarly, analysis of hESC-
vSMC conditioned media using angiogenic antibody array show the production of MMP8, 
MMP9, Serpins (E1, F1) and TIMP-1. Additionally, the hESC-vSMCs also secrete various 
other angiogenic and antiangiogenic factors. These findings indicate the synthetic function of 
hESC-vSMCs. Contraction of hESC-vSMCs upon stimulation with carbachol is reminiscent 
of their contractile function. These results suggest that hESC-vSMCs possess the essential 
characteristics needed to support the formation of in-vitro microvasculature.      
In summary, improved protocols for differentiation of hESCs could yield highly purified 
cultures of hESC-vSMCs. These hESC-vSMCs display the molecular and functional 












Figure 48. Flow cytometry analysis VEGFR2, CD34, CD31 and PDGFRβ expression upon 
differentiation of hESCs towards paraxial mesoderm lineage. 
(a) Schematic representation of differentiation of H1-hESCs towards paraxial mesoderm by sequential 
treatment with CHIR99021 (+GSKi) and bFGF for 24 hours each followed by exposure to VEGF for 3 
days. Representative flow cytometry overlays display the kinetics of co-expression of VEGFR2 and 
CD34 (b), CD31 and CD34 (c), CD31 and PDGFRβ (d), and CD34 and PDGFRβ (e) over 5 day period 
of differentiation of H1-hESCs, in the presence of VEGF after initial treatment with GSKi and bFGF 







Figure 49. Flow cytometry analysis of co-expression of CD34, CD31 and PDGFRβ upon 
differentiation of hESCs towards paraxial mesoderm lineage. 
Representative flow cytometry overlays display the kinetics of co-expression of CD31, CD34 and 
PDGFRβ after 5 days of differentiation of H1-hESCs, in the presence of VEGF for 3 days after initial 
treatment with GSKi and bFGF for 24 hours each. Left panel shows the co-expression of CD31 and 








Figure 50. Terminal differentiation of PDGFRβ+CD34-CD31- paraxial mesoderm intermediates 
to vSMCs under serum-free conditions. 
(a) Schematic representation of differentiation of hESCs to paraxial mesoderm intermediates 
(PDGFRβ+CD34-CD31-) cells by sequential treatment with CHIR99021 (+GSKi), bFGF, followed by 




 cells were sorted using flow cytometry after 5 days of 
differentiation and further differentiated towards vSMCs under the influence of PDGFbb under serum-
free conditions. (b) Representative photomicrographs show the spindle-shaped morphology of H1-
vSMCs. mRNA profiles of pan-endothelial (c), and vSMC markers (d) after differentiation of H1-
hESCs towards vSMCs. For gene expression plots, the levels of expression were normalized to 
corresponding β-ACTIN values and are represented as relative to that of undifferentiated hESCs. Error 






Figure 51. Flow cytometry and immunocytochemical analysis of hESC-derived vSMCs. 
(a) Representative flow cytometry overlays display the expression of surface markers related to 
endothelial (CD34, CD31), vSMC/pericytes (PDGFRβ, NG2), and mesenchymal (CD73, CD90, 
CD105) cells. The overlays show co-expression of (i) CD34 and CD31; (ii) NG2 and PDGFRβ; (iii) 
CD73 and PDGFRβ; (iv) PDGFRβ and CD31; (v) CD90 and PDGFRβ; and (vi) CD105 and PDGFRβ. 
(b) Representative flow cytometry histogram overlays show the expression of intracellular protein 
αSMA, calponin (CNN1) and smooth muscle myosin heavy chain (MYH11). (c) Photomicrographs 
display the intracytoplasmic expression of smooth muscle-related proteins αSMA and CNN1 by H1-






Figure 52. Contractility and ECM production by hESC-derived vSMCs. 
The photomicrographs show the contractility of H1-vSMCs after 30 minute stimulation with carbachol 
(a) and lack of contraction when stimulated with carbachol after 1 hour preincubation with atropine 
(b). The photomoicrographs on the left and right side represent the pictures taken before and after 
stimulation with carbachol and arrows point at the cells that have contracted. (c) Photomicrographs 









Figure 53. Angiocrine secretory profile of hESC-derived vSMCs using angiogenesis antibody 
array. 
(a) Representative scan of angiogenesis antibody arrays demonstrating the secretion of various 
angiocrine factors by H1- vSMCs. Array images are obtained from 10-minute exposure of X-ray film. 
(b) Graphical representation of the relative amounts of angiocrine factors secreted by H1-vSMCs. The 
bars represent relative amounts of factors secreted based on densitometric analysis of relative pixel 
density of the blots. Figure 54 provides the complete densitometric analysis of all the 55 angiocrine 








Figure 54. Survey of secretory profile of 55 angiocrines by hESC-derived vSMCs using angiogenesis antibody array. 
Graphical representation of the relative amounts of 55 angiocrine factors secreted by H1-vSMCs analyzed using angiogenesis antibody array. The bars represent relative 








Figure 55. Comparison of angiocrines secreted by hESC-derived vSMCs and hESC-derived ECs 
using angiogenesis antibody array. 
Graphical representation of the relative amounts of selected angiocrine factors among H1-vSMCs and 
H1-Art-ECs (a), H1-vSMCs and H1-Ven-ECs (b). The bars represent relative amounts of factors 
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7. Fabrication of in-vitro vascularized tissue equivalents using hESC-derived 
arterial ECs and vSMCs 
 
7.1. Introduction 
One of the major obstacles challenging successful tissue engineering is the scaffold 
vascularization that can support the survival of implanted cells in-vivo (Novosel et al., 2011). 
Tissue constructs could be vascularized, either by promoting the invasion of host vasculature 
into the graft or by using vascular cells within the graft that could form vascular networks and 
integrate with the host vasculature (Kaully et al., 2009; Rivron et al., 2008). However, studies 
have shown that prevascularization of the tissue construct enables accelerated engraftment of 
the implanted tissues by anastomoses of graft vasculature with host vasculature (Chen et al., 
2009; Tremblay et al., 2005). Additionally, protocols to fabricate in-vitro 3D vascularized 
tissue equivalents could provide an in-vitro platform to study vascular morphogenesis, 
angiogenesis modulating factors, barrier properties of ECs (permeability) and also aid in 
development and testing of various vascular pharmaceutical products.  
7.2. Objective 
To investigate the potential of, 
1. hESC-Art-ECs to self-assemble into microvascular networks within a 3D 
microenvironment under serum-free conditions. 
2. hESC-vSMCs to support and stabilize the microvascular networks formed by hESC-Art-
ECs. 
3. PEG-Fibrin gels to support the fabrication of in-vitro vascularized tissue equivalents. 
7.3. Materials and Methods 
7.3.1. Fluorescent labeling of hESC-derived arterial ECs and vSMCs 
To enable visualization of cells within a 3D culture system, the hESC-derived vascular cells 
were fluorescently labeled. To fluorescently label H1-Art-ECs, H1-hESCs expressing 
enhanced green fluorescent protein (eGFP) was used. The H1-hESCs expressing eGFP was 
established by members of A/P Cao Tong. Briefly, H1-hESCs grown on mouse embryonic 
fibroblasts were single cell dissociated using accutase and transfected with a plasmid 
construct consisting of pAcGFP1-1 backbone with pCAG-GFP promoter (Clontech) using X-
tremeGENE HP DNA Transfection Reagent (Roche). The transfected H1-hESCs were seeded 
onto mouse embryonic fibroblast feeders and medium was supplemented with Y27632 




attachment. With every passage colonies expressing eGFP were manually selected and 
passaged to obtain H1-hESC colonies with homogeneous expression of eGFP. These H1-
hESCs expressing eGFP were then transferred to feeder-free system over Matrigel (BD 
Biosciences) and mTeSR1 (StemCell Technologies). After the H1-hESCs were adapted to 
feeder-free system for more than 5 passages were differentiated using sequential modulation 
of Wnt, FGF, BMP and VEGF signaling pathways as described earlier in Chapter 5. After 5 
days of differentiation, H1-hESCs expressing eGFP, CD34 and CD31 were sorted using 
FACS and differentiated further towards arterial ECs in ESFM supplemented with EGF, 
bFGF and VEGF as described in Chapter 5. The H1-Art-EC
eGFP+
 were cultured for at least 3 
passages before characterization and use for co-culture studies. 
To fluorescently label hESC-derived vSMCs, the H1-hESCs were differentiated to vSMCs as 
described in Chapter 6. The H1-vSMCs were then transduced with a reporter lentiviral 
construct encoding DsRed2 gene. This part of the research was done in collaboration with Dr. 
Gan Shu Uin (Department of Surgery, National University of Singapore). Briefly, WPT-
DsRed2 lentivirus was produced by transient transfection of 5x10
6
 293T cells seeded in 10cm 
tissue culture plates 24 hours before transfection via polyethylenimine-mediated transfection 
method with 5μg pWPT-DsRed2 vector, 3.75μg helper plasmid pPax2, and 1.75 μg of MD2G 
envelope plasmids (gifts from Dr. D Trono, University of Geneva, Geneva, Switzerland). 
Fresh medium was added 14-16 hours after transfection. Following supernatant filtration 
through a 0.45μm filter, the viral titer on 293T cells was determined using flow cytometry. 
SMCs were infected with supernatant containing pWPT-DsRed2 at a multiplicity of infection 
(MOI) of 5, and sorted for DsRed2 positivity subsequently. The H1-vSMC
DsRed+
 were cultured 
for at least 3 passages before characterization and use for co-culture studies. 
7.3.2. Flow cytomerty analysis and sorting 
Flow cytometry analysis of differentiated cells for cell surface antigens (CD34, CD31, 
VEGFR2, PDGFRβ, NG2, CD90, CD73, CD105) were performed and analyzed as previously 
described under Section 4.3.4. The labeled cells were analyzed using Dako Cytomation CyAn 
ADP.  For sorting paraxial mesoderm intermediates, the cells labeled with surface markers 
were sorted using a Dako Cytomation MoFlo high speed flow cytometer. The flow cytometry 
data was further analyzed using FlowJo v7.6.5 (TreeStar). 
7.3.3. Fabrication and culture of 3D tissue equivalents 
Fibrinogen from bovine plasma (MP Biomedicals, Cat. No. 154165) and polyethylene glycol- 
4-arm, succinimidyl glutarate terminated (Sigma, Cat No. 565768; 10,000 Da; PEG) were 




published (Natesan et al., 2012; Natesan et al., 2011). Briefly, fibrinogen was reconstituted at 
a concentration of 80mg/ml in 0.1 M sodium bicarbonate (pH8.3) at room temperature with 
gentle shaking for 1 hour and aliquots stored at -80
0
C (Appendix V). PEG was reconstituted 
at a concentration of 8mg/ml at aliquots stored at -20
0
C. To fabricate PEGylated fibrin gels, 
fibrinogen and PEG were mixed in a ratio of 40:1 such that the final concentrations of 
fibrinogen and PEG in the gel would be 10 mg/ml and 0.25 mg/ml respectively. The resultant 
PEG-fibrinogen solution was incubated at 37
0





) were suspended in appropriate volumes of media and 
mixed with PEG-Fibrinogen solution (Appendix VI). Thrombin (Sigma) was used to aid the 
gelation of PEG-fibrinogen solution. Thrombin (100U/ml) was mixed with calcium chloride 
(40mM) in a ratio of 1:3 to yield a final concentration of 12.5U/ml in the gel. The PEG-
fibrinogen-cell suspension was allowed to undergo gelation by addition of equal volume of 
thrombin-calcium chloride solution. The cell-gel mixture was pipetted into a 12-well culture 
insert (9mm) or into angiogenesis µ-slides (ibidi), incubated at 37
0
C for 10 minutes for 
complete gelation. After the incubation, the gels were incubated with ESFM supplemented 
with bFGF (20ng/ml), EGF (10ng/ml) and VEGF (10ng/ml). 
7.3.4. Optimization of density of ECs in the 3D co-culture system 
To determine the optimal concentration of ECs and vSMCs within the co-culture system 
different densities of ECs were used. The ratio of vSMCs/ pericytes to ECs is reported to vary 
from 1:1 to 1:100 depending on the tissue in the body (Shepro and Morel, 1993). We used a 
fixed vSMCs to ECs ratio of 1:10 for all the experiments. For optimization experiments, H1-
Art-ECs
eGFP+








 ECs per ml of PEG-
fibrin gel with H1-vSMCs
DsRed+
 at a density corresponding to a ratio of 1:10 (vSMCs:ECs). 
For these experiments, the 3D PEG-fibrin gels were casted into angiogenesis µ-slides (ibidi).  
Images of microvascular networks were captured using laser scanning confocal microscope at 
a 10x magnification after 6 days of culture. The individual z-stacks of the resultant images 
were stacked into a single two-dimensional image using Olympus Fluoview ver.3.0 viewer. 
7.3.5. Confocal Imaging of 3D tissue equivalents 
To facilitate imaging of 3D tissue equivalents, the PEG-fibrin gels were casted into 
angiogenesis µ-slides (ibidi). µ-slide angiogenesis is a special slide with 15 microwells 
available primarily for assessing endothelial tube formation over Matrigel (Figure 18). Each 
microwell of the µ-slide is of 5mm in diameter and contains another smaller microwell 
compartment of 4mm diameter and 0.8 mm depth. The inner well is designed to hold the 
matrix/ 3D scaffold (volume=10mm
3







The 3D tissue equivalents with H1-Art-ECs
eGFP+
 with or without H1-vSMCs
DSR+
 were imaged 
by confocal microscope (Olympus FluoView™ FV1000). Imaging fields consisted of 4-5 
randomly selected fields within each microwell of the 3D co-culture. Z-stacks were obtained 
at 4x, 10x, 20x and 60x magnifications at various time points that include 0, 3, 6, 9, 12, 15, 
and 18 days. The z-stacks obtained were processed using Imaris v6.1.5 software. 
7.3.6. In-vitro 3D permeability assay  
To assess the permeability of vascular channels in-vitro in a 3D microenvironment a model 
using inverse permeability was recently developed (Grainger and Putnam, 2011). Briefly, 
dextran-Texas Red conjugated (molecular weight of 70kDa, Invitrogen) was used as the tracer 
dye to assess the permeability of the microvessels. To enable visualization using confocal 
microscopy, 3D vascularized tissue constructs were fabricated using H1-Art-ECseGFP+ and 
H1-vSMCs (non-fluorescent). After 18-21 days of culture, the 3D vascularized constructs 
were incubated with dextran (5mg/ml) in ESFM for 30 minutes at 37
o
C, washed thrice with 
PBS (for 10 minutes each) and imaged using laser-scanning confocal microscope. In some 
experiments, the 3D constructs were preincubated with histamine (100µM, Sigma) for 5 
minutes before incubation with dextran. 
7.3.7. Statistical Analysis 
All tube formation assays were performed in triplicates with duplicate readings each. The 
total tube length (expressed in pixels), number of tubes and number of branching points were 
analyzed using WimTube Key Metrics Program (Wimasis GmbH, Munich, Germany). One-
way ANOVA with Bonferroni post-hoc test was used to determine significance between 
groups using GraphPad Prism 4.02.  
7.4. Results 
7.4.1. Fluorescent labeling of hESC-Art-ECs 
To facilitate visualization of the ECs within the 3D environment, the hESC-Art-ECs were 
differentiated from H1-hESCs expressing eGFP (Figure 56). The differentiated cells 
displayed characteristic cobblestone morphology and almost all of the cells expressed eGFP 
(Figure 56). Using flow cytometry, the proportion of H1-Art-ECs expressing eGFP and 
endothelial markers were analyzed. Bivariate flow cytometry plots reveal ~100% of the cells 
express eGFP and these cells co-express CD31 (~100%), CD34 (~92%) and VEGFR2 
(~98%) indicating the endothelial characteristic of these cells (Figure 56). These eGFP 






7.4.2. Fluorescent labeling of hESC-vSMCs 
To enable the visualization of vSMCs within the 3D environment, the hESC-vSMCs were 
differentiated to PDGFRβ+CD34-CD31- cells from H1-hESCs as described earlier in Chapter 
6. The PDGFRβ+CD34-CD31- cells were sorted by FACS and differentiated to H1-vSMCs. 
The H1-vSMCs were then transduced with lentivirus encoding DS-Red2. The H1-vSMCs 
after transduction were passaged for 2-3 passages before characterization and usage for 
further studies. The H1-vSMCs after transduction maintained the spindle-shaped morphology 
and almost all of the cells expressed DS-Red2 (Figure 57). However, the intensity of 
fluorescence was heterogeneous with some of the cells been bright and certain others faint. 
Using flow cytometry, the proportion of H1-vSMCs expressing DS-Red2, and perivascular 
markers were analyzed. Bivariate flow cytometry plots reveal almost 100% of the cells 
express DsRed2, however there were two populations corresponding to the intensity of 
fluorescence (Figure 57). These cells co-expressed CD73 (~100%), CD90 (~48%) and 
PDGFRβ (~74%) while they lacked the expression of CD34 and CD31 similar to the H1-
vSMCs before the transduction (Figure 57). These DS-Red2 expressing H1-vSMCs would be 
referred to as H1-vSMCs
DsRed+
.  
7.4.3. Co-culture of H1-hESC derived ECs and vSMCs within PEG-fibrin gels 
To fabricate 3D vascularized tissue equivalents and visualize the self-assembly of ECs into 





cultured within PEG-fibrin gels casted into angiogenesis µ-slides (ibidi). Each gel occupied 
the inner well of the µ-slides and occupied a volume of 10mm
3
 (4mm x 4mm x 0.8mm). To 
validate the ability of these cells to form microvascular networks in larger formats, the 3D 
vascularized tissue equivalents were fabricated within 12-well culture inserts using 300mm
3
 
of PEG-fibrin gel. Further to provide the serum-free conditions, the 3D tissue equivalents 
were cultured in ESFM supplemented with EGF, bFGF and VEGF. 
7.4.3.1. Optimization of seeding density of ECs within the 3D PEG-fibrin co-culture 
system 
To determine the optimal concentration of ECs and vSMCs within the co-culture system 
different densities of ECs were used. The ratio of vSMCs/ pericytes to ECs is reported to vary 
from 1:1 to 1:100 depending on the tissue in the body (Shepro and Morel, 1993). We used a 
fixed vSMCs to ECs ratio of 1:10 for all the experiments. For optimization experiments, H1-
Art-ECs
eGFP+








 ECs per ml of PEG-
fibrin gel with H1-vSMCs
DsRed+




Various parameters related to microvascular networks that include total length of the vascular 
network, total number of tubes and the number of branching points within the network were 
used to narrow down on the optimal density of ECs for further experiments. Density 
optimization studies showed a significant increase in the total tube length, number of tubes, 
and number of branching points with increase in the seeding density of ECs (Figure 58). 
Based on these experiments, a density of 2.5x10
6
 ECs per ml of PEG-fibrin gels with vSMCs 
at a ratio of 1:10 (vSMCs:ECs) were used for further studies. 
7.4.3.2. Bicellular environment results in stable microvascular networks 
To investigate whether H1-Art-ECs could self-assemble into microvascular network, H1-Art-
ECs
eGFP+
 at density of 2.5x10
6
 ECs per ml of PEG-fibrin gel were cultured within µ-slides. 
After 1 day of culture most of the H1-Art-ECs
eGFP+
 were primarily rounded, while some of the 
ECs had elongated cytoplasm indicating endothelial sprouting. Though, the H1-Art-ECs
eGFP+
 
formed short anastomosing cords of ECs after 4 days of culture, by 6
th
 day of culture the 





day of culture no cells were visible for visualization by confocal microscopy.  
On the other hand, when H1-Art-ECs
eGFP+
 were co-cultured with H1-vSMCs
DsRed+
, the ECs 
formed robust microvascular networks that increased in number, length, and complexity with 
increasing days of culture (Figure 60). Further, these bicellular microvascular networks were 
stable in culture for 3 weeks (Figure 60). Furthermore, the size of PEG-fibrin gel constructs 
remained the same (~zero shrinkage) for the entire 3-week period.  
Based on these results we speculate that the inability of H1-Art-ECs to form stable 
microvascular networks within PEG-fibrin gels is due to the lack of H1-vSMCs within the 
culture system. While, the addition of H1-vSMCs into the culture milieu, resulted in 
formation of stable microvascular networks. 
7.4.3.3. Vascular morphogenesis within PEG-fibrin gels 
We next sought to investigate the morphological changes during the formation and maturation 
of microvascular networks within PEG-fibrin gels under serum-free conditions. Starting from 
1
st




 within PEG-fibrin 
gels, z-stack images were obtained over a period of 3 weeks (i.e., days 1, 4, 6, 9, 12, 15, 21) 
using confocal microscopy. After culturing for 1 day, though most of the cells were rounded, 
vacuoles were observed within many of these ECs and sprouting of a few ECs, with the 
vacuolation extending into the sprouts as well (Figure 61). On the other hand, the vSMCs 




After 4 days of culture, tubulogenesis progressed rapidly resulting in extensive sprouting, 
network formation and occasional endothelial tubules with open lumen (Figure 61). The 
DsRed2-expressing H1-vSMCs were seen to have longer processes with some of the cells/ 
cellular processes in close proximity to the eGFP-expressing endothelial tubules. After 6 days 
of culture, the eGFP-expressing endothelial tubules could be seen to be thicker, with more 
complex network formation and open, inter-connected lumen-like structure (Figure 61). After 
day 6, the network of endothelial tubules seems to become more complex forming a 





 formed bicellular microvascular networks within PEG-fibrin 
gels within a week, and matured further in terms of thickness, anastomosis and network 
formation. Further, the bicellular microvascular networks were stable over a period of 3 
weeks.  





 reveal the presence of DsRed2-expressing H1-vSMCs just on 
the periphery of the eGFP-expressing endothelial tubules (Figure 60, 61). Also, some of the 
H1-vSMCs
DSR+
 are seen to encircle the endothelial tubules.  
Hence, using ibidi µ-slides we were able to fabricate micro-3D vascularized tissue constructs. 
To validate the utility of hESC-derived vascular cells in scaling up to a macro-3D constructs, 
PEG-Fibrin gels were casted within 9mm-culture inserts using 300µl of PEG-fibrin. Figure 
62 shows the naked eye view of the construct after 21 days of culture. Confocal imaging of 
the construct reveals anastomosing network of microvascular channels within the in-vitro 
vascularized tissue equivalent (Figure 62). Hence, the hESC-derived vascular cells and PEG-
fibrin gels could be utilized to engineer in-vitro 3D vascularized tissue equivalents.  
7.4.3.4. In-vitro assessment of permeability of the microvascular channels 
To assess the permeability of microvascular channels within the in-vitro 3D vascularized 
tissue equivalents, we used the ability of dextran-Texas Red (Molecular weight of 70kDa) to 
permeabilize the vascular channels. Confocal imaging of the 3D constructs after incubation 
with the tracer dye revealed that most of the microvessels were impermeable to the dye 
(Figure 63). On the other hand, pre-incubation of the constructs with histamine resulted in 
marked increase in the permeability of the microvascular channels as evidenced by the 
presence of aggregates of the tracer dye within the lumen (Figure 63). Hence, the 
microvascular channels within in-vitro 3D vascularized tissue equivalents were mature in 
terms of their barrier function, and also were capable of regulating the permeability in 





All tissues in the body except skin, cartilage and cornea require presence of a vascular 
network for nutrient and oxygen supply. Hence, tissue engineering and regeneration of tissues 
and organs require the formation of vascular network within the implant. Various strategies 
for vascularization using scaffolds, cells and local delivery of angiogenic factors have been 
investigated to enhance the ingrowth of vessels from the host into the implant (Novosel et al., 
2011). However, this process involves considerable amount of time for neovascularization of 
the implant. Hence, use of large grafts is not clinically feasible as the cells in the core of the 
implants undergo necrosis due to lack of nutrition (Johnson et al., 2011; Tsigkou et al., 2010). 
An alternative approach is to prevascularize the tissue construct in-vitro or in-vivo to expedite 
the process of blood supply for the implant. Secondly, establishment of 3D prevascularized 
tissue equivalents would aid in development and testing of pharmaceutical products which 
otherwise are limited to use of conventional monolayer cell culture systems and/or animal 
experiments. 
ECs have an inherent capability to self-assemble upon 2D direct co-culture or 3D culture 
within angiogenic biomaterial. However, the development of a vasculature of mature and 
functional vasculature depends not only on the ECs but also requires the interaction with 
mural cells (vSMCs/ pericytes) (Carmeliet and Conway, 2001; Ghanaati et al., 2011; Jain, 
2003). Additionally, they require the ECM to adhere, migrate and assemble into anastomosing 
network of vascular channels. In addition to providing a scaffold for the ECs to form vascular 
networks, the ECM also acts as a growth factor sink by sequestering and releasing various 
growth factors and other signaling molecules (Kubota et al., 1988; Sahni et al., 2000; Sahni 
and Francis, 2000; Sahni et al., 2006). Many studies have demonstrated the ability of primary 
ECs in the presence of supporting cells (pericytes, SMCs, fibroblasts, MSCs) form 
microvascular networks when cultured within 3D microenvironment (Chen et al., 2009; 
Grainger and Putnam, 2011; Lesman et al., 2011; Montano et al., 2010; Tsigkou et al., 2010). 
Recently, self-organization of vascular networks from human PSC-derived vascular cells in a 
synthetic matrix that integrates with the host circulation has been reported (Kusuma et al., 
2013). 
In this chapter, we demonstrate that hESC-derived arterial ECs in the presence of hESC-
derived vSMCs form mature and stable microvascular networks within PEG-Fibrin gels under 
serum-free conditions. The presence of hESC-derived vSMCs seems to be a prerequisite for 
the formation of stable microvascular networks, as the vascular networks formed by hESC-
derived arterial ECs undergo early regression in the absence of hESC-derived vSMCs. Hence, 




network similar to the observations in-vivo and in-vitro (Carmeliet and Conway, 2001; Fuchs 
et al., 2007; Jain, 2003; Kolbe et al., 2011; Lesman et al., 2011; Montano et al., 2010). The 
supportive function of the hESC-derived vSMCs could be due to direct contact or through 
paracrine signaling. Though detailed studies were not carried out to elucidate the mechanism 
of support, the observation of close proximity of hESC-derived vSMCs and endothelial 
channels especially at the branch points seems to suggest a supportive role through direct 
contact. Additionally, in the previous chapter it is shown that hESC-derived vSMCs secrete 
various positive and negative regulators of angiogenesis (Chapter 6, Figure 53). Hence, 
through these angiocrine molecules the hESC-derived vSMCs could support the formation 
and maturation of endothelial channels. Various co-culture studies have shown that 2D 
culture of mural cells and ECs lead to organization of ECs into anastomosing cords over the 
mural cells indicating the role of direct contact. The paracrine role of mural cell secreted 
factors in organotypic vessel formation has been reported by various studies (Antonelli-
Orlidge et al., 1989; Evensen et al., 2009; Kolbe et al., 2011). 
The density and extent of microvascular networks formed seem to depend on the density of 
hESC-derived ECs within the 3D construct. The number of tubules, branch points and their 
total length increased with increase in density of ECs seeded within the construct. Based on 
these observations, hESC-derived ECs were used at a density of 2.5x10
6
 cells/ ml of the 
construct along with hESC-vSMCs at a ratio of 10:1. Though various seeding densities of 
ECs were studied the effect of varying densities of hESC-derived vSMCs were not 
investigated.  
Various scaffolds have been used for engineering of vascularized tissues in-vitro and in-vivo. 
Scaffold vascularization using primary and hESC-derived vascular cells has been reported in 
hyaluronic acid, alginate, and dextran-based hydrogels (Hanjaya-Putra et al., 2011; Hanjaya-
Putra and Gerecht, 2009), fibrin gels (Chen et al., 2009; Lesman et al., 2011; Montano et al., 
2010), PEG-Fibrin gels (Natesan et al., 2012; Natesan et al., 2011), collagen gels (Koike et 
al., 2004; Wang et al., 2007), PLGA/PLLA scaffolds (Laschke et al., 2008; Levenberg et al., 
2005; Tsigkou et al., 2010) and other natural, synthetic and hybrid biomaterials. Fibrin-based 
scaffolds are an attractive option due to its angiogenic, biocompatible and biodegradable 
nature. However, fibrin lacks stiffness and undergoes rapid degradation both in-vitro and in-
vivo (Dikovsky et al., 2006). Stiffness of the fibrin hydrogels could be controlled by 
crosslinking with synthetic polymers like PEG (Dikovsky et al., 2006; Natesan et al., 2011). 
Hence, we investigated the potential of PEGylated-fibrin based scaffold and hESC-derived 
vascular cells for fabrication of in-vitro vascularized tissue constructs. The hESC-derived 




Additionally, the size of the PEG-Fibrin gel construct remained constant throughout the 3-
week culture period indicating the stability of the construct. 
Fluorescent labeling of hESC-derived ECs and vSMCs enabled the documentation of the 
distinct steps in the formation of microvascular networks. The microvascular network 
formation starts with the formation of intracellular vacuolation, followed by extension of 
endothelial cytoplasmic processes, organization of adjacent ECs into anastomosing cords, 
coalescence of the these vacuoles between adjacent ECs, recruitment of vSMCs, formation of 
endothelial tubules with patent lumen and increase in thickness of the vascular channels. 
Using PEG-fibrin gels, we found that hESC-derived vascular cells could self-assemble to 
form microvascular networks within 6-9 days that undergoes further maturation and is stable 
for 3 weeks in-vitro. Some of the earlier studies utilized histology, phase contrast and electron 
microscopy to study the various morphogenetic events during the formation of microvascular 
networks (Hanjaya-Putra et al., 2011; Montano et al., 2010). Though fluorescent labeling 
enabled us to easily track the various morphogenetic events during the formation 
microvascular network, the early events like basement membrane formation/ disruption, 
pinocytosis could probably be studied with more details using electron microscopy. Hence, 
our in-vitro vascularized tissue equivalent based on PEG-fibrin gel and hESC-derived 
vascular cells could provide a valuable platform to study the early morphogenetic events in 
vasculogenesis and angiogenesis in-vitro. Additionally, the fluorescent labeling allowed us to 
track the formation of vascular networks in a non-invasive manner.  
In this part of the study we demonstrate the fabrication of in-vitro vascularized tissue 
equivalent using co-culture of hESC-derived ECs and -vSMCs within PEG-Fibrin gels is 
possible. Fibrin has been well-demonstrated in the literature as an angiogenic natural 
biomaterial both in-vivo and in-vitro (Ahmed et al., 2008; Lesman et al., 2011; Montano et al., 
2010; Shaikh et al., 2008). Both fibrin and PEG has been approved by US-FDA for various 
clinical applications. In the current study, we used bovine fibrinogen to fabricate the PEG-
Fibrin gels for economic reasons. However, we believe that the protocol could be replicated 
using human fibrinogen, but needs further studies for validation.  
Functionality of in-vitro microvascular networks is usually defined as integration with the 
host vessels upon in-vivo implantation. In addition to the integration, these vessels need to 
possess sufficient barrier properties and also respond to inflammatory signals that increase/ 
decrease the permeability of the vessels. To assess the permeability of the implanted 
microvessels in-vivo, studies use fluorescent tracers and/or non-invasive live imaging (Samuel 
et al., 2013). In-vitro equivalent of permeability testing, typically measures the 




mural cells) in a transwell system (Adams et al., 2013). To assess the permeability of vascular 
channels in-vitro in a 3D microenvironment, a model using inverse permeability was recently 
developed (Grainger and Putnam, 2011). The principle behind this model of inverse 
permeability is that mature microvessels are impermeable to dextrans over a molecular weight 
of 65kDa, and a tracer would be able to enter inside the lumen of leaky vascular channels, 
while it cannot enter inside a vascular channel with mature, competent cell-cell endothelial 
junctions. We adapted this method of inverse permeability to assess the barrier properties of 
the microvascular networks within hESC-derived in-vitro vascularized tissue equivalents. The 
microvascular channels were generally impermeable to the tracer dye (dextran-texas red), 
while responded to treatment with histamine resulting in increased leakiness of the 
microvessels as evidenced by the presence of tracer dye into the lumen of these microvessels. 
The permeability assessment reveals the maturity and functionality of the hESC-derived 
microvascular channels in-vitro. Though in the original methodology proposed by Grainger 
and Putnam employed assessment of permeability after fixation, we were able to assess the 
permeability on live cultures due to the fluorescent labeling of ECs. Hence, we believe that 
these in-vitro vascularized tissue equivalents could be used as a research model to assess/ 
screen novel compounds for their effect on vascular permeability on a 3D platform. 
In conclusion, we demonstrate that in-vitro prevascularized tissue equivalents could 
fabricated using hESC-Art-ECs and hESC-vSMCs co-cultured within PEG-fibrin gels under 
serum-free conditions. Additionally, the role of hESC-vSMCs in supporting the formation of 
stable microvascular networks is demonstrated. Further, use of micro 3D constructs using 
ibidi µ-slides could provide in establishment of an economical and high-throughput platform 






Figure 56. Characterization of hESCs and hESC-derived ECs for eGFP expression. 
Photomicrographs display the expression of eGFP by H1-hESCs
eGFP+
 colonies (a) and H1-Art-ECs
eGFP+
 
cells (b) under 4x and 10x magnifications. (c) Flow cytometry plots display the co-expression of eGFP 
and CD31, CD34, VEGFR2 by H1-Art-ECs
eGFP+







Figure 57. Characterization of hESC-derived vSMCs for DS-Red2 expression. 
(a) Photomicrographs display the expression of DsRed2 by H1-vSMCs
DsRed+
 cells. (b) Flow cytometry 
plts display the co-expression of DsRed2 and endothelial-related markers (CD34,CD31), vSMC-related 






Figure 58. Optimization of seeding density of ECs within the 3D PEG-fibrin co-culture system. 
The bar graphs represent the various parameters of microvascular networks formed by H1-Art-ECs
eGFP+
 
when seeded with H1-vSMCs
DsRed2+
 at a ratio of 10:1 within PEG-Fibrin gels. The parameters of the 
microvascular networks represented are (a) total length of the vascular network, (b) total number of 




Figure 59. Kinetics of development of microvascular networks by hESC-ECs 
The representative photomicrographs display the 3D projection of the confocal z-stack images of the 
microvascular network formed by H1-Art-ECs
eGFP+
 cells after 3D culture in PEG-Fibrin gels for 1, 4 
and 6 days. The series of images show the sprouting of ECs to form anastomosing cords after 4 days of 






Figure 60. Kinetics of development of microvascular networks by hESC-ECs and –vSMCs. 
The representative photomicrographs display the 3D projection of the confocal z-stack images of the 
microvascular network formed by H1-Art-ECs
eGFP+
 (green) and H1-vSMCs
DsRed2+ 
(red) cells after 3D 
co-culture in PEG-Fibrin gels for 1, 4, 6, 9, 12, 15, and 21 days. The series of images show the 
sprouting of ECs that forms anastomosing cords after 4-6 days of culture and undergoes maturation in 
terms of thickness and interconnectivity of the endothelial networks with prolonged culture. Scale bar: 







Figure 61. Vascular morphogenesis and maturation of hESC-derived microvascular networks. 
The representative photomicrographs display the 3D projection of the confocal z-stack images of the 
microvascular network formed by H1-Art-ECs
eGFP+
 (green) and H1-vSMCs
DsRed2+ 
(red) cells after 3D 
co-culture in PEG-Fibrin gels for varying periods. All images except (a) consist of 4 parts. The upper-
left portion represents the image of a single z-plane with corresponding x-z (bottom-left) and y-z (top-
right) cross-sectional images of the microvascular networks; and the lower-right corner represents the 
3D projection of the confocal z-stack images. (a) 1 day after 3D co-culture, most of the ECs were 
rounded, but a few of the ECs displayed vacuoles (yellow arrowheads). (b) After 4 days the ECs 
displayed tubulogenesis resulting in extensive sprouting, network formation. Some of these endothelial 
tubules displayed vacuoles/ lumen (yellow arrowheads) and others were resembled cords (white 
arrowheads). With progression of 3D co-culture (c-f) the endothelial networks grew thicker in size and 
displayed lumen-like structures (thin-yellow arrows). Additionally, the DsRed2-expressing H1-vSMCs 
(thin-white arrows) are seen in close proximity to the eGFP-expressing endothelial tubules. Further 
these vSMCs are seen to be on the periphery of the endothelial tubules. Also, the vSMCs are seen 
in/near the branch points of the endothelial networks. Higher magnification of the endothelial tubules 
shows a clear lumen (g, h). The photomicrographs in (g, h) represent the z-stacks at different layers of 
the same 3D image. These lumenized structures are surrounded by ECs that display regularly 
alternating nuclei (thick-white arrows) and cytoplasm (thick-yellow arrows). Scale bar in (a-f) 50µm; 






Figure 62. In-vitro vascularized tissue equivalent. 
The figures show the in-vitro vascularized tissue equivalent fabricated within a 9mm-culture insert. (a) 
PEG-Fibrin gel with microvascular networks after 21 day culture period measuring ~9mm in diameter. 
Scale: each unit equals 1 mm. (b,c) The representative photomicrographs display the 3D perspective of 
the confocal z-stack images of the microvascular network formed by H1-Art-ECs
eGFP+
 (green) and H1-
vSMCs
DsRed2+ 
(red) cells after 3D co-culture in PEG-Fibrin gels for 21 days within a 9mm-culture 






Figure 63. Assessment of vascular permeability of microvascular networks. 
The representative photomicrographs display the 3D projection of the confocal z-stack images of the 
microvascular network formed by H1-Art-ECs
eGFP+
 (green) and H1-vSMCs (not visible) after 3D co-
culture in PEG-Fibrin gels. All images except consist of 4 parts. The upper-left portion represents the 
image of a single z-plane with corresponding x-z (bottom-left) and y-z (top-right) cross-sectional 
images of the microvascular networks; and the lower-right corner represents the 3D projection of the 
confocal z-stack images. Permeability of the vascular channels was assessed using dextran-texas red 
(red particles/ clumps). (a-c) The microvascular channels were generally impermeable to the dextran 
molecule i.e., the dextran molecules are seen outside the vessel wall, and the lumen is clear. (d-h) 
However, upon preincubation of the vascular channels with histamine, resulted in permeabilization of 
the dextran molecule into the lumen (white arrows) of the microvascular channels, indicating the 
leakiness in response to histamine. The cross-sectional view of the microvessels shows the presence of 


















8. Conclusions and outlook for the future 
 
In the past few decades, significant advancement has been achieved in the field of tissue 
engineering and regeneration. However, one of the major obstacles challenging the success of 
tissue engineering is the vascularization of the tissue construct. Engineered tissue equivalents 
could be vascularized either in-vivo or in-vitro. Fabrication of vascularized tissue equivalents 
in-vitro has been shown to offer superior and rapid engraftment after implantation into a host 
and successful regeneration of tissue. Additionally, in-vitro vascularized tissue equivalents 
could offer potential avenues for developing/ screening new compounds especially in the field 
of vascular pharmacology.  
Engineering vascularized tissue equivalents requires the co-operation of a triad of vascular 
cells (ECs and mural cells), signaling molecules involved in the angiogenic cascade and 
biomaterial that supports angiogenesis. ECs and mural cells like vSMCs form the building 
blocks of the vascular system, while the biomaterials and angiogenic molecules provide the 
physical, chemical and biological cues/ support needed for the formation of network of 
vascular channels. ECs and vSMCs could be obtained from various natal and post-natal 
sources. However, obtaining sufficient quantities of healthy and functional cells from these 
cell sources especially in the elderly and those with co-morbid diseases are quite challenging. 
In this regard, hESCs offer a potential alternative and unlimited source of vascular cells. 
However, differentiating the hESCs towards vascular cells suffers from two major issues: 
efficient and scalable differentiation towards terminally differentiated cells and avoidance of 
xenogeneic products in the culture milieu.  
This doctoral work has chosen to focus on developing protocols for efficiently directing the 
differentiation of hESCs to a homogenous population of endothelial subtypes and vSMCs in a 
relatively animal-product free microenvironment, which could be used to engineer 
vascularized tissue equivalents. This objective was addressed in phases as summarized below 
and in Figure 64. 
Phase 1: Rapid induction of hESCs towards primitive streak-like stage under feeder-free, 
chemically-defined conditions (Chapter 4):   
Efficient commitment of epiblasts cells to PS is a requisite for the formation of mesoderm and 
endoderm. In this phase, the hESCs were directed towards PS through modulation of Wnt/β-
Catenin signaling pathway using an inhibitor of glycogen synthase kinase-3 (GSK3) under 




plasma fibronectin in a chemically-defined media (Stemdiff APEL) under the influence of 
GSK-3 inhibitor (CHIR99021) resulted in a temporal upregulation of genes related to PS, 
mesoderm and endoderm accompanied by downregulation of genes related to pluripotency 
and neuroectoderm. Short-term inhibition of GSK-3 (24 hours) showed maximal upregulation 
of genes related to PS indicating the emergence of PS-like cells. The identity of PS-like cells 
was confirmed by their ability to commit towards mesoderm and endoderm under the 
influence of bFGF and Activin A respectively. 
 
Figure 64. Summary of the findings of the study. 
The schematic summarizes the findings demonstrated in this study. Refer to the text for detailed 
explanations. Briefly, hESCs were directed to primitive streak-like cells using GSKi and these cells 
could be further directed towards lateral plate and paraxial mesoderm subtypes by modulation of bFGF, 
BMP4 and VEGF signaling pathways. The lateral plate mesoderm could be further directed to 
endothelial progenitors that could be differentiated to venous and arterial endothelial phenotypes by 
modulating the concentration of VEGF. Similarly, the paraxial mesoderm intermediates could be 
directed to vSMCs. Further, in-vitro 3D vascularized tissue equivalents could be engineered using co-





Phase 2: Differentiation of PS to lateral plate mesoderm and endothelial lineage under feeder-
free, chemically-defined conditions (Chapter 4): 
The hESC-derived PS-like cells were directed towards lateral plate mesoderm and endothelial 
lineage through modulation of mesoderm and vascular lineage inducing factors that include 
bFGF, BMP4, and VEGF. Differentiation of GSKi-treated hESCs with bFGF followed by 
BMP4 and VEGF resulted in a rapid (5 days) and highly efficient induction (90-95%) of H1- 
and H9-hESCs to VEGFR2, CD34 and CD31 expressing endothelial progenitor cells. This 
protocol to differentiate hESCs to endothelial progenitors is novel in terms of rapid induction 
(5days versus 10-15days), high proportion (90-95% versus 2-40%) and minimal use of 
xenogeneic products. To our knowledge, this is the most rapid and efficient protocol so far to 
derive endothelial progenitors from hESCs. 
In phase 1, 2 and 4, the use of xenogeneic products were reduced by the use of human plasma 
fibronectin as substrate and chemically-defined animal product-free medium (Stemdiff 
APEL) for the differentiation. However, components like BSA were used to reconstitute 
growth factors bFGF and VEGF. The use of BSA could be avoided in the future by use of 
carrier-free growth factors. 
Phase 3: Differentiation of hESC-derived endothelial progenitors to ECs, in particular arterial 





 endothelial progenitors derived from hESCs were sorted using FACS and 
differentiated further over fibronectin coated plates. Differentiation of these cells using 
endothelial serum-free medium yielded cells with endothelial characteristics. Under serum-
containing conditions, VEGF has been reported to have a strong arterialization effect in a 
dose-dependent manner with higher concentrations favoring arterial fate. However, under 
serum-free conditions, we found that high concentrations (25-50 ng/ml) resulted in apoptosis 
of the cells, while at low concentrations (10 ng/ml) aided differentiation towards a 
homogenous population of ECs expressing arterial markers. While differentiation under the 
absence of VEGF, resulted in a homogenous population of ECs expressing venous markers. 
Derivation of arterial and venous ECs from hESCs and use of serum-free endothelial medium 
has not been reported so far. The hESC-derived arterial and venous ECs showed 
heterogeneity in terms of their gene expression pattern, ability to migrate and close a scratch 
wound, and secretion of various angiocrines factors. Additional functional studies, especially 
in-vivo studies are needed to further validate the functional heterogeneity between the hESC-




phenotype under serum-free conditions might throw more light on the differentiation 
conditions required. 
In this this novel protocol, the use of xenogeneic products were reduced by the use of human 
plasma fibronectin as substrate and endothelial serum-free medium. Though the components 
of the endothelial serum-free medium are proprietary, we believe the medium might contain 
animal-derived components like BSA or insulin commonly present in other serum-free media 
formulations. To avoid the use of xenogeneic products and derive clinically competent ECs, 
endothelial medium free of animal-derived components need to be developed in the future. 
Phase 4: Differentiation of PS to paraxial mesoderm under feeder-free, chemically-defined 
conditions (Chapter 6). 
In this study, the hESCs were differentiated towards paraxial mesoderm through modulation 
of mesoderm and vascular lineage inducing factors that include bFGF, and VEGF. Treatment 
of GSKi-treated hESCs with bFGF and VEGF resulted in two distinct population of cells, one 
expressing lateral plate mesoderm related markers (VEGFR2, CD34 and CD31) and the other 
lacking them but expressing paraxial mesoderm and vSMC-related marker, PDGFRβ. The 
later population accounted for ~35% after 5 days of differentiation.  
Phase 5: Differentiation of hESC-derived paraxial mesoderm intermediates to vSMCs under 
feeder- and serum-free conditions (Chapter 6). 
Differentiation of FACS sorted hESC-derived paraxial mesoderm intermediates 
(PDGFRβ+CD34-CD31-) under the influence of PDGFbb in a custom-made serum-free media 
yielded spindle-shaped cells that expressed cell surface and intracellular markers related to 
vSMCs. These cells exhibited contractile property upon stimulation with carbachol. It is well 
established that vSMCs interact with ECs to support the formation and maturation of vascular 
channels (Carmeliet, 2000; Jain, 2003). Hence, the angiocrine secretory profile of hESC-
vSMCs was surveyed using angiogenesis antibody array. The results showed that hESC-
vSMCs secrete various angiogenic and antiangiogenic factors.  
During embryogenesis, vSMCs have a diverse source of origins that include lateral plate 
mesoderm, paraxial mesoderm and neural crest. Very few protocols employ a lineage-directed 
approach for vSMC differentiation. The present protocol of differentiation of vSMCs from 
paraxial mesoderm intermediates is one of the other two publications reported in the literature 
(Cheung et al., 2012; Tan et al., 2013a). 
In this this novel protocol, the use of xenogeneic products were reduced by the use of custom 




and insulin. To avoid the use of xenogeneic products and derive clinically competent vSMCs, 
smooth muscle medium free of animal-derived components needs to be developed in the 
future.  
Phase 6: Engineer in-vitro 3D vascularized tissue equivalents using hESC-derived vascular 
cells under serum-free conditions (Chapter 6). 
Though many reports have reported the utility of hESC-derived ECs and vSMCs in aiding 
neovascularization, very few reports have demonstrated the use of these cells in engineering 
in-vitro vascularized tissue equivalents. To engineer in-vitro 3D vascularized tissue 
equivalents, hESC-derived arterial ECs with or without hESC-vSMCs were cultured within 
PEG-Fibrin gels under serum-free conditions. hESC-derived arterial ECs formed 
anastomosing cords within PEG-fibrin gels, but regressed within a week in the absence of 
support from hESC-vSMCs. In the presence of hESC-vSMCs, the ECs formed anastomosing 
network of microvessels with patent lumen and were stable for 3 weeks in culture. 
Additionally, the use of fluorescently labeled hESC-derived vascular cells enabled non-
invasive and live visualization of the microvascular networks. Further, we assessed the  
maturity and functionality of the microvessels by inverse permeability. The hESC-derived 
microvessels were mature in terms of their barrier function, and also were capable of 
regulating the permeability in responsive to physiological stimulus like histamine. 
Though the use of xenogeneic products in this phase of the study was reduced by use of 
endothelial serum-free medium, the fibrinogen used was of bovine origin. We used bovine 
fibrinogen in this study for economic reasons. However, from clinical standpoint future 
studies are needed to evaluate the vascularization potential using fibrinogen of human origin. 
Fibrin is well established as being highly angiogenic, biodegradable and biocompatible, but is 
associated poor mechanical characteristics and degradation. One of the most commonly 
established approaches to improve fibrin’s weak mechanical properties is by conjugating the 
fibrinogen molecules with PEG. The PEG-Fibrin gels used in this study was stable during the 
3 week culture period and displayed no contraction or degradation under serum-free 
conditions. 
Limitations and future outlook 
Though our novel and efficient differentiation system for differentiating hESCs towards ECs 
and vSMCs and the utility of these cells in engineering 3D in-vitro vascularized tissue 




1. Though in each phase of the project, we were able to reduce the use of xenogeneic 
products, certain components like BSA, bovine insulin, bovine fibrinogen needs to be 
replaced. Hence, further reductions in the use of such xenogeneic products are possible 
and could advance the research output more close to clinical translation.  
2. We found differences in the arterial and venous phenotypes at molecular and in-vitro 
functional levels. However, in-vivo studies are needed to establish functional differences 
between the two phenotypes.  
3. In the current study, the ability of hESC-derived arterial ECs to form microvascular 
networks within PEG-fibrin gels was studied. Studies on the effect of hESC-derived 
venous ECs in place of arterial ECs are needed, as these two endothelial phenotypes 
demonstrated differences at molecular and functional levels.  
4. In this study, the ECs and vSMCs were used at a fixed ratio of 10:1. However, the ratio of 
these two cell types varies widely depending on the tissue. Hence, additional studies are 
needed to fine-tune the ratio of ECs to vSMCs.  
5. One of the major concerns with the use of hESC-derived products is the probability of 
teratoma formation. In-vivo studies to validate the safety of hESC-derived ECs and 
vSMCs are currently under investigation.  
6. Further, from a clinical translation point-of-view in-vivo studies are needed to investigate 
the ability of these in-vitro vascularized tissue equivalents to integrate with the host 
tissue.  
7. Additionally, investigating the utility of 3D vascularized system in screening novel 
angiogenic and anti-angiogenic compounds in a 3D microenvironment would be 
promising.  
8. Using ibidi µ-slides we were able to engineer micro-3D constructs. This system could aid 
in establishment of economic and high-throughput in-vitro platform to study/ screen 
angiogenic and anti-angiogenic compounds in the future.  
9. In-vitro vascularized tissue equivalents could aid in developing more complex tissues like 
full thickness skin equivalents and vascularized bone. Currently, work is in progress in 
investigating the utility of our hESC-derived in-vitro vascularized tissue equivalents for 
engineering vascularized skin and bone tissues. 
In conclusion, the hESC-derived 3D in-vitro system to fabricate vascularized tissue 
equivalents is a reproducible system that mimics the natural physiology of ECs to self-
assemble into microvascular networks. Thus our novel system provides a step forward 
towards engineering vascularized tissues/ organs with potential for clinical translational 
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Sequences of primers used for real time RT-PCR. 
Gene 
















83 bp NM_000442.4 
CD34 
F: 5- AAATCCTCTTCCTCTGAGGCTGGA-3’ 
R: 5- AAGAGGCAGCTGGTGATAAGGGTT-3’ 
216 bp NM_001773.2 
CNN1 
F: 5’-GTCCACCCTCCTGGCTTT-3’                             
R: 5’-AAACTTGTTGGTGCCCATCT-3’                     









































































































370 bp NM_003106.2 
TAGLN 
F: 5’-GGCAGCTTGGCAGTGACC-3’                       
R: 5’-TGGCTCTCTGTGAATTCCCTCT-3’                                
















345 bp NM_000552.3 
αSMA 
F: 5’-CACTGTCAGGAATCCTGTGA-3’  
R: 5’-CAAAGCCGGCCTTACAGA-3’                        








List of antibodies used for flow cytometry. 
Protein Antibody details Dilution Clone Catalogue Supplier 
CD31-APC 
Anti-Human; Mouse monoclonal 
IgG1 




Anti-Human; Mouse monoclonal 
IgG1 
1:50 4H11 12-0349 eBioscience 
PDGFRβ-
FITC 
Anti-Human; Mouse monoclonal 
IgG1 




Anti-Human; Mouse monoclonal 
IgG1 




Anti-Human; Mouse monoclonal 
IgG1 
1:25 AD2 17-0739 eBioscience 
CD105-PE 
Anti-Human; Mouse monoclonal 
IgG1 




Anti-Human; Mouse monoclonal 
IgG1 




Anti-Human; Mono monoclonal 
IgG2a 




Chemokine (C-X-C) Receptor 4 
Anti-Human; Mouse monoclonal 
IgG2a 












Ephrin Receptor B4 
Anti-Human; Rat monoclonal IgG1 





Anti-Human; Mouse monoclonal 
IgG2a 










Vascular Endothelial Cadherin 
Anti-Human; Mouse monoclonal 
IgG2B 




















Alexa Flour 488 isotype control 










Phycoerythrin isotype control 









Allophycocyanin isotype control 
Anti-Human; mouse monoclonal IgG1 








List of antibodies used for immunocytochemistry 
Protein Antibody details Dilution Clone Catalogue Supplier 
Alkaline 
Phosphatase 
Anti-Human; Rabbit polyclonal 
IgG 




Anti-Human; Rabbit polyclonal 
IgG 
1:200 Polyclonal AB20680 Abcam 
Brachyury 
Anti-Human; Mouse monoclonal 
IgG2B 
1:200 605502 MAB2085 R&D Systems 
Calponin 
Anti-Human; Mouse monoclonal 
IgG1 
1:200 CALP AB700 Abcam 
CD31 
Anti-Human; Mouse monoclonal 
IgG1 
1:200 9G11 BBA7 R&D Systems 
Collagen-IV 
Anti-Human; Mouse monoclonal 
IgG 
1:300 COL-94 C1926 Sigma-Aldrich 
Fibronectin 
Anti-Human; Rabbit polyclonal 
IgG 
1:300 Polyclonal F3648 Sigma-Aldrich 
Laminin 
Anti-Human; Rabbit polyclonal 
IgG 




Anti-Human; Mouse monoclonal 
IgG 




Anti-Human; Rabbit polyclonal 
IgG 
1:200 Polyclonal AB19857 Abcam 
SSEA-4 


















Anti-Human; Mouse monoclonal 
IgG2B 
1:200 123413 MAB9381 R&D Systems 
vWF 
Anti-Human; Rabbit polyclonal 
IgG 
1:800 Polyclonal GTX26994 GeneTex 
αSMA 
Anti-Human; Mouse monoclonal 
IgG2A 
1:100 1A4 MAB1420 R&D Systems 
β-Catenin 
Anti-Human; Rabbit polyclonal 
IgG 
1:200 Polyclonal AB16051 Abcam 
Secondary 
antibody 
Alexa Fluor 488 
Goat anti-rabbit IgG (H+L) 





Alexa Fluor 488 
Goat anti-mouse IgG (H+L) 






Protein Antibody details Dilution Clone Catalogue Supplier 
Secondary 
antibody 
Alexa Fluor 594 
Goat anti-rabbit IgG (H+L) 





Alexa Fluor 594 
Goat anti-mouse IgG (H+L) 









The location of controls and captured antibodies in the Human Angiogenesis Array is listed 
below. The picture shows the coordinates of each control/ captured antibody in the array. 
 
 




A1, A2 Reference Spots 
  
A5, A6 Activin-A 
  
A7, A8 ADAMTS-1 
 
A Disintegrin-like and 
Metalloproteinase Domain with 
Thrombospondin Motifs 1 
A9, A10 Angiogenin ANG 
 
A11, A12 Angiopoietin-1 Ang-1 
 
A13, A14 Angiopoietin-2 Ang-2 
 
A15, A16 Angiostatin/Plasminogen 
  
A17, A18 Amphiregulin AR 
 
A19, A20 Artemin 
  
A23, A24 Reference Spots 
  
B1, B2 Coagulation Factor-III TF 
 
B3, B4 CXCL16 
  
B5, B6 DPPIV CD26 Dipeptidyl peptidase IV  
B7, B8 EGF 
 
Epidermal Growth Factor 
B9, B10 EG-VEGF PK1 
Endocrine Gland-derived Vascular 
Endothelial Growth Factor 
B11, B12 Endoglin CD105 
 
B13, B14 Endostatin/Collagen XVIII 
 
B15, B16 Endothelin-1 ET-1 
 
B17, B18 FGF acidic FGF-1; aFGF 
 
B19, B20 FGF basic FGF-2; bFGF 
 
B21, B22 FGF-4 
  
B23, B24 FGF-7 KGF 
 
C1, C2 GDNF 
 








C3, C4 GM-CSF 
 
Granulocyte Macrophage Growth Factor 
C5, C5 HB-EGF 
 
Heparin Binding EGF-like Growth 
Factor 
C7, C8 HGF 
 
Hepatocyte Growth Factor 
C9, C10 IGFBP-1 
 
Insulin-like Growth Factor Binding 
Protein 1 
C11, C12 IGFBP-2 
 
Insulin-like Growth Factor Binding 
Protein 2 
C13, C14 IGFBP-3 
 
Insulin-like Growth Factor Binding 
Protein 3 
C15, C16 IL-1β IL-1F2 Interleukin-1β 
C17, C18 IL-8 CXCL8 Interleukin-8 
C19, C20 LAP TGF-β1 
 
C21, C22 Leptin 
  
C23, C24 MCP-1 CCL2 
monocyte chemotactic and activating 
factor (MCAF) 
D1, D2 MIP-1α CCL3 Macrophage Inflammatory Protein-1α 
D3, D4 MMP-8 
 
Matrix Metalloproteinase-8 
D5, D6 MMP-9 
 
Matrix Metalloproteinase-9 
D7, D8 NRG1-β1 HRG1-β1 Neuregulin 
D9, D10 Pentraxin-3 PTX3; TSG-14 TNF-stimulated gene 14 
D11, D12 PD-ECGF 
 
Platelet-derived Endothelial Cell 
Growth Factor 
D13, D14 PDGF-AA 
 
Platlet-derived Growth Factor-AA 
D15, D16 PDGF-AB/PDGF-BB 
 
Platlet-derived Growth Factor-AB/BB 
D17, D18 Persephin 
  
D19, D20 Platelet Factor-4 PF4; CXCL4 
 
D21, D22 PlGF 
 
Placenta-derived Growth Factor 
D23,D24 Prolactin 
  
E1, E2 Serpin-B5 Maspin 
 
E3, E4 Serpin-E1 PAI-1 
 
E5, E6 Serpin-F1 PEDF 
 
E7, E8 TIMP-1 
 
Tissue Inhibitor of MetalloProteinases-1 
E9, E10 TIMP-4 
 
Tissue Inhibitor of MetalloProteinases-2 
E11, E12 Thrombospondin-1 TSP-1 
 
E13, E14 Thrombospondin-2 TSP-2 
 
E15, E16 uPA 
 
Uraokinase-type Plasminogen Activator 
E17, E18 Vasohibin 
  
E19, E20 VEGF 
 
Vascular Endothelial Growth Factor 
E21, E22 VEGF-C 
 
Vascular Endothelial Growth Factor-C 
F1, F2 Reference Spots 
  









Fibrinogen from Bovine Plasma [Cat. No. 154165; MP Biomedicals]  
- Stock Concentration: 80mg/ml 
- 400mg of fibrinogen is dissolved in 5ml of 0.1M NaHCO3 (pH8.3) at room temperature 
with gentle shaking for 2 hours. Then the stock solution is stored at -80 
0
C as 200/500µl 
aliquots. 
 
Human Plasma Fibronectin [Cat No. 33016015; GIBCO] 
- Stock Concentration: 5mg/ml 
- 5mg of fibrinogen is dissolved in 5ml of sterile distilled water at room temperature with 
gentle shaking for 15 minutes. Then the stock solution is stored at -80 
0
C as 200/500µl 
aliquots. 
 
Polyethylene glycol-4-arm, succinimidyl glutarate terminated [Cat No. 565768; Sigma; 
PEG-(GS)4]  
- 10,000 Da  
- Stock Concentration: 8mg/ml 
- 250mg of PEG-(GS)4 is dissolved in 3.042ml of sterile PBS and allowed to dissolve for 
10mins at room temperature. Then sterile PBS is added to a total volume of 30.042ml. 
Then the stock solution is stored at -20 
0
C as 50µl aliquots. 
 
Recombinant Human bFGF [Cat No. 233-FB-025; R&D Systems] 
- Stock Concentration: 10ng/µl 
- 25µg of bFGF is dissolved in 2.5ml of sterile 0.1% BSA/PBS. Then the stock solution is 
stored at -20 
0
C as 100/200µl aliquots. 
 
Recombinant Human BMP4 [Cat No. 314-BP-010/CF; R&D Systems] 
- Stock Concentration: 100ng/µl 
- 10µg of BMP4 is dissolved in 100µl of sterile PBS. Then the stock solution is stored at -
20 
0
C as 10/20µl aliquots. 
 
Recombinant Human EGF [Cat No. 236-EG-200; R&D Systems] 
- Stock Concentration: 10ng/µl 
- 200µg of EGF is dissolved in 20ml of sterile 0.1% BSA/PBS. Then the stock solution is 
stored at -20 
0





Recombinant Human PDGFbb [Cat No. PHG0045; GIBCO] 
- Stock Concentration: 10ng/µl 
- 100mM acetic acid is prepared by adding 5.75 µl of Acetic acid to 1ml of sterile 0.1% 
BSA/PBS 
- 10µg of PDGFbb is dissolved in in 100µl of 100mM acetic acid in 0.1% BSA/PBS and 
allowed to dissolve for 10 minutes. Then 900µl of sterile 0.1% BSA/PBS is added to 





Recombinant Human VEGF [Cat No. PHC9394; GIBCO] 
- Stock Concentration: 10ng/µl 
- 10µg of VEGF is dissolved in 1ml of sterile 0.1% BSA/PBS. Then the stock solution is 
stored at -20 
0
C as 100/200µl aliquots. 
  
Thrombin from Human Plasma [Cat No. T6884-100UN; Sigma] 
- Stock Concentration: 100U/ml 
- 100U of thrombin is dissolved in 1ml of sterile distilled water. Then the stock solution is 
stored at -20 
0











Fabrication of PEG-Fibrin gel 
Appropriate volumes of individual components for fabrication of 100µl PEG-Fibrin gel 
- Solution A (PEG-Fibrinogen Solution) 
 Fibrinogen (80mg/ml)   : 12.50 µl 
 PEG-(GS)4 (8mg/ml)   : 3.13 µl 
- Solution B (Cell suspension) 
 Cells suspended in ESFM  : 34.37 µl 
- Solution C (Thrombin-CaCl2 Solution) 
 Thrombin (100U/ml)   : 25.00 µl 
 Calcium chloride solution (40mM) : 75.00 µl 
 
Protocol 
- Solution A is made by mixing fibrinogen (80mg/ml) and PEG (8mg/ml) in a ratio of 40:1 
such that the final concentrations of fibrinogen and PEG in the gel would be 10mg/ml and 
0.25 mg/ml respectively. The resultant PEG-fibrinogen solution is incubated at 37
0
C for 
20 minutes.  
- In the meantime, the cells to be encapsulated are suspended in appropriate volumes of 
media (Solution B)  
- Solution C is prepared by mixing thrombin (100U/ml) with calcium chloride (40mM) in a 
ratio of 1:3 to yield a final concentration of 12.5U/ml in the gel.  
- After 20 minutes of incubation, Solution A is mixed with Solution B to form PEG-
Fibrinogen-Cell suspension.  
- Then the PEG-fibrinogen-cell suspension is allowed to undergo gelation by addition of 
equal volume of Solution C. Immediately, the cell-gel mixture is pipetted into appropriate 
culture wells and incubated at 37
0
C for 10 minutes for complete gelation. [Note: the gel 
undergoes initial gelation within 10-15 seconds] 
- After the incubation, the gels are incubated in ESFM supplemented with bFGF (20ng/ml), 
EGF (10ng/ml) and VEGF (10ng/ml). 
